|
HCV | Abstract Library |
|
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
|
|
|
|
4. | The associations between invasive group A streptococcal disease and infection with influenza, varicella, or hepatitis C viruses: A data linkage study, Victoria, Australia |
|
Int J Infect Dis. 2024 Apr:141:106969. doi: 10.1016/j.ijid.2024.02.012. Epub 2024 Feb 21.
Jessie J Goldsmith 1, Christy Vu 2, Ziheng Zhu 2, Jennifer H MacLachlan 3, Tilda N Thomson 2, Patricia Therese Campbell 3, Katherine B Gibney 3
|
|
|
|
|
6. | Treating Hepatitis C Virus Infection in Jails as an Offset to Declines in Treatment Activity in the Community, New York City, NY, 2014-2020 |
|
AJPM Focus. 2024 Jan 6;3(2):100185. doi: 10.1016/j.focus.2024.100185. eCollection 2024 Apr.
Justin Chan 1 2, Matthew J Akiyama 3 4, Emily Julian 3, Rodrigue Joseph 3, Wendy McGahee 3, Zachary Rosner 2 3, Patricia Yang 3, Ross MacDonald 2 5
|
|
|
|
|
|
|
|
|
|
|
11. | Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study |
|
BMC Infect Dis. 2024 Feb 23;24(1):251. doi: 10.1186/s12879-024-09124-3.
Snehal S Lopes 1, Irene Pericot-Valverde 2, Paula J Lum 3, Lynn E Taylor 4, Shruti H Mehta 5, Judith I Tsui 6, Judith Feinberg 7 8, Arthur Y Kim 9 10, Brianna L Norton 11 12, Kimberly Page 13, Cristina Murray-Krezan 14, Jessica Anderson 13, Alison Karasz 15, Julia Arnsten 11 12, Phillip Moschella 16 17 18, Moonseong Heo 1, Alain H Litwin 19 20 21
|
|
|
|
|
13. | Birth Outcomes Among People with Hepatitis C in Pregnancy - Three U.S. States, 2018-2021 |
|
Matern Child Health J. 2024 Feb 28. doi: 10.1007/s10995-024-03917-3. Online ahead of print.
Kate R Woodworth 1, Suzanne M Newton 2, Ayzsa Tannis 3, Megan R Reynolds 2, Emily O Olsen 2, Lindsey Sizemore 4, Heather Wingate 4, Lauren Orkis 5, Bethany Reynolds 5, Nicole Longcore 6, Nadia Thomas 6, Shin Y Kim 2, Lakshmi Panagiotakopoulos 7, Carolyn Wester 7, Dana Meaney Delman 2, Suzanne M Gilboa 2, Van T Tong 2
|
|
|
14. | Validation of dried blood spots for capturing hepatitis C virus diversity for genomic surveillance |
|
J Viral Hepat. 2024 Feb 16. doi: 10.1111/jvh.13924. Online ahead of print.
Damien C Tully 1 2, Karen A Power 3, Jacklyn Sarette 3, Thomas J Stopka 4, Peter D Friedmann 5, P Todd Korthuis 6, Hannah Cooper 7, April M Young 8, David W Seal 9, Ryan P Westergaard 10, Todd M Allen 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21. | Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions |
|
Lancet Gastroenterol Hepatol. 2024 Feb 14:S2468-1253(23)00335-7.doi: 10.1016/S2468-1253(23)00335-7. Online ahead of print.
Alison D Marshall 1, Alex R Willing 2, Abe Kairouz 2, Evan B Cunningham 2, Alice Wheeler 2, Nicholas O'Brien 3, Vidura Perera 3, John W Ward 4, Lindsey Hiebert 4, Louisa Degenhardt 5, Behzad Hajarizadeh 2, Samantha Colledge 6, Matthew Hickman 7, Danielle Jawad 8, Jeffrey V Lazarus 9, Gail V Matthews 10, Andrew Scheibe 11, Peter Vickerman 7, Gregory J Dore 2, Jason Grebely 2; Global HCV and HIV Treatment Restrictions Group
Collaborators
Global HCV and HIV Treatment Restrictions Group:
N Sargsyants, L Suleymanova, N Salkic, M Simonova, T Nemeth-Blazic, V Mravcik, K Kivimets, R Salupere, M Butsashvili, G Soselia, M Makara, I Tolmane, L Jancoriene, S Stratulat, R Flisiak, L Gheorghe, R Cernat, A Lakhov, O Stanevich, P Jarcuska, M Peck-Radosavljevic, G Robaeys, A Øvrehus, G Foster, J Sutinen, M Farkkila, H Rautiainen, S Vuoti, D Nikolova, J M Pawlotsky, J Rockstroh, V Sypsa, G Papatheodoridis, S Olafsson, E Feeney, E Teti, C Seguin-Devaux, J Pocock, S Reiff, N McDougall, M Van der Valk, O Dalgard, R Tato Marinho, J Dillon, E Peters, K Bojovic, M Maticic, M Kåberg, P Bruggmann, B Healy, V H Chong, S Yi, J Tucker, L R Pasaribu, J Tanaka, E A Ashley, M R Abu Hassan, N S Mohammed, H K Chan, S Gidaagaya, K P Kyi, K Hyung Joon, B Chin, P C Baladjay, J H Kao, T Wansom, B da Cruz, B Flower, E Ehsan, M Al Mahtab, L Khandu, A S Bhadoria, M Alavi, P Kc, S Hamid, S Biryukov, D Alymbaeva, A Alaei, S Bakieva, D Flichman, R F Carmo, E Valdez, C P Cortes, F Contreras, E Teran, P Velez-Moller, T Jagnarine, M Mills, D Goodman-Meza, J Sánchez, J J Montenegro-Idrogo, A M Lugo Canales, J Davy, A Alexander, S Gerona, R Perazzo, D Balak, A Kelly-Hanku, A Fineanganofo, E Gane, N Raymond, N Debzi, K Sridharan, I Waked, D Turner, O Shibolet, A Al Muzaini, M El Nakib, D S Sheriff, T Brahni, T Essayagh, S Essayagh, D Hjaija, K Al-Naamani, F M Sanai, H Pasquale, S Bedri, M Chakroun, A Ghrabi, U S Akarca, V Falcao, S Edmond Gbedo, S Ouoba, F Nyabenda, M Rocher Mbella, A Mahamat Moussa, T Youssouf, Y Boniface, T Akilimali Shindano, M E Hamida, A Mongo, C Mapapa, H Desalegn, E L A Embinga, G Ndow, Y Nartey, M Cisse, M A Djalo, M Mugambi, M Nyakowa, M K Jeuronlon, J Ngoma, R Manitrala Ramanampamonjy, K Naik, M D Soyjaudah, E Filipe, E Nnakelu, J Serumondo, M Mbodj, M Patino, M K Aalto, P Waweru, A Dagnra, P Ocama, A Maghimbi, B M Hamooya, L Katsidzira, C Rios, M Thormann, N Al Marzooqi,
|
|
|
22. | Hepatitis C Virus Testing, Infection, and Cases Reported Through Public Health Surveillance During Expanded Screening Recommendations, United States, 2013-2021 |
|
Public Health Rep. 2024 Feb 12:333549231224199. doi: 10.1177/00333549231224199.Online ahead of print.
Kathleen N Ly 1, Justin K Niles 2, Ruth B Jiles 1, Harvey W Kaufman 2, Mark K Weng 1, Priti Patel 1, William A Meyer 3rd 2, William W Thompson 1, Nicola D Thompson 1
|
|
|
|
|
24. | Assessing Physicians' Recommendations for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Testing Among Minority Populations in Greater Philadelphia and New York City |
|
J Community Health. 2024 Jan 29. doi: 10.1007/s10900-023-01316-3. Online ahead of print.
Thoin F Begum 1, Vidya S Patil 2, Lin Zhu 2 3, Ming-Chin Yeh 4, Evelyn González 5, Marilyn A Fraser 6, Wenyue Lu 2, Steven Zhu 7, Nathaly Rubio-Torio 8, Grace X Ma 2 3, Yin Tan 2
|
|
|
|
|
|
|
27. | Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study |
|
J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023.12.020.Online ahead of print.
Moonseong Heo 1, Brianna L Norton 2, Irene Pericot-Valverde 3, Shruti H Mehta 4, Judith I Tsui 5, Lynn E Taylor 6, Paula J Lum 7, Judith Feinberg 8, Arthur Y Kim 9, Julia Arnsten 2, Sophie Sprecht-Walsh 6, Kimberly Page 10, Alain H Litwin 11; HERO Study Group; National Stakeholder Advisory Board
Collaborators
Alain H Litwin 12, Moonseong Heo 12, Irene Pericot-Valverde 12, Hagan Walker 12, Ashley Coleman 12, Shruti H Mehta 13, Courtney Borsuk 13, Brian Dickerson 13, Oluwaseun Falade-Nwulia 13, Michael Fingerhood 13, Taryn Haselhuhn 13, Angela Mason 13, Juhi Moon 13, Yngvild Olsen 13, Vickie Walters 13, Arthur Y Kim 14, Jillian M Roche 14, William Schmitt 14, Virginia Lijewski 14, Anita Pitts 14, Syeda Raji 14, Taniya Silva 14, Fiona Evans 14, Hope Koene 14, Joelle Brown 14, Brianna Norton 15, Linda Agyemang 15, Julia Arnsten 15, Alison Karasz 15, Paul Meissner 15, Kiara Lora 15, Jennifer Hidalgo 15, Irene Soloway 15, Karen Jefferson 15, Joyce Wong 15, Andrea Kermack 15, Melissa Stein 15, Gilian Joseph 15, Karyn London 15, Lincoln Allen 15, Venecia Marte 15, Tatiana Vera 15, Romy Alvarez 15, M Diane Mckee 16, Paula J Lum 17, Ellen S Stein 17, Anne F Luetkemeyer 17, Caycee Cullen 17, Gurjot Gill 17, Hannah Tierney 17, Scott Shapiro 17, Soraya Azari 17, Joanna Eveland 17, Daniel Berrner 17, Pauli Grey 17, Jordan Akerley 17, Kimberly Page 18, Katherine Wagner 18,
|
|
|
|
|
29. | Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe |
|
Pediatr Infect Dis J. 2024 Feb 2. doi: 10.1097/INF.0000000000004271. Online ahead of print.
Farihah Malik 1, Siobhan Crichton 2, Yulia Plotnikova 3, Inga Latysheva 4, Anna Samarina 5, Maria Pokorska-Spiewak 6, Marisa Navarro Gomez 7, Heather Bailey 8, Claire Thorne 1, Ali Judd 2, Anna Turkova 2, Intira Jeannie Collins 2
|
|
|
|
|
31. | Piloting a simplified bio-behavioural survey methodology, the BBS-Lite, among people who inject drugs in Georgia |
|
Int J Drug Policy. 2024 Jan 16:104326. doi: 10.1016/j.drugpo.2024.104326. Online ahead of print.
Maka Gogia 1, Ekaterine Ruadze 2, Tamar Kasrashvili 3, Bradley Mathers 4, Keith Sabin 5, Annette Verster 6, Virginia Macdonald 6, Maia Butsashvili 7, George Kamkamidze 7, Irma Khonelidze 2, Ketevan Stvilia 2
|
|
|
|
|
33. | Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies |
|
Lancet HIV. 2024 Jan 12:S2352-3018(23)00267-9. doi: 10.1016/S2352-3018(23)00267-9.Online ahead of print.
Rachel Sacks-Davis 1, Daniela K van Santen 2, Anders Boyd 3, Jim Young 4, Ashleigh Stewart 5, Joseph S Doyle 6, Andri Rauch 7, Catrina Mugglin 7, Marina Klein 8, Marc van der Valk 9, Colette Smit 10, Inmaculada Jarrin 11, Juan Berenguer 12, Karine Lacombe 13, Maria-Bernarda Requena 14, Linda Wittkop 15, Olivier Leleux 16, Fabrice Bonnet 17, Dominique Salmon 18, Gail V Matthews 19, Rebecca Guy 19, Natasha K Martin 20, Tim Spelman 21, Maria Prins 22, Mark Stoove 23, Margaret Hellard 24; InCHEHC Collaboration
Collaborators
InCHEHC Collaboration:
Margaret E Hellard, Rachel Sacks-Davis, Daniela K van Santen, Ashleigh Stewart, Tianhui Ke, Yanqin Zhang, Mark Stoove, Rebecca Guy, Alisa Pedrana, Jason Asselin, Joshua Dawe, Anna Wilkinson, Anders Boyd, Colette Smit, Marc van der Valk, Janke Schinkel, Linda Wittkop, Dominique Salmon, Philippe Sogni, Laure Esterle, Camille Gilbert, Laurence Merchadou, Stephanie Gillet, Coralie Khan, Fabrice Bonnet, Olivier Leleux, Fabien Le Marec, Adelaide Perrier, Gail Matthews, Ineke Shaw, Marianne Martinello, Tanya Applegate, Joanne Carson, Joseph S Doyle, Brendan Harney, Melissa Bryant, Inmaculada Jarrin Vera, Juan Berenguer, Belen Alejos, Jeffrey V Lazarus, Cristina Moreno, Rebecca Izquierdo, Marta Rava, Marina Klein, Shouao Wang, Jessica Lumia, Costa Pexos, Hansi Peiris, Sahar Saeed, Erica Moodie, Jim Young, Neora Pick, Brian Conway, Mark Hull, Alex Wong, John Gill, Lisa Barrett, Jeff Cohen, Joseph Cox, Pierre Cote, Shariq Haider, Danielle Rouleau, Marie-Louise Vachon, Anita Rachlis, Roger Sandre, Sharon Walmsley, Aida Sadr, Curtis Cooper, Steve Sanche, Andri Rauch, Catrina Mugglin, Luisa Salazar-Viscaya, Katharina Kusejko, Maria Prins, Kris Hage, Karine Lacombe, Maria-Bernada Requena, Pierre-Marie Girard, Matthieu Brucker, Jean-Paul Vincensini
|
|
|
34. | Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility |
|
Int J Drug Policy. 2024 Jan 27:125:104317. doi: 10.1016/j.drugpo.2024.104317.Online ahead of print.
M B MacIsaac 1, B Whitton 2, J Anderson 3, S Cogger 3, D Vella-Horne 3, M Penn 3, T Weeks 3, K Elmore 3, D Pemberton 3, R J Winter 4, T Papaluca 1, J Howell 1, M Hellard 5, M Stoové 6, D Wilson 7, A Pedrana 8, J S Doyle 8, N Clark 9, J A Holmes 1, A J Thompson 10
|
|
|
|
|
|
|
|
|
|
|
39. | Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study |
|
Value Health. 2024 Feb;27(2):216-225. doi: 10.1016/j.jval.2023.10.013. Epub 2023 Nov 10.
Qinglu Cheng 1, Heather Valerio 2, Evan B Cunningham 2, Sophy T F Shih 2, David Silk 2, Anna Conway 3, Carla Treloar 4, Carolyn Murray 5, Charles Henderson 6, Janaki Amin 7, Phillip Read 8, Gregory J Dore 2, Jason Grebely 2; ETHOS Engage Study Group
Collaborators
- ETHOS Engage Study Group:
Jason Grebely, Gregory J Dore, David Silk, Nicky Bath, Carla Treloar, Andrew Milat, Adrian Dunlop, Janaki Amin, Jo Holden, Carolyn Murray, Charles Henderson, Kyle Leadbeatter, Emma Day, Nikitah Habraken, Olivia Dawson, Louisa Degenhardt, Clarke Scott, Phillip Read, Jason Grebely, Gregory J Dore, David Silk, Heather Valerio, Shane Tillakeratne, Philippa Marks, Indika Jayasinghe, Maria Martinez, Hannah Reid, Valerie Gleeson, Jodi Van Dyk, Gerard Estivill Mercade, Alison D Marshall, Stephanie Obeid, A Wheeler, Samira Hosseini Hooshyar, Beth Catlett, Andrey Verich, Anna Conway, Amanda Erratt, Alice Wheeler, Nadine Ezard, David Reid, Carla Gorton, Jeremy Hayllar, Thao Lam, Adrian Dunlop, Prasun Datta, Alex Wade, Sally Spruce, Vicky Cock, Mark Cornwell, Krista Zohrab, Michael Christmass, Craig Connelly, Angela Cooper, Mark Montebello, Robert Cherry, Julie Dyer, Shikha Arawal, Elke Press, Nadine Horasak, Rhondda Lewis, Astrid Carthew, Daniel Morris, Kathy Donohue, Kathy Griffiths, Jason Dalla Lana, Sue Shin, Connie Graf, Adele Hampson, Siyu Qian, Danielle Brown, Amber Lautier, Cate Curran, Carina Burns, Ravina Raidu, Kylie Stolzenhein, Wanda Brabender, Kelly Somes, Nargis Abram, Rick Turne, Stuart Larter, Fiona Goodberg, Jennifer Luksza, Michelle Hall, Susan Hazelwood, Charlotte Ismay, Krista Zohrab, Belinda McClurg, Cherie Mincham, Kali Barlow, Anita Hoskins, Kate Salisbury, Julie Markham, Jacky Talmet, Sandy Dunn, Amanda Mitchell, Andrew McKinnon, Fionnualh Smyth, Lisa Snell, Elizabeth Laing, Martin Clark, Justin Dorigo, Louise Carman, Brent Fergusson, Bonny Puszka, Gai Duncan, Fiona Baker, Jayde Walsh, Leeann Walsh, Sara Adey, Rodd Hinton, Melanie Joyce, Cheryl Woods, Alain Jenart, Hope Everingham, Louisa Jansen, Lucy Pepolim, Kathy Clark, Lyn Murphy, Joel Iliffe
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46. | Frequency of Children Diagnosed with Perinatal Hepatitis C, United States, 2018-2020 |
|
Emerg Infect Dis. 2024 Jan;30(1):202-204. doi: 10.3201/eid3001.230315. Epub 2023 Dec 8.
Suzanne M Newton, Kate R Woodworth, Daniel Chang, Lindsey Sizemore, Heather Wingate, Leah Pinckney, Anthony Osinski, Lauren Orkis, Bethany D Reynolds, Cynthia Carpentieri, Umme-Aiman Halai, Caleb Lyu, Nicole Longcore, Nadia Thomas, Aprielle Wills, Amanda Akosa, Emily O'Malley Olsen, Lakshmi Panagiotakopoulos, Nicola D Thompson, Suzanne M Gilboa, Van T Tong
|
|
|
|
|
48. | Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program |
|
Clin Mol Hepatol. 2024 Jan;30(1):64-79. doi: 10.3350/cmh.2023.0287. Epub 2023 Nov 21.
Ming-Ying Lu 1 2 3, Chung-Feng Huang 2 3 4, Chao-Hung Hung 5, Chi-Ming Tai 6 7, Lein-Ray Mo 8, Hsing-Tao Kuo 1 9, Kuo-Chih Tseng 10 11, Ching-Chu Lo 12, Ming-Jong Bair 13 14, Szu-Jen Wang 15, Jee-Fu Huang 2 3, Ming-Lun Yeh 2 3, Chun-Ting Chen 16 17, Ming-Chang Tsai 18, Chien-Wei Huang 19, Pei-Lun Lee 20, Tzeng-Hue Yang 21, Yi-Hsiang Huang 22 23, Lee-Won Chong 24 25, Chien-Lin Chen 26, Chi-Chieh Yang 27, Sheng-Shun Yang 28, Pin-Nan Cheng 29, Tsai-Yuan Hsieh 16, Jui-Ting Hu 30, Wen-Chih Wu 31, Chien-Yu Cheng 32, Guei-Ying Chen 33, Guo-Xiong Zhou 34, Wei-Lun Tsai 35, Chien-Neng Kao 36, Chih-Lang Lin 37, Chia-Chi Wang 38, Ta-Ya Lin 39, Chih-Lin Lin 40, Wei-Wen Su 41, Tzong-Hsi Lee 42, Te-Sheng Chang 43, Chun-Jen Liu 44, Chia-Yen Dai 2 3, Jia-Horng Kao 44, Han-Chieh Lin 22 23, Wan-Long Chuang 2 3, Cheng-Yuan Peng 45 46, Chun-Wei- Tsai 47, Chi-Yi Chen 48, Ming-Lung Yu 1 2 3 5; TACR Study Group
|
|
|
49. | Incidence of hepatitis C virus infection in the prison setting: The SToP-C study |
|
Viral Hepat. 2024 Jan;31(1):21-34. doi: 10.1111/jvh.13895. Epub 2023 Nov 7.
Behzad Hajarizadeh 1, Joanne M Carson 1, Marianne Byrne 1, Jason Grebely 1, Evan Cunningham 1, Janaki Amin 2, Peter Vickerman 3, Natasha K Martin 4, Carla Treloar 5, Marianne Martinello 1, Andrew R Lloyd 1, Gregory J Dore 1; SToP-C study group
|
|
|
50. | Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort) |
|
Drug Alcohol Rev. 2023 Dec 22. doi: 10.1111/dar.13802. Online ahead of print.
Tangui Barré 1, Marc Bourlière 1 2, Lucia Parlati 3, Clémence Ramier 1, Fabienne Marcellin 1, Camelia Protopopescu 1, Vincent Di Beo 1, Carole Cagnot 4, Celine Dorival 5, Jérôme Nicol 5, Fabien Zoulim 6 7 8, Fabrice Carrat 9, Patrizia Carrieri 1; ANRS/AFEF Hepather Study group
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
65. | Reflex Hepatitis C Virus Viral Load Testing Following an Initial Positive Hepatitis C Virus Antibody Test: A Global Systematic Review and Meta-analysis |
|
Clin Infect Dis. 2023 Oct 13;77(8):1137-1156. doi: 10.1093/cid/ciad126.
Yusha Tao 1 2, Weiming Tang 1 2 3, Emmanuel Fajardo 4, Mengyuan Cheng 1 2, Shiyi He 5, Jennifer S Bissram 6, Lindsey Hiebert 7, John W Ward 7, Roger Chou 8, Francisco Rodríguez-Frías 9 10, Philippa Easterbrook 4, Joseph D Tucker 2 3 11
|
|
|
|
|
67. | Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study |
|
Am J Transplant. 2023 Oct 21:S1600-6135(23)00796-7. doi: 10.1016/j.ajt.2023.10.006.Online ahead of print.
Wesam Aleyadeh 1, Elizabeth C Verna 2, Hany Elbeshbeshy 3, Mark S Sulkowski 4, Coleman Smith 5, Jama Darling 6, Richard K Sterling 7, Andrew Muir 8, Lucy Akushevich 9, Danie La 10, Norah Terrault 11, Michael W Fried 6, Jordan J Feld 12
|
|
|
|
|
|
|
70. | Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): A stepped wedge cluster randomized trial |
|
Clin Infect Dis. 2023 Nov 22:ciad711. doi: 10.1093/cid/ciad711. Online ahead of print.
Håvard Midgard 1 2, Kristian Braathen Malme 2 3, Charlotte Meinich Pihl 4 5, Riikka Mari Berg-Pedersen 6, Lars Tanum 7 8, Ingvild Klundby 9, Anne Haug 10, Ida Tveter 11, Ronny Bjørnestad 12, Inge Christoffer Olsen 13, Ane-Kristine Finbråten 4 5, Olav Dalgard 2 3
|
|
|
71. | Real-world Experiences in the Transplantation of Hepatitis C-NAAT-positive Organs |
|
Transplant Direct. 2023 Oct 10;9(11):e1539. doi: 10.1097/TXD.0000000000001539.eCollection 2023 Nov.
Julie M Steinbrink 1, Jennifer Byrns 2, Carl Berg 3, Matthew Kappus 3, Lindsay King 3, Matthew J Ellis 4, Scott Sanoff 4, Richa Agarwal 5, Adam D DeVore 5, John M Reynolds 6, Matthew G Hartwig 7, Carmelo Milano 7, Debra Sudan 8, Eileen K Maziarz 1, Jennifer Saullo 1, Barbara D Alexander 1, Cameron R Wolfe 1
|
|
|
|
|
73. | Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis |
|
Liver Int. 2023 Dec;43(12):2625-2644. doi: 10.1111/liv.15705.Epub 2023 Oct 10.
Stephanie C Munari 1, Michael W Traeger 1 2, Vinay Menon 1, Ned H Latham 1, Lakshmi Manoharan 1, Niklas Luhmann 3, Rachel Baggaley 3, Virginia MacDonald 3, Annette Verster 3, Nandi Siegfried 4, Brian Conway 5, Marina Klein 6, Julie Bruneau 7, Mark A Stoové 1, Margaret E Hellard 1 2 8, Joseph S Doyle 1 8
|
|
|
|
|
|
|
|
|
|
|
|
|
79. | Associations of hepatitis C virus (HCV) antibody positivity with opioid, stimulant, and polysubstance injection among people who inject drugs (PWID) in rural U.S. communities |
|
Int J Drug Policy. 2023 Oct 6:104222. doi: 10.1016/j.drugpo.2023.104222. Online ahead of print.
Angela T Estadt 1, William C Miller 2, David Kline 3, Bridget M Whitney 4, April M Young 5, P Todd Korthuis 6, Thomas J Stopka 7, Judith Feinberg 8, William A Zule 9, Mai T Pho 10, Peter D Friedmann 11, Ryan P Westergaard 12, Kellene V Eagen 13, Andrew Seaman 14, Jimmy Ma 15, Vivian F Go 16, Kathryn E Lancaster 17
|
|
|
80. | Reinfection incidence and risk among people treated for recent hepatitis C virus infection |
|
AIDS. 2023 Oct 1;37(12):1883-1890. doi: 10.1097/QAD.0000000000003651. Epub 2023 Jul 17.
Marianne Martinello 1, Joanne M Carson 1, Marc Van Der Valk 2 3, Jürgen K Rockstroh 4, Patrick Ingiliz 5, Margaret Hellard 6 7, Mark Nelson 8, Thomas Lutz 9, Sanjay Bhagani 10, Arthur Y Kim 11, Mark Hull 12, Christiane Cordes 13, Juhi Moon 14, Jordan J Feld 15, Ed Gane 16, Andri Rauch 17, Julie Bruneau 18, Elise Tu 1, Tanya Applegate 1, Jason Grebely 1, Gregory J Dore 1 19, Gail V Matthews 1 19; React Study Group
|
|
|
|
|
82. | Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies |
|
J Viral Hepat. 2023 Sep;30(9):775-786. doi: 10.1111/jvh.13863. Epub 2023 Jun 20.
Adam Trickey 1, Suzanne M Ingle 1, Anders Boyd 2 3 4, M John Gill 5, Sophie Grabar 6 7, Inma Jarrin 8 9, Niels Obel 10, Giota Touloumi 11, Robert Zangerle 12, Andri Rauch 13, Christopher T Rentsch 14 15, Derek D Satre 16 17, Michael J Silverberg 17, Fabrice Bonnet 18 19, Jodie Guest 20 21, Greer Burkholder 22, Heidi Crane 23, Ramon Teira 24, Juan Berenguer 25, Christoph Wyen 26, Sophie Abgrall 27 28, Mojgan Hessamfar 18 19, Peter Reiss 2 29 30, Antonella d'Arminio Monforte 31, Kathleen A McGinnis 14, Jonathan A C Sterne 1 32 33, Linda Wittkop 18 34 35; Antiretroviral Therapy Cohort Collaboration
|
|
|
83. | Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis |
|
Viruses. 2023 Sep 29;15(10):2026. doi: 10.3390/v15102026.
Steven Flamm 1, Eric Lawitz 2, Brian Borg 3, Michael Charlton 4, Charles Landis 5, K Rajender Reddy 6, Mitchell Shiffman 7, Angel Alsina 8, Charissa Chang 9, Natarajan Ravendhran 10, Candido Hernandez 11, Christophe Hézode 11, Stacey Scherbakovsky 11, Renee-Claude Mercier 11, Didier Samuel 12
|
|
|
84. | Hepatitis C and obstetric morbidity in a substance use disorder clinic: A role for telemedicine? |
|
Am J Obstet Gynecol MFM. 2023 Nov 9:101219. doi: 10.1016/j.ajogmf.2023.101219.Online ahead of print.
Cassandra J Trammel 1, Shannon Beerman 2, Bree Goodman 2, Laura Marks 3, Ms Melissa Mills 2, Michael Durkin 3, Nandini Raghuraman 2, Ebony B Carter 2, Anthony O Odibo 2, Amanda C Zofkie 2, Jeannie C Kelly 2
|
|
|
|
|
86. | Incidence of hepatitis C virus infection in the prison setting: The SToP-C study |
|
Viral Hepat. 2023 Nov 7. doi: 10.1111/jvh.13895. Online ahead of print.
Behzad Hajarizadeh 1, Joanne M Carson 1, Marianne Byrne 1, Jason Grebely 1, Evan Cunningham 1, Janaki Amin 2, Peter Vickerman 3, Natasha K Martin 4, Carla Treloar 5, Marianne Martinello 1, Andrew R Lloyd 1, Gregory J Dore 1; SToP-C study group
Collaborators
Stuart Loveday, Nicky Bath, Tony Butler, Georgina Chambers, Roy Donnelly, Colette McGrath, Julia Bowman, Lee Trevethan, Katerina Lagios, Luke Grant, Terry Murrell, Victor Tawil, Annabelle Stevens, Libby Topp, Alison Churchill, Kate Pinnock, Steven Drew, Mary Harrod, Pip Marks, Mahshid Tamaddoni, Stephanie Obeid, Gerard Estivill Mercade, Maria Martinez, William Rawlinson, Malinna Yeang, Matthew Wynn, Christiana Willenborg, Angela Smith, Ronella Williams, Brigid Cooper, Kelly Somes, Carina Burns, Camilla Lobo, Karen Conroy, Luke McCredie, Carolyn Café, Jodie Anlezark
|
|
|
|
|
|
|
|
|
|
|
|
|
92. | Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy |
|
JAMA Netw Open. 2023 Sep 5;6(9):e2335715. doi: 10.1001/jamanetworkopen.2023.35715.
Emily J Cartwright 1 2, Chloe Pierret 3, Caroline Minassian 3, Denise A Esserman 4, Janet P Tate 4 5, Matthew B Goetz 6 7, Debika Bhattacharya 6 7, David A Fiellin 5 8 9, Amy C Justice 4 5 8 9, Vincent Lo Re 3rd 10, Christopher T Rentsch 3 4 5
|
|
|
|
|
|
|
|
|
|
|
97. | A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study |
|
J Hepatol. 2023 Sep;79(3):635-644.doi: 10.1016/j.jhep.2023.04.019. Epub 2023 Apr 26.
Yumi Sheehan 1, Evan B Cunningham 2, Amanda Cochrane 3, Marianne Byrne 2, Tracey Brown 3, Colette McGrath 3, Lise Lafferty 4, Nicodemus Tedla 5, Gregory J Dore 2, Andrew R Lloyd 2, Jason Grebely 2
|
|
|
98. | Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons |
|
Viral Hepat. 2023 Sep 12. doi: 10.1111/jvh.13887. Online ahead of print.
Amy Johnson 1, Jessica Shearer 1, Craig Thompson 2, Ryan Jelley 1, Jodi Aldridge 2, Caroline Allsop 1, Jenna Kerry 1, Dee Jones 2, Francesca McCullough 1, Carolyn Miller 1, Manoj Valappil 3, Yusri Taha 3, Steven Masson 1 4, Tony Jefferson 5, Colin Lawton 5, Lee Christensen 5, Stuart McPherson 1 4
|
|
|
|
|
|
|
|
|
|
|
103. | Connecting patients notified with hepatitis C to treatment (CONNECT Study): A randomized controlled trial of active case management by a health department to support primary care practitioners |
|
Int J Drug Policy. 2023 Sep 13:121:104184. doi: 10.1016/j.drugpo.2023.104184.Online ahead of print.
Tafireyi Marukutira 1, Rachel Barter 2, Karen P Moore 2, Margaret E Hellard 3, Jacqui Richmond 3, Kate Turner 2, Alisa E Pedrana 4, Shannon Melody 3, Fay H Johnston 2, Louise Owen 2, Wijnand van Den Boom 3, Nick Scott 3, Alexander Thompson 5, David M Iser 5, Timothy Spelman 3, Mark Veitch 2, Mark Stoové 3, Joseph S Doyle 6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
113. | Risk Factors for Perinatal Transmission of Hepatitis C Virus |
|
Obstet Gynecol. 2023 Sep 1;142(3):449-456.doi: 10.1097/AOG.0000000000005306.
Mona Prasad 1, George R Saade, Rebecca G Clifton, Grecio J Sandoval, Brenna L Hughes, Uma M Reddy, Anna Bartholomew, Ashley Salazar, Edward K Chien, Alan T N Tita, John M Thorp Jr, Torri D Metz, Ronald J Wapner, Vishakha Sabharwal, Hyagriv N Simhan, Geeta K Swamy, Kent D Heyborne, Baha M Sibai, William A Grobman, Yasser Y El-Sayed, Brian M Casey, Samuel Parry, Mobeen Rathore, Rodrigo Diaz-Velasco, Ana M Puga, Andrew Wiznia, Andrea Kovacs, David J Garry, George A Macones; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network*
|
|
|
114. | Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance |
|
Vox Sang. 2023 Sep 11. doi: 10.1111/vox.13514. Online ahead of print.
Syria Laperche 1 2, Claire Sauvage 3, Pierre Gallian 1, Saadia Jbilou 1, Elodie Pouchol 1, Jean Yves Py 1, Lila Chabli 1, Pascale Richard 1, Pascal Morel 1 4, Florence Lot 3, Pierre Tiberghien 1 4
|
|
|
|
|
|
|
|
|
118. | Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019 |
|
Lancet Public Health. 2023 Sep;8(9):e701-e716.doi: 10.1016/S2468-2667(23)00149-4.
GBD 2019 Europe Hepatitis B & C Collaborators
Collaborators
- GBD 2019 Europe Hepatitis B & C Collaborators:
Paolo Angelo Cortesi, Carla Fornari, Sara Conti, Ippazio Cosimo Antonazzo, Pietro Ferrara, Ayman Ahmed, Catalina Liliana Andrei, Tudorel Andrei, Anton A Artamonov, Maciej Banach, Carl Michael Baravelli, Till Winfried Bärnighausen, Akshaya Srikanth Bhagavathula, Nikolay Ivanovich Briko, Daniela Calina, Giulia Carreras, Sheng-Chia Chung, Mostafa Dianatinasab, Eleonora Dubljanin, Oyewole Christopher Durojaiye, Ifeanyi Jude Ezeonwumelu, Adeniyi Francis Fagbamigbe, Florian Fischer, Silvano Gallus, Ekaterina Vladimirovna Glushkova, Davide Golinelli, Giuseppe Gorini, Shoaib Hassan, Simon I Hay, Mihaela Hostiuc, Irena M Ilic, Milena D Ilic, Mihajlo Jakovljevic, Elham Jamshidi, Jacek Jerzy Jozwiak, Zubair Kabir, Joonas H Kauppila, Rovshan Khalilov, Moien Ab Khan, Khaled Khatab, Ai Koyanagi, Carlo La Vecchia, Jeffrey V Lazarus, Caterina Ledda, Miriam Levi, Platon D Lopukhov, Joana A Loureiro, Philippa C Matthews, Alexios-Fotios A Mentis, Tomislav Mestrovic, Babak Moazen, Shafiu Mohammed, Lorenzo Monasta, Francesk Mulita, Christopher J L Murray, Ionut Negoi, Bogdan Oancea, Claudia Palladino, Jay Patel, Ionela-Roxana Petcu, Maarten J Postma, David Laith Rawaf, Salman Rawaf, Esperanza Romero-Rodríguez, Milena M Santric-Milicevic, Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, Rafael Tabarés-Seisdedos, Mircea Tampa, Nuno Taveira, Arulmani Thiyagarajan, Marcos Roberto Tovani-Palone, Ronny Westerman, Mikhail Sergeevich Zastrozhin, Giampiero Mazzaglia, Lorenzo Giovanni Mantovani
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
128. | Hepatitis C Virus Elimination Programs in Louisiana and Washington: Importance of Screening and Surveillance Systems |
|
Public Health Manag Pract. 2023 Aug 18. doi: 10.1097/PHH.0000000000001808.Online ahead of print.
Andrew H Talal 1, Arpan Dharia, Shashi N Kapadia, Gia L Tyson, Susan Birch, Judy Zerzan-Thul, Donna Sullivan, Elizabeth Britton, Elaine Wethington, Christopher J Gonzalez, Mary Fliss, Brandon Mizroch, Frederic McCall, Audrey R Lloyd, Martin F Shapiro, Ricardo Franco
|
|
|
|
|
|
|
131. | Hepatitis C Treatment Initiation Among US Medicaid Enrollees |
|
JAMA Netw Open. 2023 Aug 1;6(8):e2327326. doi: 10.1001/jamanetworkopen.2023.27326.
Shashi N Kapadia 1 2, Hao Zhang 2, Christopher J Gonzalez 3, Bisakha Sen 4, Ricardo Franco 5, Kayla Hutchings 2, Elaine Wethington 6, Andrew Talal 7, Audrey Lloyd 5, Arpan Dharia 7, Martin Wells 8, Yuhua Bao 2, Martin F Shapiro 3
|
|
|
|
|
|
|
|
|
|
|
136. | The SHELTER Trial of Transplanting Hepatitis C Virus-Infected Lungs Into Uninfected Recipients |
|
Transplant Direct. 2023 Jun 28;9(7):e1504. doi: 10.1097/TXD.0000000000001504.eCollection 2023 Jul.
Peter P Reese 1 2, Joshua M Diamond 3, David S Goldberg 4, Vishnu Potluri 1 2, Stacey Prenner 5, Emily A Blumberg 6, Vivianna M Van Deerlin 7, K Rajender Reddy 5, Heather Mentch 1, Richard Hasz 8, Ashley Woodards 9, Caren Gentile 7, Jennifer Smith 7, Christian Bermudez 10, Maria M Crespo 3
|
|
|
|
|
|
|
|
|
|
|
141. | Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors |
|
Am J Gastroenterol. 2023 Jul 10. doi: 10.14309/ajg.0000000000002361. Online ahead of print.
Marcel Yibirin 1, Khalis Mustafayev 1, Jeff Hosry 1, Pooja Pundhir 1, Joseph Klingen 1, Eduardo Yepez Guevara 1, Bruno P Granwehr 1, Ahmed Kaseb 2, Aung Naing 3, Sapna Patel 4, Amishi Y Shah 5, Ferdinandos Skoulidis 6, Hussein A Tawbi 4, Lan Wang 7, Ethan Miller 7, Hao Chi Zhang 7, Amado Zurita-Saavedra 5, Harrys A Torres 1 7
|
|
|
|
|
|
|
144. | Hepatitis C virus RNA is 5 |
|
Nature. 2023 Jul;619(7971):811-818. doi: 10.1038/s41586-023-06301-3. Epub 2023 Jul 5.
Anna V Sherwood # 1, Lizandro R Rivera-Rangel # 2 3, Line A Ryberg 2 3, Helena S Larsen 2 3, Klara M Anker 1, Rui Costa 2 3, Cathrine B Vågbø 4, Eva Jakljevic 2 3, Long V Pham 2 3, Carlota Fernandez-Antunez 2 3, Gabriele Indrisiunaite 1, Agnieszka Podolska-Charlery 1, Julius E R Grothen 1, Nicklas W Langvad 1, Nicolas Fossat 2 3, Anna Offersgaard 2 3, Amal Al-Chaer 1, Louise Nielsen 2 3, Anna Kusnierczyk 4, Christina Sølund 5 6, Nina Weis 5 6, Judith M Gottwein 2 3, Kenn Holmbeck 2 3, Sandro Bottaro 7, Santseharay Ramirez 2 3, Jens Bukh 8 9, Troels K H Scheel 10 11 12, Jeppe Vinther 13
Nature. 2023 Jul;619(7971):811-818. doi: 10.1038/s41586-023-06301-3. Epub 2023 Jul 5.
Anna V Sherwood # 1, Lizandro R Rivera-Rangel # 2 3, Line A Ryberg 2 3, Helena S Larsen 2 3, Klara M Anker 1, Rui Costa 2 3, Cathrine B Vågbø 4, Eva Jakljevic 2 3, Long V Pham 2 3, Carlota Fernandez-Antunez 2 3, Gabriele Indrisiunaite 1, Agnieszka Podolska-Charlery
|
|
|
145. | Evaluation of Hepatitis C Treatment Outcomes Among Patients Enrolled in Outpatient Parenteral Antibiotic Therapy-Boston, Massachusetts, 2016-2021 |
|
Open Forum Infect Dis. 2023 Jul 5;10(7):ofad342. doi: 10.1093/ofid/ofad342.eCollection 2023 Jul.
Akash Gupta 1 2, Dina Ashour 1, Fatma M Shebl 1, Laura Platt 1 3, John J Chiosi 1 2, Sandra B Nelson 2, Kevin L Ard 2, Arthur Y Kim 2, Ingrid V Bassett 1 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
158. | Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection |
|
Addict Dis. 2023 Jul-Sep;41(3):213-224.doi: 10.1080/10550887.2022.2088978. Epub 2022 Aug 3.
Olav Dalgard 1, Alain H Litwin 2, Oren Shibolet 3, Jason Grebely 4, Ronald Nahass 5, Frederick L Altice 6, Brian Conway 7, Edward J Gane 8, Anne F Luetkemeyer 9, Cheng-Yuan Peng 10, David Iser 11, Isaias Noel Gendrano 12, Michelle M Kelly 12, Barbara A Haber 12, Heather Platt 12, Amy Puenpatom 12; CO-STAR Investigators
|
|
|
159. | Preemptive antiviral therapy in lung transplantation from hepatitis C donors results in a rapid and sustained virologic response |
|
JTCVS Open. 2023 Mar 10;14:602-614. doi: 10.1016/j.xjon.2023.02.014.eCollection 2023 Jun.
Mauricio A Villavicencio 1, Selena S Li 2, Ann Marie Leifer 2, Jenna L Gustafson 3, Asishana Osho 2, Stanley Wolfe 2, Yuval Raz 4, Jason Griffith 4, Isabel Neuringer 4, Emily Bethea 3, Thais Gift 5, Georgina Waldman 5, Todd Astor 4, Nathaniel B Langer 2, Raymond T Chung 3
|
|
|
|
|
|
|
|
|
163. | Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis |
|
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):533-552.doi: 10.1016/S2468-1253(23)00018-3. Epub 2023 Mar 27.
Adelina Artenie 1, Jack Stone 2, Hannah Fraser 2, Daniel Stewart 3, Chiedozie Arum 4, Aaron G Lim 2, Anna L McNaughton 2, Adam Trickey 2, Zoe Ward 2, Daniela Abramovitz 5, Michel Alary 6, Jacquie Astemborski 7, Julie Bruneau 8, Steven J Clipman 9, Carla S Coffin 10, Sara Croxford 11, Kora DeBeck 12, Eva Emanuel 13, Kanna Hayashi 14, Joumana G Hermez 15, Daniel Low-Beer 16, Niklas Luhmann 16, Gisela Macphail 17, Lisa Maher 18, Norah E Palmateer 19, Eshan U Patel 20, Rachel Sacks-Davis 21, Wijnand Van Den Boom 22, Daniela K van Santen 23, Josephine G Walker 24, Matthew Hickman 2, Peter Vickerman 2; HIV and HCV Incidence Review Collaborative Group
Collaborators
- HIV and HCV Incidence Review Collaborative Group:
Malvina Aladashvili, Tasnim Azim, Paul Dietze, Kostyantyn Dumchev, Jennifer R Havens, Margaret Hellard, Sharon Hutchinson, Jennifer Iversen, Ali Judd, Martin Kåberg, Ann E Kurth, Shruti H Mehta, Viktor Mravcík, Maria Prins, Sunil S Solomon, Steffanie A Strathdee, Vana Sypsa, Catherine S Todd, Jorge Valencia, Ernst Wisse
|
|
|
164. | Large-Scale, Primary Care-Based Hepatitis C Treatment in an Urban, Medically Underserved Patient Population |
|
Public Health Rep. 2023 May 26;333549231170205. doi: 10.1177/00333549231170205.Online ahead of print.
Shelly-Ann Fluker 1, Rapheisha Darby 2, Kathryn McDaniel 3, Kristi Quairoli 3, Collins Mbonu 1, Sindhu Kilakkathi 1, Sarah Koumtouzoua 1, Ram Jagannathan 4, Lesley S Miller 1
|
|
|
|
|
166. | Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment |
|
J Infect Dis. 2023 May 29;227(11):1274-1281. doi: 10.1093/infdis/jiac315.
Annelys Roque Gardner 1, Yifei Ma 2, Peter Bacchetti 3, Jennifer C Price 2, Mark H Kuniholm 4, Audrey L French 5, Stephen Gange 6, Adaora A Adimora 7, Howard Minkoff 8, Seble Kassaye 9, Igho Ofotokun 1, William Rosenberg 10, Andrea A Z Kovacs 11, Phyllis C Tien 2 12
|
|
|
167. | Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study - a prospective single-arm intervention trial |
|
Pilot Feasibility Stud. 2023 May 8;9(1):78. doi: 10.1186/s40814-023-01311-4.
Anmol Desai 1, Lauren O'Neal 2, Kia Reinis 1, Patrick Chang 1, Cristal Brown 3 4, Michael Stefanowicz 1 4, Audrey Kuang 1 3 4, Deepak Agrawal 3, Darlene Bhavnani 1, Tim Mercer 5 6 7
|
|
|
|
|
|
|
170. | Development of a Patient Activation Toolkit for Hepatitis C Virus Testing |
|
J Cancer Educ. 2023 Jun;38(3):931-939. doi: 10.1007/s13187-022-02209-0. Epub 2022 Aug 16.
Jessica Rivera Rivera 1, Lindsay N Fuzzell 2, Jennifer Garcia 2, Julie Rathwell 3 4, Edmondo J Robinson 2 5, Melody Chavez 2, Hayden Fulton 2, Ashley Whitmer 2, Ebin Mathew 2, Anna R Giuliano 3 4, Susan T Vadaparampil 6
|
|
|
|
|
|
|
|
|
|
|
|
|
176. | Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-Analysis |
|
Am J Prev Med. 2023 Jun 26;S0749-3797(23)00278-7.doi: 10.1016/j.amepre.2023.06.016. Online ahead of print.
Pilar Hernandez-Con 1, Debbie L Wilson 1, Huilin Tang 1, Ikenna Unigwe 1, Munaza Riaz 2, Natalie Ourhaan 1, Xinyi Jiang 1, Hyun Jin Song 1, Amanda Joseph 1, Linda Henry 1, Robert Cook 3, Dushyantha Jayaweera 4, Haesuk Park 5
|
|
|
|
|
|
|
|
|
|
|
|
|
182. | Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study |
|
Drug Alcohol Rev. 2023 May 30. doi: 10.1111/dar.13688. Online ahead of print.
Heather Valerio 1, Maryam Alavi 1, Alison D Marshall 1 2, Behzad Hajarizadeh 1, Janaki Amin 1 3, Matthew Law 1, Shane Tillakeratne 1, Jacob George 4, Louisa Degenhardt 5, Jason Grebely 1, Gail V Matthews 1, Gregory J Dore 1
|
|
|
183. | Prevalence of Testing for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among Medicaid Enrollees Treated With Medications for Opioid Use Disorder in 11 States, 2016-2019 |
|
Clin Infect Dis. 2023 May 24;76(10):1793-1801. doi: 10.1093/cid/ciac981.
Katherine Ahrens 1, Michael Sharbaugh 2, Marian P Jarlenski 2, Lu Tang 3, Lindsay Allen 4, Anna E Austin 5, Andrew J Barnes 6, Marguerite E Burns 7, Sarah Clark 8, Kara Zivin 9, Aimee Mack 10, Gilbert Liu 10, Shamis Mohamoud 11, Mary Joan McDuffie 12, Lindsey Hammerslag 13, Adam J Gordon 14 15, Julie M Donohue 2; Writing Committee for Medicaid Outcomes Distributed Research Network
|
|
|
|
|
|
|
|
|
|
|
188. | Impact of Hepatitis C cure on risk of mortality and morbidity in people with HIV after ART initiation |
|
2023 May 10. doi: 10.1097/QAD.0000000000003594. Online ahead of print.
Mathieu Chalouni 1 2, Adam Trickey 3, Suzanne M Ingle 3, Maria Antonia Sepuvelda 4, Juan Gonzalez 5, Andri Rauch 6, Heidi M Crane 7, M John Gill 8, Peter F Rebeiro 9, Jürgen K Rockstroh 10, Ricardo A Franco 11, Giota Touloumi 12, Didier Neau 13, Montserrat Laguno 14, Michaela Rappold 15 16, Colette Smit 17, Jonathan Ac Sterne 3, Linda Wittkop 1 2 18; Antiretroviral Therapy Cohort Collaboration (ART-CC)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
197. | Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs |
|
Drug Alcohol Depend. 2023 Jun 1;247:109878.doi: 10.1016/j.drugalcdep.2023.109878. Epub 2023 Apr 17.
Judith I Tsui 1, Paula J Lum 2, Lynn E Taylor 3, Shruti H Mehta 4, Judith Feinberg 5, Arthur Y Kim 6, Brianna L Norton 7, Jiajing Niu 8, Moonseong Heo 8, Julia Arnsten 7, Irene Pericot-Valverde 9, Aurielle Thomas 10, Kendra L Blalock 11, Andrea Radick 11, Cristina Murray-Krezan 12, Kimberly Page 13, Alain H Litwin 14; HERO Study Group
|
|
|
198. | The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis |
|
J Viral Hepat. 2023 May;30(5):448-454. doi: 10.1111/jvh.13814.Epub 2023 Mar 2.
Ira M Jacobson 1, Stefan Bourgeois 2, Phillipe Mathurin 3, Paul Thuluvath 4, Stephen D Ryder 5, Guido Gerken 6, Candido Hernandez 7, Kim Vanstraelen 7, Stacey Scherbakovsky 8, Anu Osinusi 8, Dana Tedesco 8, Graham R Foster 9
|
|
|
|
|
|
|
|
|
|
|
|
|
204. | Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis |
|
Hepatology. 2023 Apr 1;77(4):1348-1365. doi: 10.1002/hep.32731. Epub 2022 Sep 16.
Dimitri Loureiro 1 2, Issam Tout 1 2, Stéphanie Narguet 1 2, Cheikh Mohamed Bed 1 2, Morgane Roinard 1 2, Ahmad Sleiman 1 2, Nathalie Boyer 1 2, Nathalie Pons-Kerjean 3, Corinne Castelnau 1 2, Nathalie Giuly 1 2, Dorothy Tonui 1 2, Vassili Soumelis 4 5, Jamel El Benna 1, Patrick Soussan 6, Richard Moreau 1 2, Valérie Paradis 1 2, Abdellah Mansouri 1 2, Tarik Asselah 1 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
211. | Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis |
|
Cancer Med. 2023 Apr 20. doi: 10.1002/cam4.5711. Online ahead of print.
Chiara Rocha 1, Erin H Doyle 2, Chip A Bowman 3, M-Isabel Fiel 4, Ashley E Stueck 5, Nicolas Goossens 6, Kian Bichoupan 7, James F Crismale 7, Jasnit Makkar 8, Sara Lewis 9, Ponni V Perumalswami 10, Thomas D Schiano 7, Yujin Hoshida 11, Myron Schwartz 12, Andrea D Branch 7, Neal Patel 13
|
|
|
212. | Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis |
|
Cancer Med. 2023 Apr 20. doi: 10.1002/cam4.5711. Online ahead of print.
Chiara Rocha 1, Erin H Doyle 2, Chip A Bowman 3, M-Isabel Fiel 4, Ashley E Stueck 5, Nicolas Goossens 6, Kian Bichoupan 7, James F Crismale 7, Jasnit Makkar 8, Sara Lewis 9, Ponni V Perumalswami 10, Thomas D Schiano 7, Yujin Hoshida 11, Myron Schwartz 12, Andrea D Branch 7, Neal Patel 13
|
|
|
|
|
|
|
215. | Access to Hepatitis C Treatment during and after Incarceration in New Jersey, United States: A Qualitative Study |
|
Life (Basel). 2023 Apr 17;13(4):1033. doi: 10.3390/life13041033.
Samir Kamat 1, Sankeerth Kondapalli 2, Shumayl Syed 1, Gabrielle Price 1, George Danias 1, Ksenia Gorbenko 1 3, Joel Cantor 4, Pamela Valera 5 6, Aakash K Shah 7, Matthew J Akiyama 8
|
|
|
216. | Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis |
|
Hepatol Commun. 2023 Mar 17;7(4):e0082.doi: 10.1097/HC9.0000000000000082. eCollection 2023 Apr 1.
Lakshmi Manoharan 1, Ned H Latham 1, Stephanie C Munari 1, Michael W Traeger 1 2, Vinay Menon 1, Niklas Luhmann 3, Rachel Baggaley 3, Virginia Macdonald 3, Annette Verster 3, Nandi Siegfried 4, Gail V Matthews 5, Mark Stoové 1 2, Margaret E Hellard 1 2 6 7, Joseph S Doyle 1 2 6
|
|
|
|
|
|
|
219. | Elimination of hepatitis C virus in a prison: An 18-year experience |
|
Enferm Infecc Microbiol Clin (Engl Ed). 2023 Apr 26;S2529-993X(23)00128-4.doi: 10.1016/j.eimce.2023.04.015. Online ahead of print.
Maite Nogales-Garcia 1, Naiara Parraza Diez 2, Andoni Vargas Axpe 3, Rafael Velasco Garcia 3, Ane Larrabeiti-Etxebarria 4, Ignacio Roy Lopez-Cano 3, Inmaculada Atrio Alvarez 3, Asier Lopez de Arcaute Trincado 3, Eva María Fernandez Lopez de Vicuña 1, Ester Saez de Adana Arroniz 4, Carlos Martínez Martínez 4, Joseba Portu Zapirain 5
|
|
|
|
|
|
|
|
|
|
|
|
|
225. | Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK |
|
Liver Int. 2023 Apr;43(4):917-927. doi: 10.1111/liv.15528. Epub 2023 Feb 20.
Victoria Hamill 1 2, Will Gelson 3, Douglas MacDonald 4, Paul Richardson 5, Stephen D Ryder 6, Mark Aldersley 7, Stuart McPherson 8, Sumita Verma 9 10, Rohini Sharma 11, Sharon Hutchinson 1 2, Jennifer Benselin 6, Eleanor Barnes 12, Indra Neil Guha 6 13, William L Irving 6, Hamish Innes 1 2 14
|
|
|
|
|
|
|
|
|
229. | Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment |
|
Clin Infect Dis. 2023 Mar 4;76(5):913-991. doi: 10.1093/cid/ciac255.
A E Ades 1, Fabiana Gordon 1, Karen Scott 2, Intira Jeannie Collins 2, Claire Thorne 3, Lucy Pembrey 4, Elizabeth Chappell 2, Eugènia Mariné-Barjoan 5, Karina Butler 6, Giuseppe Indolfi 7, Diana M Gibb 2, Ali Judd 2
|
|
|
230. | Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy |
|
J Virus Erad. 2023 Mar 2;9(1):100319. doi: 10.1016/j.jve.2023.100319. eCollection 2023 Mar.
M Schwarz 1 2 3, C Schwarz 1 2 3, A Schütz 4, C Schwanke 4, E Krabb 4, R Schubert 4, S-T Liebich 4, D Bauer 1 2 3, L Burghart 1 2 3, L Brinkmann 1 2 3, E Gutic 1, T Reiberger 2 3, H Haltmayer 4, M Gschwantler 1 5
|
|
|
231. | Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO-PLUS study |
|
J Viral Hepat. 2023 May;30(5):397-405. doi: 10.1111/jvh.13807. Epub 2023 Feb 13.
Norah A Terrault 1 2, Jennifer Slepin 1, Rachel Kanner 1, Keri Gailloux 1, Lisa Catalli 1, Jeff McKinney 1, Stephanie Straley 1, Portia Morris 3, Rebecca Hluhanich 4, Alicia Gonzalez-Flores 5, Jennifer Dodge 2 6, Souvik Sarkar 7 8
|
|
|
|
|
|
|
234. | Hepatitis C Virus Micro-elimination Among People With HIV in San Diego: Are We on Track? |
|
Open Forum Infect Dis. 2023 Mar 22;10(4):ofad153. doi: 10.1093/ofid/ofad153.eCollection 2023 Apr.
Jaskaran S Cheema 1, William C Mathews 1, Adriane Wynn 1, Laura B Bamford 1, Francesca J Torriani 1, Lucas A Hill 1, Amutha V Rajagopal 1, Jeffrey Yin 1, Sonia Jain 2, Richard S Garfein 1, Edward R Cachay 1, Natasha K Martin 1 3
|
|
|
|
|
236. | Overall Vertical Transmission of Hepatitis C Virus, Transmission Net of Clearance, and Timing of Transmission |
|
Clin Infect Dis. 2023 Mar 4;76(5):905-912. doi: 10.1093/cid/ciac270.
Anthony E Ades 1, Fabiana Gordon 1, Karen Scott 2, Intira J Collins 2, Thorne Claire 3, Lucy Pembrey 4, Elizabeth Chappell 2, Eugènia Mariné-Barjoan 5, Karina Butler 6, Giuseppe Indolfi 7, Diana M Gibb 2, Ali Judd 2
|
|
|
237. | Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals |
|
J Viral Hepat. 2023 Mar 5. doi: 10.1111/jvh.13826. Online ahead of print.
Ranya Selim 1, Stuart C Gordon 1 2, Yueren Zhou 3, Talan Zhang 4, Mei Lu 4, Yihe G Daida 5, Joseph A Boscarino 6, Mark A Schmidt 7, Sheri Trudeau 4, Loralee B Rupp 8, Humberto C Gonzalez 1 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
246. | Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility |
|
Med J Aust. 2023 Mar 14. doi: 10.5694/mja2.51885. Online ahead of print.
Michael B MacIsaac 1 2, Bradley Whitton 1, Adrian Hubble 1, Shelley Cogger 3, Matthew Penn 3, Anthony Weeks 3, Kasey Elmore 3, David Pemberton 3, Jenine Anderson 3, Rebecca Howard 1, Una McKeever 1, Timothy Papaluca 1 2, Margaret E Hellard 4 5 6, Mark Stoove 4 5, David Wilson 4, Alisa Pedrana 4 5, Joseph Doyle 4 6, Nico Clark 3 7, Jacinta Holmes 1 2, Alexander J Thompson 1 2
|
|
|
|
|
|
|
|
|
250. | Global reporting of progress towards elimination of hepatitis B and hepatitis C |
|
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7.Epub 2023 Feb 8.
Fuqiang Cui 1, Sarah Blach 2, Casimir Manzengo Mingiedi 3, Monica Alonso Gonzalez 4, Ahmed Sabry Alaama 5, Antons Mozalevskis 6, Nicole Séguy 6, Bharat Bhushan Rewari 7, Po-Lin Chan 8, Linh-Vi Le 8, Meg Doherty 9, Niklas Luhmann 9, Philippa Easterbrook 9, Mae Dirac 10, Catherine de Martel 11, Shevanthi Nayagam 12, Timothy B Hallett 12, Peter Vickerman 13, Homie Razavi 2, Olufunmiayo Lesi 9, Daniel Low-Beer 14
|
|
|
|
|
252. | Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study) |
|
Clin Infect Dis. 2023 Feb 8;76(3):e607-e612. doi: 10.1093/cid/ciac680.
Malte B Monin 1 2, Patrick Ingiliz 3, Thomas Lutz 4, Stefan Scholten 5, Christiane Cordes 6, Maria Martínez-Rebollar 7, Christoph D Spinner 8, Mark Nelson 9, Michael Rausch 10, Sanjay Bhagani 11, Lars Peters 12, Thomas Reiberger 13, Stefan Mauss 14, Jürgen K Rockstroh 1 2 15, Christoph Boesecke 1 2 15; PROBE-C study group
|
|
|
|
|
|
|
|
|
|
|
257. | Evaluation of a pilot emergency department linkage to care program for patients previously diagnosed with Hepatitis C |
|
J Viral Hepat. 2023 Feb;30(2):129-137. doi: 10.1111/jvh.13774. Epub 2022 Dec 8.
Zak Hyde 1, Raúl Roura 1, Danielle Signer 1, Anuj Patel 1, Jacob Cohen 1, Mustapha Saheed 1, Sherilyn Brinkley 2, Risha Irvin 2, Mark S Sulkowski 2, David L Thomas 2, Richard E Rothman 1 2, Yu-Hsiang Hsieh 1
|
|
|
258. | A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019 |
|
Euro Surveill. 2023 Feb;28(6):2200184. doi: 10.2807/1560-7917.ES.2023.28.6.2200184.
Anthony Nardone 1, Lina Nerlander 2, Erika Duffell 2, Marta Valenciano 1, Maria Buti 3, Cristina Marcos-Fosch 3, Tatjana Nemeth-Blažic 4, Odette Popovici 5, Adriana Vince 6, Petruta Violeta Filip 7, Tajana Filipec 8, Mirjana Lana Kosanovic Licina 9, Boris Luksic 10, Diana Nonkovic 11, Corina Silvia Pop 7, Fabiana Radu 7, Irina Teodorescu 12, Adriana Violeta Topan 13
|
|
|
259. | Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study |
|
Int J Drug Policy. 2023 Feb 27;114:103982. doi: 10.1016/j.drugpo.2023.103982.Online ahead of print.
Jason Grebely 1, Rosie Gilliver 2, Tony McNaughton 3, Anna Conway 4, Evan Cunningham 4, Charles Henderson 3, Brett Hadlow 2, Katrina Molloy 2, Anna Doab 2, Shane Tillakeratne 4, Lucy Pepolim 3, Mary Ellen Harrod 3, Gregory J Dore 4, Phillip Read 5
|
|
|
|
|
261. | How the rural risk environment underpins hepatitis C risk: Qualitative findings from rural southern Illinois, United States |
|
Int J Drug Policy. 2023 Feb;112:103930. doi: 10.1016/j.drugpo.2022.103930. Epub 2023 Jan 13.
Suzan M Walters 1, David Frank 2, Marisa Felsher 3, Jessica Jaiswal 4, Scott Fletcher 5, Alex S Bennett 6, Samuel R Friedman 7, Lawrence J Ouellet 8, Danielle C Ompad 2, Wiley Jenkins 9, Mai T Pho 10
|
|
|
262. | Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: A cross-sectional analysis |
|
J Viral Hepat. 2023 Feb;30(2):160-171. doi: 10.1111/jvh.13780. Epub 2022 Dec 20.
Zoë R Greenwald 1 2, Zachary Bouck 1 2, Elizabeth McLean 2, Kate Mason 3, Bernadette Lettner 3, Jennifer Broad 3, Zoë Dodd 4, Tanner Nassau 5, Ayden I Scheim 2 5 6, Dan Werb 2 7 8
|
|
|
|
|
|
|
|
|
266. | Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH) |
|
JHEP Rep. 2022 Oct 28;5(1):100614. doi: 10.1016/j.jhepr.2022.100614. eCollection 2023 Jan.
Fabienne Marcellin 1, Sylvie Brégigeon-Ronot 2, Clémence Ramier 1, Camelia Protopopescu 1, Camille Gilbert 3, Vincent Di Beo 1, Claudine Duvivier 4 5 6 7, Morgane Bureau-Stoltmann 1, Eric Rosenthal 1 8, Linda Wittkop 3 9, Dominique Salmon-Céron 10 11, Patrizia Carrieri 1, Philippe Sogni 11 12 13, Tangui Barré 1; ANRS CO13 HEPAVIH Study Group; Scientific Committee; Clinical Centers (ward: participating physicians); Data collection; Management, statistical analyses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
278. | Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts |
|
BMC Public Health. 2023 Jan 7;23(1):54. doi: 10.1186/s12889-022-14911-1.
Emma Robinson # 1 2, Christopher J Byrne # 3 4 5, James Carberry 1 2, Andrew Radley 2 6, Lewis J Beer 7, Sarah K Inglis 7, Jan Tait 1, Iain Macpherson 2, David Goldberg 8 9, Sharon J Hutchinson 8 9, Matthew Hickman 10, John F Dillon 1 2
|
|
|
|
|
|
|
281. | The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Linkage-to-Care Trial: rationale and design of an emergency department-based randomized clinical trial of linkage-to-care strategies for hepatitis C |
|
Trials. 2023 Jan 27;24(1):63.doi: 10.1186/s13063-022-07018-w.
Sarah E Rowan 1 2, Jason Haukoos 3 4 5, Kevin F Kamis 2, Emily Hopkins 6 7, Stephanie Gravitz 6 7, Carolynn Lyle 6 7, Alia A Al-Tayyib 2 8, Edward M Gardner 1 2, James W Galbraith 9, Yu-Hsiang Hsieh 10, Michael S Lyons 11, Richard E Rothman 10, Douglas A E White 12, Jake R Morgan 13 14, Benjamin P Linas 14 15, Allison L Sabel 16 17, David L Wyles 1; DETECT Hep C Trials Investigators
|
|
|
282. | Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States |
|
Drug Alcohol Depend. 2022 Dec 1;241:109673. doi: 10.1016/j.drugalcdep.2022.109673.Epub 2022 Oct 22.
Po-Hung Chen 1, Karine Yenokyan 2, Anthony T Fojo 3, Heidi E Hutton 4, Catherine R Lesko 2, Mary E McCaul 4, Cui Yang 5, Edward R Cachay 6, Heidi M Crane 7, Jeffrey M Jacobson 8, H Nina Kim 7, Mari M Kitahata 7, Kenneth H Mayer 9, Richard D Moore 10, Sonia Napravnik 11, Michael Saag 12, Bryan Lau 13, Geetanjali Chander 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
289. | Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial |
|
Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1112-1127.doi: 10.1016/S2468-1253(22)00275-8.
Alain H Litwin 1, Paula J Lum 2, Lynn E Taylor 3, Shruti H Mehta 4, Judith I Tsui 5, Judith Feinberg 6, Arthur Y Kim 7, Brianna L Norton 8, Moonseong Heo 9, Julia Arnsten 8, Paul Meissner 10, Alison Karasz 11, M Diane Mckee 11, John W Ward 12, Nirah Johnson 13, Irene Pericot-Valverde 14, Linda Agyemang 8, Ellen S Stein 2, Aurielle Thomas 15, Courtney Borsuk 4, Kendra L Blalock 5, Samuel Wilkinson 16, Katherine Wagner 17, Jillian Roche 7, Cristina Murray-Krezan 18, Jessica Anderson 17, Vanessa Jacobsohn 19, Anne F Luetkemeyer 2, Oluwaseun Falade-Nwulia 20, Kimberly Page 17; HERO Study Group
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
299. | Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease |
|
Kidney Int. 2022 Dec;102(6):1228-1237. doi: 10.1016/j.kint.2022.07.012.
Paul Martin 1, Ahmed A Awan 2, Marina C Berenguer 3, Annette Bruchfeld 4, Fabrizio Fabrizi 5, David S Goldberg 6, Jidong Jia 7, Nassim Kamar 8, Rosmawati Mohamed 9, Mário Guimarães Pessôa 10, Stanislas Pol 11, Meghan E Sise 12, Ethan M Balk 13, Craig E Gordon 14, Gaelen Adam 13, Michael Cheung 15, Amy Earley 15, Michel Jadoul 16
|
|
|
|
|
301. | Hepatitis B and C virus infection in patients with Systemic and Cutaneous Lupus Erythematosus |
|
New Microbiol. 2022 Dec;45(4):296-303.
Alessandra Lo Presti 1, Fulvia Ceccarelli 2, Maria Dorrucci 1, Francesca Farchi 1, Carmelo Pirone 2, Cristina Garufi 2, Catia Valdarchi 1, Francesca Romana Spinelli 2, Cristiano Alessandri 2, Paola Chionne 1, Elisabetta Madonna 1, Giulio Pisani 3, Antonio Martina 3, Matteo Simeoni 3, Roberto Bruni 1, Massimo Ciccozzi 4, Giancarlo Iaiani 5, Anna Rita Ciccaglione 1, Enea Spada 1, Fabrizio Conti 2
|
|
|
302. | HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago |
|
J Public Health (Oxf). 2022 Dec 1;44(4):891-899. doi: 10.1093/pubmed/fdab190.
Sandra Tilmon 1, A Aronsohn 2, B Boodram 3, L Canary 4, S Goel 5, T Hamlish 6, S Kemble 7, D S Lauderdale 8, J Layden 9, K Lee 1, A J Millman 4, N Nelson 4, K Ritger 10, I Rodriguez 1, N Shurupova 11, J Wolf 12, D Johnson 1
|
|
|
|
|
|
|
|
|
306. | Treating Hepatitis C in Individuals With Previous Incarceration: The Veterans Health Administration, 2012-2019 |
|
Am J Public Health. 2022 Dec 8;e1-e4. doi: 10.2105/AJPH.2022.307152. Online ahead of print.
Laura Hawks 1, Emily A Wang 1, Adeel A Butt 1, Stephen Crystal 1, D Keith McInnes 1, Vincent Lo Re 3rd 1, Emily J Cartwright 1, Lisa B Puglisi 1, Lamia Y K Haque 1, Joseph K Lim 1, Amy C Justice 1, Kathleen A McGinnis 1
|
|
|
|
|
308. | Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study |
|
Clin Infect Dis. 2022 Nov 14;75(10):1809-1819. doi: 10.1093/cid/ciac246.
Joanne M Carson 1, Gregory J Dore 1, Andrew R Lloyd 1, Jason Grebely 1, Marianne Byrne 1, Evan Cunningham 1, Janaki Amin 2, Peter Vickerman 3, Natasha K Martin 4, Carla Treloar 5, Marianne Martinello 1, Gail V Matthews 1, Behzad Hajarizadeh 1; Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C) Study Group
|
|
|
309. | Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use |
|
Int J Drug Policy. 2022 Nov 13;111:103906. doi: 10.1016/j.drugpo.2022.103906.Online ahead of print.
Max Spaderna 1, Sarah Kattakuzhy 2, Sun Jung Kang 3, Nivya George 4, Phyllis Bijole 5, Emade Ebah 6, Rahwa Eyasu 6, Onyinyechi Ogbumbadiugha 6, Rachel Silk 6, Catherine Gannon 7, Ashley Davis 6, Amelia Cover 6, Britt Gayle 6, Shivakumar Narayanan 4, Maryland Pao 8, Shayamasundaran Kottilil 6, Elana Rosenthal 6
|
|
|
|
|
|
|
|
|
|
|
314. | Timing of Positive Hepatitis C Virus Test Results During and 1 Year Before Pregnancy |
|
Obstet Gynecol. 2022 Dec 1;140(6):997-999. doi: 10.1097/AOG.0000000000004980.Epub 2022 Nov 2.
Kate R Woodworth 1, Suzanne M Newton, Emily O Olsen, Ayzsa Tannis, Lindsey Sizemore, Heather Wingate, Lauren Orkis, Bethany Reynolds, Nicole Longcore, Nadia Thomas, Angelica Bocour, Aprielle Wills, Shin Y Kim, Lakshmi Panagiotakopoulos, Carolyn Wester, Dana Delman Meaney, Suzanne M Gilboa, Van T Tong
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
323. | Association between Immunologic Markers and Cirrhosis in Individuals from a Prospective Chronic Hepatitis C Cohort |
|
Cancers (Basel). 2022 Oct 27;14(21):5280. doi: 10.3390/cancers14215280.
Ilona Argirion 1, Jalen Brown 1, Sarah Jackson 1, Ruth M Pfeiffer 1, Tram Kim Lam 2, Thomas R O'Brien 1, Kelly J Yu 1, Katherine A McGlynn 1, Jessica L Petrick 3, Ligia A Pinto 4, Chien-Jen Chen 5 6, Allan Hildesheim 1, Hwai-I Yang 5 7 8 9, Mei-Hsuan Lee 7, Jill Koshiol 1
|
|
|
|
|
|
|
|
|
327. | Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection |
|
J Am Heart Assoc. 2022 Oct 4;11(19):e026473.doi: 10.1161/JAHA.122.026473.Epub 2022 Sep 21.
Raynell Lang 1 2, Elizabeth Humes 2, Brenna Hogan 2, Jennifer Lee 2, Ralph D'Agostino 3, Joseph Massaro 4, Arthur Kim 5 6, James B Meigs 6 7, Leila Borowsky 7, Wei He 7, Asya Lyass 3, David Cheng 8, H Nina Kim 9, Marina B Klein 10, Edward R Cachay 11, Ronald J Bosch 12, M John Gill 1, Michael J Silverberg 13, Jennifer E Thorne 14, Kathleen McGinnis 15, Michael A Horberg 16, Timothy R Sterling 17, Virginia A Triant 5 7, Keri N Althoff 2
|
|
|
|
|
|
|
330. | Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study |
|
Int J Drug Policy. 2022 Oct 11;110:103876. doi: 10.1016/j.drugpo.2022.103876.Online ahead of print.
Heather Valerio 1, Anna Conway 2, Maryam Alavi 3, Carla Treloar 4, David Silk 3, Carolyn Murray 5, Charles Henderson 6, Janaki Amin 7, Phillip Read 8, Louisa Degenhardt 9, Michael Christmass 10, Mark Montebello 11, Gregory J Dore 3, Jason Grebely 3, ETHOS Engage Study Group
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
338. | Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection |
|
J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13761. Online ahead of print.
Julia L Casey 1 2, Gregory J Dore 3, Jason Grebely 3, Gail V Matthews 3, Vera Cherepanov 1, Marianne Martinello 3, Philippa Marks 3, Harry L A Janssen 1, Bettina E Hansen 1 4, Rupert Kaul 5 6, Sonya A MacParland 7 8, Adam J Gehring 1 5, Jordan J Feld 1 2
|
|
|
339. | Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort |
|
Front Oncol. 2022 Oct 13;12:983238. doi: 10.3389/fonc.2022.983238. eCollection 2022.
Maryam Darvishian 1 2, Terry Tang 1, Stanley Wong 3, Mawuena Binka 3 4, Amanda Yu 3, Maria Alvarez 3, Héctor Alexander Velásquez García 3, Prince Asumadu Adu 3 4, Dahn Jeong 3 4, Sofia Bartlett 3, Mohammad Karamouzian 3 5 6, Jean Damascene Makuza 3 4, Jason Wong 3, Alnoor Ramji 4, Ryan Woods 1 7, Mel Krajden 3 4, Naveed Janjua 3 4, Parveen Bhatti 1 2
|
|
|
|
|
|
|
342. | Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020) |
|
Int J Drug Policy. 2022 Nov;109:103872. doi: 10.1016/j.drugpo.2022.103872.Epub 2022 Oct 3.
Norah Palmateer 1, Victoria Hamill 2, Anne Bergenstrom 3, Harriet Bloomfield 4, Lara Gordon 5, Jack Stone 5, Hannah Fraser 5, Thomas Seyler 3, Yuejiao Duan 4, Richard Tran 4, Kirsten Trayner 2, Christopher Biggam 2, Shanley Smith 2, Peter Vickerman 5, Matt Hickman 5, Sharon Hutchinson 2
|
|
|
|
|
|
|
345. | Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost? |
|
Can J Gastroenterol Hepatol. 2022 Oct 14;2022:3449938. doi: 10.1155/2022/3449938.eCollection 2022.
David Stephen Prince 1 2 3, Julia Di Girolamo 1 2, Joseph Louis Pipicella 1 2, Melissa Bagatella 1, Tahrima Kayes 1 2, Frank Alvaro 1 4, Michael Maley 1 3 4, Hong Foo 1 4 5, Paul MacConachie Middleton 1 2 3 6 7, Miriam Tania Levy 1 2 3
|
|
|
346. | Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugs |
|
J Subst Abuse Treat. 2022 Sep;140:108768. doi: 10.1016/j.jsat.2022.108768. Epub 2022 Mar 18.
Alison Karasz 1, Reena Singh 2, M Diane McKee 3, Krupa Merchant 4, Arthur Y Kim 5, Kimberly Page 6, Irene Pericot-Valverde 7, Ellen S Stein 8, Lynn E Taylor 9, Katherine Wagner 10, Alain H Litwin 11
|
|
|
347. | Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs |
|
J Viral Hepat. 2022 Oct;29(10):908-918. doi: 10.1111/jvh.13723. Epub 2022 Jul 5.
Michael W Traeger 1 2, Daniela K van Santen 1 2 3, Rachel Sacks-Davis 1 2, Jason Asselin 1, Allison Carter 4 5 6, Joseph S Doyle 1 7, Alisa Pedrana 1 2, Anna L Wilkinson 1 2, Jessica Howell 1 8 9, Rebecca Thatcher 10, John Didlick 11, Basil Donovan 4 12, Rebecca Guy 4, Margaret E Hellard 1 7 13, Mark A Stoové 1 2, Australia Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood Borne Viruses (ACCESS)
|
|
|
|
|
349. | Non-targeted hepatitis C virus screening in acute care healthcare settings in the Southern Appalachian region |
|
J Am Coll Emerg Physicians Open. 2022 Sep 12;3(5):e12819. doi: 10.1002/emp2.12819.eCollection 2022 Oct.
Cody A Chastain 1, Cathy A Jenkins 2, Michelle Rose 3, Daniel Moore 4, Diana Parker 5, Barbra Cave 6, Jane Crowe 7, Sarah Adams 7, Marrieth G Rubio 8, Rachel Potter 9, Kimberly Quedado 10, Ian D Jones 11, Jin H Han 12, Wesley H Self 13
|
|
|
|
|
351. | The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population |
|
Open Forum Infect Dis. 2022 Sep 2;9(9):ofac445. doi: 10.1093/ofid/ofac445.eCollection 2022 Sep.
Nicole D Ferrante 1 2, Craig W Newcomb 2, Kimberly A Forde 3, Charles E Leonard 2 4, Jessie Torgersen 2 5, Benjamin P Linas 6, Sarah E Rowan 7, David L Wyles 7, Jay Kostman 8, Stacey B Trooskin 5 8, Vincent Lo Re 3rd 2 5
|
|
|
|
|
|
|
354. | HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic |
|
J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13746. Online ahead of print.
Lukas Hartl 1 2, Mathias Jachs 1 2, David Bauer 1 2, Benedikt Simbrunner 1 2, David Chromy 1 2 3, Teresa Binter 1 2, Lisa Steininger 1 2, Caroline Schwarz 2 4, Michael Schwarz 2 4, Lukas Burghart 2 4, Robert Strassl 5, Michael Trauner 1, Michael Gschwantler 4, Mattias Mandorfer 1 2, Thomas Reiberger 1 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
370. | Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection |
|
J Viral Hepat. 2022 Aug;29(8):646-653. doi: 10.1111/jvh.13701.Epub 2022 May 26.
Lewis Beer 1, Sarah Inglis 1, Amy Malaguti 2, Christopher Byrne 1 3, Christian Sharkey 4, Emma Robinson 3 4, Kirsty Gillings 5, Andrew Radley 6, Adrian Hapca 1, Brian Stephens 4, John Dillon 3 4
|
|
|
|
|
|
|
373. | Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study |
|
Ann Intern Med. 2022 Sep;175(9):1221-1229. doi: 10.7326/M21-4119. Epub 2022 Aug 9.
Jason Grebely 1, Gregory J Dore 1, Frederick L Altice 2, Brian Conway 3, Alain H Litwin 4, Brianna L Norton 4, Olav Dalgard 5, Edward J Gane 6, Oren Shibolet 7, Ronald Nahass 8, Anne F Luetkemeyer 9, Cheng-Yuan Peng 10, David Iser 11, Isaias Noel Gendrano 12, Michelle M Kelly 12, Peggy Hwang 12, Ernest Asante-Appiah 12, Barbara A Haber 12, Eliav Barr 12, Michael N Robertson 12, Heather Platt 12
|
|
|
|
|
|
|
|
|
377. | Hepatitis C virus infection preceding an outbreak of HIV among persons who inject drugs- Kanawha County, West Virginia, 2019-2021 |
|
Clin Infect Dis. 2022 Jul 29;ciac619. doi: 10.1093/cid/ciac619. Online ahead of print.
Alana G Hudson 1, Robert A Bonacci 2 3, Anne C Moorman 4, McKenna Penley 5 6, Suzanne M Wilson 1, Jessica L Hoffman 1, Erica R Thomasson 7 8, R Paul McClung 3, Danae Bixler 4
|
|
|
|
|
379. | Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK Study |
|
Open Forum Infect Dis. 2022 Jul 28;9(8):ofac350. doi: 10.1093/ofid/ofac350.eCollection 2022 Aug.
Timothy Papaluca 1, Anne Craigie 1, Lucy McDonald 1, Amy Edwards 1, Rebecca Winter 1, Annabelle Hoang 1, Alex Pappas 1, Aoife Waldron 1, Kelsey McCoy 1, Mark Stoove 2, Joseph Doyle 2, Margaret Hellard 2, Jacinta Holmes 1, Michael MacIsaac 1, Paul Desmond 1, David Iser 1, Alexander J Thompson 1
|
|
|
|
|
|
|
|
|
|
|
|
|
385. | A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study |
|
Viruses. 2022 Jul 16;14(7):1555. doi: 10.3390/v14071555.
Anna Conway 1 2, Heather Valerio 1, Maryam Alavi 1, David Silk 1, Carla Treloar 2, Behzad Hajarizadeh 1, Alison D Marshall 1 2, Marianne Martinello 1, Andrew Milat 3, Adrian Dunlop 4 5, Carolyn Murray 6, Bianca Prain 6, Charles Henderson 7, Janaki Amin 8, Phillip Read 9, Pip Marks 1, Louisa Degenhardt 10, Jeremy Hayllar 11, David Reid 12, Carla Gorton 13, Thao Lam 14, Michael Christmass 15 16, Alexandra Wade 17 18, Mark Montebello 19, Gregory J Dore 1, Jason Grebely 1, ETHOS Engage Study Group
|
|
|
386. | LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients |
|
Biomark Med. 2022 Aug;16(11):839-846. doi: 10.2217/bmm-2021-0596. Epub 2022 Jul 5.
Akif Altinbas 1, Jacinta A Holmes 1, Shadi Salloum 1, Anna Lidofsky 1, Nadia Alatrakchi 1, Ma Somsouk 2, Peter Hunt 2, Steven Deeks 2, Kara W Chew 3, Georg Lauer 1, Annie Kruger 1, Wenyu Lin 1, Raymond T Chung 1
|
|
|
|
|
|
|
|
|
390. | VirA+EmiC project: Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department |
|
J Viral Hepat. 2022 Jul;29(7):559-568. doi: 10.1111/jvh.13676. Epub 2022 Apr 9.
Gaia Nebbia 1, Murad Ruf 2, Laura Hunter 3, Sooria Balasegaram 4, Terry Wong 5, Ranjababu Kulasegaram 6, Julian Surey 7 8, Zana Khan 9, Jack Williams 10, Basel Karo 11, Luke Snell 1, Barnaby Flower 12, Hannah Evans 4 13, Sam Douthwaite 1
|
|
|
|
|
392. | Sex-Specific Risk Factors and Health Disparity Among Hepatitis C Positive Patients Receiving Pharmacotherapy for Opioid Use Disorder: Findings From a Propensity Matched Analysis |
|
J Addict Med. 2022 Jul-Aug;16(4):e248-e256. doi: 10.1097/ADM.0000000000000937.Epub 2021 Nov 18.
Brittany B Dennis 1, Leslie J Martin, Leen Naji, Daud Akhtar, George Cholankeril, Donghee Kim, Nitika Sanger, Alannah Hillmer, Caroul Chawar, Alessia D'Elia, Balpreet Panesar, Andrew Worster, David C Marsh, Tim O'Shea, Monica Bawor, Lehana Thabane, Zainab Samaan, Aijaz Ahmed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399. | Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, Canada |
|
Liver Int. 2022 Jul;42(7):1528-1535. doi: 10.1111/liv.15237. Epub 2022 Mar 28.
Kyle A Thompson 1, Gabriel Blank 2, Junine Toy 1, David M Moore 1 2, Nathan Lachowsky 3, Nicanor Bacani 1, Wendy Zhang 1, Paul Sereda 1, Viviane D Lima 1 2, Rolando Barrios 1, Julio S G Montaner 1 2, Mark W Hull 1 2
|
|
|
400. | Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R) |
|
Viruses. 2022 Jul 14;14(7):1541. doi: 10.3390/v14071541.
Markus Cornberg 1, Albrecht Stoehr 2, Uwe Naumann 3, Gerlinde Teuber 4, Hartwig Klinker 5, Thomas Lutz 6, Hjördis Möller 7, Dennis Hidde 8, Kristina Lohmann 8, Karl-Georg Simon 9
|
|
|
|
|
|
|
|
|
404. | Hepatitis C virus (HCV) seroprevalence, RNA detection, and genotype distribution across Florida, 2015-2018 |
|
Prev Med. 2022 Aug;161:107136. doi: 10.1016/j.ypmed.2022.107136. Epub 2022 Jul 5.
Brittney L Dickey 1, Anna E Coghill 1, Julie A Rathwell 1, Richard R Reich 2, Susan T Vadaparampil 3, Shannon M Christy 4, Richard Roetzheim 5, Elizabeth Shenkman 6, Anna R Giuliano 7
|
|
|
|
|
406. | Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication |
|
J Hepatol. 2022 Jul;77(1):55-62. doi: 10.1016/j.jhep.2022.01.027. Epub 2022 Feb 12.
Peter P Mueller 1, Qiushi Chen 2, Turgay Ayer 3, Gizem S Nemutlu 1, Ali Hajjar 1, Emily D Bethea 4, Mary Linton B Peters 5, Brian P Lee 6, Naveed Z Janjua 7, Fasiha Kanwal 8, Jagpreet Chhatwal 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
414. | Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV |
|
HIV Med. 2022 Jul;23(6):620-628. doi: 10.1111/hiv.13218. Epub 2021 Dec 23.
Sarah J Willis 1, H Nina Kim 2, Chad J Achenbach 3, Edward R Cachay 4, Katerina A Christopoulos 5, Heidi M Crane 2, Ricardo A Franco 6, Christopher B Hurt 7, Mari M Kitahata 2, Richard D Moore 8, Michael J Silverberg 9, Phyllis C Tien 5 10, Daniel Westreich 11, Julia L Marcus 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
422. | Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression |
|
Lancet HIV. 2022 Jun;9(6):e414-e427.doi: 10.1016/S2352-3018(22)00077-7.
Samira Hosseini-Hooshyar 1, Behzad Hajarizadeh 2, Sahar Bajis 2, Matthew Law 2, Naveed Z Janjua 3, Daniel S Fierer 4, David Chromy 5, Jürgen K Rockstroh 6, Thomas C S Martin 7, Patrick Ingiliz 8, Chien-Ching Hung 9, Gregory J Dore 2, Marianne Martinello 2, Gail V Matthews 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
433. | Hepatitis C Virus Reflex Testing Protocol in an Emergency Department |
|
West J Emerg Med. 2022 Feb 28;23(2):108-114. doi: 10.5811/westjem.2021.10.52468.
Jacob J Manteuffel 1, Madison S Lee 1, Rebecca M Bussa 1, Noor L Sabagha 1, Kaleem Chaudhry 1, Jacob E Ross 1, Megan R Cook 1, Jo-Ann K Rammal 1, Karthik Sridasyam 1, Howard A Klausner 1, Linoj P Samuel 2, Joseph B Miller 1
|
|
|
434. | Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study |
|
Eur J Neurol. 2022 Feb;29(2):400-412. doi: 10.1111/ene.15138. Epub 2021 Nov 2.
Luis Ibáñez-Samaniego 1 2 3, Marta Rapado-Castro 4 5 6, Lucia Cabrero 2 3, Cristina Navarrete 1, Seila García-Mulas 1, Adriana Ahumada 1, Laura Marquez 1, Maria Dolores Pérez 1, Diego Rincon 1 2 3 6, Rafael Bañares 1 2 3 6, Rita Garcia-Martinez 2 3 6 7
|
|
|
|
|
|
|
|
|
|
|
|
|
440. | Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice |
|
World J Gastroenterol. 2022 Mar 28;28(12):1226-1238.doi: 10.3748/wjg.v28.i12.1226.
Nadia Marascio 1, Salvatore Rotundo 2, Angela Quirino 1, Giovanni Matera 1, Maria Carla Liberto 1, Chiara Costa 2, Alessandro Russo 2, Enrico Maria Trecarichi 2, Carlo Torti 3
|
|
|
|
|
|
|
443. | Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial |
|
Aliment Pharmacol Ther. 2022 Jun;55(12):1512-1523.doi: 10.1111/apt.16953. Epub 2022 May 10.
Christopher J Byrne 1 2, Andrew Radley 3, Sarah K Inglis 2, Lewis Beer 2, Nicki Palmer 4, Minh Duc Pham 5 6, Kate Allardice 6, Huan Wang 7, Emma Robinson 8, Monika Hermansson 9, Dimitri Semizarov 9, Brendan Healy 4, Joseph S Doyle 5 6, John F Dillon 1 8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
450. | Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use |
|
Antimicrob Chemother. 2022 Apr 27;77(5):1396-1403.doi: 10.1093/jac/dkac051.
Kristina M Brooks 1, Jose R Castillo-Mancilla 2, Mary Morrow 3, Samantha Mawhinney 3, Sarah E Rowan 2 4, David Wyles 2 4, Joshua Blum 4, Ryan Huntley 1, Lana Salah 1, Arya Tehrani 1, Leah C Jimmerson 1, Laura Roon 1, Lane R Bushman 1, Peter L Anderson 1, Jennifer J Kiser 1
|
|
|
|
|
|
|
453. | A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial |
|
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):307-317.doi: 10.1016/S2468-1253(21)00397-6. Epub 2022 Jan 10.
Sunil S Solomon 1, Sandra Wagner-Cardoso 2, Laura Smeaton 3, Leonard A Sowah 4, Chanelle Wimbish 5, Gregory Robbins 6, Irena Brates 3, Christine Scello 7, Annie Son 8, Anchalee Avihingsanon 9, Benjamin Linas 10, Donald Anthony 11, Estevão Portela Nunes 2, Dimas A Kliemann 12, Khuanchai Supparatpinyo 13, Cissy Kityo 14, Pablo Tebas 15, Jaclyn Ann Bennet 16, Jorge Santana-Bagur 17, Constance A Benson 18, Marije Van Schalkwyk 19, Nelson Cheinquer 8, Susanna Naggie 20, David Wyles 21, Mark Sulkowski 22
|
|
|
|
|
455. | Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response |
|
Clin Gastroenterol Hepatol. 2022 Feb;20(2):438-446.doi: 10.1016/j.cgh.2021.01.026. Epub 2021 Jan 22.
Zobair M Younossi 1, Andrei Racila 2, Andrew Muir 3, Marc Bourliere 4, Alessandra Mangia 5, Rafael Esteban 6, Stefan Zeuzem 7, Massimo Colombo 8, Michael Manns 9, George V Papatheodoridis 10, Maria Buti 6, Anand Chokkalingam 11, Anuj Gaggar 11, Fatema Nader 12, Issah Younossi 12, Linda Henry 12, Maria Stepanova 12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
467. | Individualized Provider Feedback Increased HIV and HCV Screening and Identification in a New York City Emergency Department |
|
AIDS Patient Care STDS. 2022 Mar;36(3):106-114. doi: 10.1089/apc.2021.0225.
Jason Zucker 1, Lawrence Purpura 1 2, Fereshteh Sani 3, Simian Huang 1, Aaron Schluger 4, Kenneth Ruperto 5, Jacek Slowkowski 5, Susan Olender 1, Matt Scherer 1, Delivette Castor 1, Peter Gordon 1
|
|
|
|
|
469. | A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study |
|
Hepatology. 2021 Dec;74(6):2952-2964.doi: 10.1002/hep.32053.Epub 2021 Aug 26.
Mark S Sulkowski 1, Juhi S Moon 1, Kenneth E Sherman 2, Giuseppe Morelli 3, Jama M Darling 4, Andrew J Muir 5, Mandana Khalili 6, Dawn A Fishbein 7, Federico Hinestrosa 8, Mitchell L Shiffman 9, Adrian Di Bisceglie 10, K Rajender Reddy 11, Brian Pearlman 12, Anna S Lok 13, Michael W Fried 4, Paul W Stewart 14, Joy Peter 3, Summer Wadsworth 15, Scott Kixmiller 16, Anquenette Sloan 17, Monika Vainorius 4, Patrick M Horne 3, Larry Michael 14, Meichen Dong 14, Donna M Evon 4, Jodi B Segal 18, David R Nelson 3, PRIORITIZE Study Team
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
476. | Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination |
|
Liver Int. 2022 Feb 27. doi: 10.1111/liv.15216. Online ahead of print.
Roberta D'Ambrosio 1, Giuliano Rizzardini 2, Massimo Puoti 3, Stefano Fagiuoli 4, Maria Paola Anolli 1, Claudia Gabiati 5, Federico D'Amico 3, Luisa Pasulo 4, Umberto Restelli 6 7, Massimo Colombo 8, Pietro Lampertico 1 9
|
|
|
|
|
|
|
479. | Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study |
|
Liver Int. 2022 Feb 26. doi: 10.1111/liv.15211. Online ahead of print.
Fred Poordad 1, Franco Felizarta 2, Betty B Yao 3, J Scott Overcash 4, Tarek Hassanein 5, Kosh Agarwal 6, Edward Gane 7, David Shaw 8, Michael Waters 4, Preethi Krishnan 3, Andrew Topp 3, Margaret Burroughs 3, Frederik Nevens 9
|
|
|
|
|
|
|
|
|
483. | Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist |
|
J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661. Online ahead of print.
Lauren D Nephew 1 2, Yumin Wang 3, Kawthar Mohamed 4, Deborah Nichols 5, Susan M Rawl 2 6, Eric Orman 1, Archita P Desai 1, Kavish R Patidar 1, Marwan Ghabril 1, Naga Chalasani 1, Monica L Kasting 2 7
|
|
|
|
|
485. | Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy |
|
PLoS One. 2022 Mar 23;17(3):e0265811. doi: 10.1371/journal.pone.0265811. eCollection 2022.
Kiana Yazdani 1, Katerina Dolguikh 1, Wendy Zhang 1, Sara Shayegi-Nik 1 2, Jessica Ly 1, Shaughna Cooper 1, Jason Trigg 1, Sophia Bartlett 3 4, Rolando Barrios 1 3, Julio S G Montaner 1, Kate Salters 1 5
|
|
|
|
|
|
|
488. | The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study |
|
J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664. Online ahead of print.
Jessica Howell 1 2 3 4, Michael W Traeger 1 2, Bridget Williams 1, Chloe Layton 5, Joseph S Doyle 1 6, Ned Latham 1 7, Bridget Draper 1 2, Frances Bramwell 5, Dean Membrey 5, Maggie Mcpherson 8, Janine Roney 9, Mark Stoové 1, Alexander J Thompson 3 4, Margaret E Hellard 1 2 6 10, Alisa Pedrana 1 2
|
|
|
489. | Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis |
|
Lancet Gastroenterol Hepatol. 2022 Mar 15;S2468-1253(21)00471-4.doi: 10.1016/S2468-1253(21)00471-4. Online ahead of print.
Evan B Cunningham 1, Alice Wheeler 2, Behzad Hajarizadeh 2, Clare E French 3, Rachel Roche 4, Alison D Marshall 5, Guillaume Fontaine 6, Anna Conway 5, Braulio M Valencia 2, Sahar Bajis 2, Justin Presseau 7, John W Ward 8, Louisa Degenhardt 9, Gregory J Dore 2, Matthew Hickman 10, Peter Vickerman 10, Jason Grebely 2
|
|
|
|
|
|
|
492. | Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset |
|
J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672. Online ahead of print.
Jake R Morgan 1, Elizabeth Marsh 2, Alexandra Savinkina 2, Sonjelle Shilton 3, Shaun Shadaker 4, Tengiz Tsertsvadze 5, George Kamkamidze 6, Maia Alkhazashvili 7, Tim Morgan 8, Pam Belperio 8, L Backus 8, Waheed Doss 9, Gamal Esmat 9, Mohamed Hassany 9, Aisha Elsharkawy 9, Wafaa Elakel 9, Mai Mehrez 9, Graham R Foster 10, Kinge Wose 11, Kara W Chew 12, Charles S Chasela 13, Ian M Sanne 14, Yin M Thanung 15, Anne Loarec 16, Khawar Aslam 17, Suna Balkan 18, Philippa J Easterbrook 19, Benjamin P Linas 2 20
|
|
|
|
|
|
|
|
|
|
|
497. | Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial |
|
JAMA Netw Open. 2022 Mar 1;5(3):e222427. doi: 10.1001/jamanetworkopen.2022.2427.
Shivan J Mehta 1 2, Jessie Torgersen 1, Dylan S Small 3, Colleen P Mallozzi 4 5, John D McGreevey 3rd 1 4 5, Charles A L Rareshide 1 6, Chalanda N Evans 1 6, Mika Epps 4, David Stabile 4, Christopher K Snider 2 6, Mitesh S Patel 1 3 6 7 8
|
|
|
|
|
499. | Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019 |
|
Epidemiol Infect. 2021 Dec 6;150:e7. doi: 10.1017/S0950268821002624.
Anna Lee Wilkinson 1 2, Alisa Pedrana 1 2, Michael W Traeger 1 2, Jason Asselin 1, Carol El-Hayek 1, Long Nguyen 1, Victoria Polkinghorne 1, Joseph S Doyle 1 3, Alexander J Thompson 4 5, Jessica Howell 1 2 4 5, Nick Scott 1 2, Wayne Dimech 6, Rebecca Guy 7, Margaret Hellard 1 2 3 8, Mark Stoové 1 2, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood-borne viruses AND sexually transmissible infections (ACCESS)
|
|
|
|
|
|
|
|
|
503. | Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial |
|
Clin Infect Dis. 2021 Oct 5;73(7):e2164-e2172. doi: 10.1093/cid/ciaa1500.
Joseph S Doyle 1 2, Daniela K van Santen 1 3, David Iser 2 4, Joe Sasadeusz 2 5, Mark O'Reilly 6, Brendan Harney 1 2, Michael W Traeger 1 3, Janine Roney 2, Julia C Cutts 1, Anna L Bowring 1, Rebecca Winter 1 4, Nick Medland 7, Christopher K Fairley 7, Richard Moore 8, B K Tee 9, Jason Asselin 1, Carol El-Hayek 1, Jennifer F Hoy 2, Gail V Matthews 10, Maria Prins 11 12, Mark A Stoové 1 3, Margaret E Hellard 1 2 3 13
|
|
|
|
|
505. | Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment |
|
Aliment Pharmacol Ther. 2022 Mar 2. doi: 10.1111/apt.16830. Online ahead of print.
Mark Sulkowski 1, Laura E Telep 2, Massimo Colombo 3, Francois Durand 4, K Rajender Reddy 5, Eric Lawitz 6, Marc Bourlière 7 8, Nelson Cheinquer 2, Stacey Scherbakovsky 2, Liyun Ni 2, Lindsey Force 2, Heribert Ramroth 2, Anuj Gaggar 2, Anand P Chokkalingam 2, Meghan E Sise 9
|
|
|
506. | Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation |
|
Intern Med J. 2021 Nov;51(11):1927-1934. doi: 10.1111/imj.15037. Epub 2021 Oct 28.
James Haridy 1 2 3, Guru Iyngkaran 1 2 4, Amanda Nicoll 1 3 5, Kate Muller 6, Mark Wilson 7, Alan Wigg 6, Jeyamani Ramachandran 6, Renjy Nelson 8 9, Stephen Bloom 3 5, Joseph Sasadeusz 10, Sally Watkinson 10, Anton Colman 11, Rosalie Altus 6, Emma Tilley 6, Jeffrey Stewart 6 9, Geoff Hebbard 2, Danny Liew 12, Edmund Tse 8 11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
515. | Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection |
|
Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393. Online ahead of print.
Guiseppe Indolfi 1, Deirdre Kelly 2, Gabriella Nebbia 3, Raffaele Iorio 4, Anna Mania 5, Vania Giacomet 6, Leszek Szenborn 7, Jiang Shao 8, Mun Sang Yue 8, Chia-Hsiang Hsueh 8, Bandita Parhy 8, Kathryn Kersey 8, Alessandra Mangia 9, Malgorzata Pawlowska 10, Sanjay Bansal 11
|
|
|
|
|
|
|
|
|
519. | Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018) |
|
Clin Infect Dis. 2022 Feb 11;ciac124. doi: 10.1093/cid/ciac124. Online ahead of print.
Stuart C Gordon 1, Eyasu H Teshale 2, Philip R Spradling 2, Anne C Moorman 2, Joseph A Boscarino 3, Mark A Schmidt 4, Yihe G Daida 5, Loralee B Rupp 6, Sheri Trudeau 7, Jiaqi Zhang 7, Mei Lu 7, CHeCS Investigators
|
|
|
520. | Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis |
|
Clin Transl Gastroenterol. 2022 Feb 9. doi: 10.14309/ctg.0000000000000462.Online ahead of print.
Hamish Innes 1 2 3, Alex J Walker 4, Jennifer Benselin 5, Jane I Grove 5, Vincent Pedergnana 6 7, Shang-Kuan Lin 7, John McLauchlan 8, Sharon J Hutchinson 1 3, Eleanor Barnes 7, William L Irving 5, Indra Neil Guha 5, HCV Research UK; & STOP-HCV Consortia; HCV Research UK; & STOP-HCV Consortia
|
|
|
|
|
|
|
523. | A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure |
|
Hepatology. 2021 Dec;74(6):2974-2987. doi: 10.1002/hep.32086.
Brooke Wyatt 1, Ponni V Perumalswami 1 2 3, Anna Mageras 1, Mark Miller 1, Alyson Harty 1, Ning Ma 1, Chip A Bowman 4, Francina Collado 1, Jihae Jeon 1, Lismeiry Paulino 1, Amreen Dinani 1, Douglas Dieterich 1, Li Li 1, Maxence Vandromme 1, Andrea D Branch
|
|
|
|
|
|
|
526. | Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064) |
|
Open Forum Infect Dis. 2021 Jun 27;8(8):ofab334. doi: 10.1093/ofid/ofab334.eCollection 2021 Aug.
Lisa R Metsch 1, Daniel J Feaster 2, Lauren K Gooden 1, Carmen Masson 3, David C Perlman 4, Mamta K Jain 5, Tim Matheson 6, C Mindy Nelson 2, Petra Jacobs 7, Susan Tross 8, Louise Haynes 9, Gregory M Lucas 10, Jonathan A Colasanti 11, Allan Rodriguez 12, Mari-Lynn Drainoni 13, Georgina Osorio 4, Ank E Nijhawan 5, Jeffrey M Jacobson 14, Meg Sullivan 13, David Metzger 15, Pamela Vergara-Rodriguez 16, Ronald Lubelchek 17, Rui Duan 2, Jacob N Batycki 2, Abigail G Matthews 18, Felipe Munoz 18, Eve Jelstrom 19, Raul Mandler 20, Carlos Del Rio 11
|
|
|
|
|
|
|
|
|
530. | Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy |
|
2021 Jul 22;13(15):3694. doi: 10.3390/cancers13153694.
Robert Flisiak 1, Dorota Zarebska-Michaluk 2, Ewa Janczewska 3, Tadeusz Lapinski 1, Magdalena Rogalska 1, Ewa Karpinska 4, Tomasz Mikula 5, Beata Bolewska 6, Jolanta Bialkowska 7, Katarzyna Flejscher-Stepniewska 8, Krzysztof Tomasiewicz 9, Kornelia Karwowska 10, Monika Pazgan-Simon 11, Anna Piekarska 12, Hanna Berak 13, Olga Tronina 14, Aleksander Garlicki 15, Jerzy Jaroszewicz 16
|
|
|
|
|
|
|
533. | 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs |
|
Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8.
Judith I Tsui 1, Michael P Barry 2 3, Elizabeth J Austin 4 5, Elsa W Sweek 4 5 6, Elyse Tung 7 8, Ryan N Hansen 7 8, Michael Ninburg 9, John D Scott 10, Sara N Glick 11 3, Emily C Williams 5 6
|
|
|
|
|
|
|
|
|
|
|
|
|
539. | Strategic treatment optimization for HCV (STOPHCV1): a randomized controlled trial of ultrashort duration therapy for chronic hepatitis C |
|
Wellcome Open Res. 2021 Jul 29;6:93. doi: 10.12688/wellcomeopenres.16594.2.eCollection 2021.
Graham S Cooke 1 2, Sarah Pett 3 4 5, Leanne McCabe 3, Chris Jones 1 2, Richard Gilson 4 5, Sumita Verma 6, Stephen D Ryder 7, Jane D Collier 8, Stephen T Barclay 9, Aftab Ala 10, Sanjay Bhagani 11, Mark Nelson 12, Chinlye Ch'Ng 13, Ben Stone 14, Martin Wiselka 15, Daniel Forton 16, Stuart McPherson 17, Rachel Halford 18, Dung Nguyen 19, David Smith 19, Azim Ansari 19, Emily Dennis 3, Fleur Hudson 3, Eleanor J Barnes 19 20, Ann Sarah Walker 3
|
|
|
|
|
|
|
|
|
543. | Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study |
|
Int J Environ Res Public Health. 2021 Jul 3;18(13):7144.doi: 10.3390/ijerph18137144.
Alessandra Mangia 1, Francesco Scaglione 2, Pierluigi Toniutto 3, Mario Pirisi 4, Nicola Coppola 5, Giovanni Di Perri 6, Gema Alvarez Nieto 7, Stefano Calabrese 7, Candido Hernandez 8, Valentina Perrone 9, Luca Degli Esposti 9, Stefano Fagiuoli 10
|
|
|
544. | Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program |
|
Int J Infect Dis. 2021 Sep;110:62-68. doi: 10.1016/j.ijid.2021.07.019. Epub 2021 Jul 14.
Raquel Borges Pinto 1, Ana Regina L Ramos 1, Leidy Tovar Padua 2, Emma Jane Swayze 3, Mary Catherine Cambou 4, Maristela Fiorini 5, Marineide Melo 6, Breno Riegel Santos 6, Ivete Cristina Teixeira Canti 6, Mara Liane Rieck Silveira 6, Maria Inês Gonzalez Solari 7, Juliana Ferraz de Correa 7, Kara Chew 4, Ivana Rosângela Dos Santos Varella 6, Karin Nielsen-Saines 8
|
|
|
|
|
|
|
547. | Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort |
|
Int J Drug Policy. 2021 Oct;96:103422.doi: 10.1016/j.drugpo.2021.103422. Epub 2021 Aug 21.
Joanne M Carson 1, Behzad Hajarizadeh 2, Josh Hanson 3, James O'Beirne 4, David Iser 5, Phillip Read 6, Anne Balcomb 7, Jane Davies 8, Joseph S Doyle 9, Jasmine Yee 2, Marianne Martinello 10, Philippa Marks 2, Gregory J Dore 11, Gail V Matthews 11, REACH-C Study Group
|
|
|
|
|
549. | A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign |
|
J Viral Hepat. 2021 Nov;28(11):1624-1634.doi: 10.1111/jvh.13596. Epub 2021 Aug 28.
Anna Y Palmer 1, Kico Chan 1, Judy Gold 1 2, Chloe Layton 1, Imogen Elsum 1, Margaret Hellard 1 2 3 4 5, Mark Stoove 1 2, Joseph S Doyle 1 3, Alisa Pedrana 1 2, Nick Scott 1 2, on the EC Partnership
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
556. | High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study |
|
Open Forum Infect Dis. 2021 Jun 9;8(7):ofab267. doi: 10.1093/ofid/ofab267. eCollection 2021 Jul.
Barnaby Flower 1 2, Leanne McCabe 3, Chau Le Ngoc 1, Hung Le Manh 4, Phuong Le Thanh 4, Thuan Dang Trong 4, Thu Vo Thi 1, Hang Vu Thi Kim 1, Thanh Nguyen Tat 1, Dao Phan Thi Hong 1, An Nguyen Thi Chau 1, Tan Dinh Thi 1, Nga Tran Thi Tuyet 1, Joel Tarning 5, Cherry Kingsley 2, Evelyne Kestelyn 1, Sarah L Pett 3, Guy Thwaites 1, Vinh Chau Nguyen Van 4, David Smith 6, Eleanor Barnes 6, M Azim Ansari 6, Hugo Turner 7, Motiur Rahman 1, Ann Sarah Walker 2, Jeremy Day 1, Graham S Cooke 2
|
|
|
|
|
|
|
559. | Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study |
|
J Viral Hepat. 2021 Nov;28(11):1604-1613. doi: 10.1111/jvh.13587. Epub 2021 Oct 1.
Viola Knop 1, Daniel Hoppe 1 2, Johannes Vermehren 1, Sven Troetschler 1 3, Eva Herrmann 4, Annika Vermehren 1, Mireen Friedrich-Rust 1, Christoph Sarrazin 1 5, Jonel Trebicka 1, Stefan Zeuzem 1, Martin-Walter Welker 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
566. | High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence |
|
Am J Gastroenterol. 2021 Sep 1;116(9):1896-1904. doi: 10.14309/ajg.0000000000001332.
Philippe J Zamor 1, Ashley Brown 2, Douglas E Dylla 3, John F Dillon 4, Anne F Luetkemeyer 5, Jordan J Feld 6, David Mutimer 7, Reem Ghalib 8, Eric Crown 3, Sandra S Lovell 3, Yiran Hu 3, Christophe Moreno 9, David R Nelson 10, Massimo Colombo 11, Georgios Papatheodoridis 12, Juergen K Rockstroh 13, Richard Skoien 14, Eric Lawitz 15, Ira M Jacobson 16
|
|
|
567. | Strategies To Maximize Study Retention And Limit Attrition Bias In A Prospective Cohort Study Of Men Reporting A History Of Injecting Drug Use Released From Prison: The Prison And Transition Health Study |
|
Ashleigh Cara Stewart 1 2, Reece Cossar 3 4, Shelley Walker 3, Anna Lee Wilkinson 3 5, Brendan Quinn 3 5, Paul Dietze 3 5 6, Rebecca Winter 3 7, Amy Kirwan 3, Michael Curtis 3 5 8, James R P Ogloff 4, Stuart Kinner 5 9 10 11 12, Campbell Aitken 3 5, Tony Butler 13, Emma Woods 3, Mark Stoové 3 5
|
|
|
|
|
569. | Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation |
|
Ann Surg. 2021 Oct 1;274(4):613-620. doi: 10.1097/SLA.0000000000005070.
Michael K Turgeon 1, Shimul A Shah 2, Aaron M Delman 2, Benjamin V Tran 3, Vatche G Agopian 3, Joel P Wedd 1, Joseph F Magliocca 1, Ahyoung Kim 4, Andrew Cameron 4, Ali Olyaei 5, Susan L Orloff 5, Matthew P Anderson 6, Chandrashekhar A Kubal 6, Robert M Cannon 7, Jayme E Locke 7, Mary A Simpson 8, Mohamed E Akoad 8, Chelsey P Wongjirad 9, Juliet Emamaullee 9, Amika Moro 10, Federico Aucejo 10, Cyrus A Feizpour 11, Parsia A Vagefi 11, Mindie H Nguyen 12, Carlos O Esquivel 12, Kiran Dhanireddy 13, Vijay Subramanian 13, Alejandro Chavarriaga 14, Marwan M Kazimi 14, Maia S Anderson 15, Christopher J Sonnenday 15, Steven C Kim 16, David P Foley 16, Marwan Abdouljoud 17, Reena J Salgia 17, Dimitrios Moris 18, Debra L Sudan 18, Swaytha R Ganesh 19, Abhinav Humar 19, Majella Doyle 20, William C Chapman 20, Shishir K Maithel 1
|
|
|
|
|
|
|
572. | Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs |
|
Infect Dis. 2021 Sep 20;jiab477. doi: 10.1093/infdis/jiab477.
Kathleen M Ward 1, Oluwaseun Falade-Nwulia 1, Juhi Moon 1, Catherine G Sutcliffe 2, Sherilyn Brinkley 1, Taryn Haselhuhn 1, Stephanie Katz 1, Kayla Herne 1, Lilian Arteaga 1, Shruti H Mehta 2, Carl Latkin 3, Robert K Brooner 4, Mark S Sulkowski 1
|
|
|
573. | Impact of COVID-19-related public health measures on HCV testing in British Columbia, Canada: An interrupted time series analysis |
|
Liver Int. 2021 Sep 30. doi: 10.1111/liv.15074. Online ahead of print.
Mawuena Binka 1, Sofia Bartlett 1 2, Héctor A Velásquez García 1, Maryam Darvishian 3, Dahn Jeong 1 4, Prince Adu 1 4, Maria Alvarez 1, Stanley Wong 1, Amanda Yu 1, Hasina Samji 1 5, Mel Krajden 1 2, Jason Wong 1 4, Naveed Z Janjua 1 4
|
|
|
|
|
575. | Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study |
|
J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617. Online ahead of print.
Valerio Rosato 1, Antonio Ascione 2, Riccardo Nevola 3, Anna Ludovica Fracanzani 4, Guido Piai 5, Vincenzo Messina 6, Ernesto Claar 1, Carmine Coppola 7, Luca Fontanella 2, Rosa Lombardi 4, Laura Staiano 7, Giovanna Valente 5, Maria Chiara Fascione 3, Chiara Giorgione 3, Annalisa Mazzocca 3, Raffaele Galiero 3, Pasquale Perillo 1, Aldo Marrone 3, Ferdinando Carlo Sasso 3, Luigi Elio Adinolfi 3, Luca Rinaldi 3
|
|
|
|
|
577. | Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study |
|
Dig Liver Dis. 2021 Sep 27;S1590-8658(21)00776-3. doi: 10.1016/j.dld.2021.09.007.Online ahead of print.
Vincenza Calvaruso 1, Salvatore Petta 2, Donatella Ferraro 3, Claudia La Mantia 2, Gerlando Gibilaro 2, Giada Reina 2, Velia Chiara Di Maio 4, Anna Licata 5, Francesca Ceccherini-Silberstein 4, Vito Di Marco 2, Antonio Craxì 2
|
|
|
578. | Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals |
|
Cancer Epidemiol Biomarkers Prev. 2021 Sep 28. doi: 10.1158/1055-9965.EPI-21-0742.Online ahead of print.
Jennifer O Lam 1, Leo B Hurley 2, Jennifer B Lai 3, Varun Saxena 4 5, Suk Seo 6 7, Scott Chamberland 8, Charles P Quesenberry Jr 2, Jamila H Champsi 4, Joanna Ready 9, Elizabeth Y Chiao 10 11 12, Julia L Marcus # 13, Michael J Silverberg # 2
|
|
|
|
|
|
|
|
|
582. | Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals |
|
Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):643-656.doi: 10.1080/17474124.2021.1877136. Epub 2021 Feb 15.
Riccardo Nevola 1, Luca Rinaldi 1, Letizia Zeni 1, Ciro Romano 1, Aldo Marrone 1, Raffaele Galiero 1, Pia Clara Pafundi 1, Carlo Acierno 1, Erica Vetrano 1, Luigi Elio Adinolfi 1
|
|
|
583. | Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs |
|
J Hepatol. 2021 Oct 8;S0168-8278(21)02103-6. doi: 10.1016/j.jhep.2021.09.038.Online ahead of print.
Alan Yeung 1, Norah E Palmateer 2, John F Dillon 3, Scott A McDonald 2, Shanley Smith 2, Stephen Barclay 4, Peter C Hayes 5, Rory N Gunson 6, Kate Templeton 7, David J Goldberg 8, Matthew Hickman 9, Sharon J Hutchinson 2
|
|
|
584. | Turning the tide on hepatitis C-related liver transplantation: the return on investment in hepatitis C treatment in Australia and New Zealand |
|
Liver Transpl. 2021 Oct 8. doi: 10.1002/lt.26329. Online ahead of print.
Jess Howell 1 2 3 4, Avik Majumdar 5 6, Michael Fink 7 8, Mandy Byrne 7, Geoff McCaughan 5 6, Simone I Strasser 5 6, Michael Crawford 5 6, Peter Hodgkinson 9, Katherine A Stuart 9, Caroline Tallis 9, John Chen 10, Alan Wigg 10, Robert Jones 7 8, Bryon Jaques 11, Gary Jeffrey 11 12, Leon Adams 11 12, Michael C Wallace 11 12, Stephen Munn 13, Ed Gane 13 14, Alex Thompson 1 2, Paul Gow 1 7
|
|
|
|
|
586. | BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial |
|
Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181. Online ahead of print.
Eric J Lawitz 1, Diane E Shevell 2, Giridhar S Tirucherai 2, Shuyan Du 2, Warner Chen 2, Uma Kavita 2, Angie Coste 1, Fred Poordad 1, Morten Karsdal 3, Mette Nielsen 3, Zachary Goodman 4, Edgar D Charles 2
|
|
|
|
|
588. | Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure |
|
Nat Commun. 2021 Oct 20;12(1):6105. doi: 10.1038/s41467-021-25649-6.
David A Smith 1, Carlota Fernandez-Antunez 2, Andrea Magri 1, Rory Bowden 3, Nimisha Chaturvedi 4, Jacques Fellay 4 5 6, John McLauchlan 7, Graham R Foster 8, William L Irving 9, STOP-HCV Consortium; Peter Simmonds 1, Vincent Pedergnana 10, Santseharay Ramirez 2, Jens Bukh 2, Eleanor Barnes 1, M Azim Ansari 11 12
|
|
|
|
|
|
|
591. | Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR |
|
J Hepatol. 2021 Sep 27;S0168-8278(21)02043-2. doi: 10.1016/j.jhep.2021.09.013.Online ahead of print.
Roberta D'Ambrosio 1, Elisabetta Degasperi 2, Maria Paola Anolli 2, Ilaria Fanetti 2, Marta Borghi 2, Roberta Soffredini 2, Massimo Iavarone 2, Giulia Tosetti 2, Riccardo Perbellini 2, Angelo Sangiovanni 2, Vana Sypsa 3, Pietro Lampertico 4
|
|
|
592. | Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections |
|
Transplant Direct. 2021 Sep 7;7(10):e762. doi: 10.1097/TXD.0000000000001222.eCollection 2021 Oct.
Zoe A Stewart 1, Jeffrey Stern 1, Nicole M Ali 1, Harmit S Kalia 1, Karen Khalil 1, Srijana Jonchhe 1, Elaina P Weldon 1, Rebecca A Dieter 1, Tyler C Lewis 1, Nur Funches 1, Sudara Crosby 1, Monique Seow 1, Jonathan C Berger 1, Nabil N Dagher 1, Bruce E Gelb 1, Anthony C Watkins 1, Nader Moazami 1, Deane E Smith 1, Zachary N Kon 2, Stephanie H Chang 1, Alex Reyentovich 1, Luis F Angel 1, Robert A Montgomery 1, Bonnie E Lonze 1
|
|
|
593. | Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting |
|
Transplant Direct. 2021 Sep 7;7(10):e761. doi: 10.1097/TXD.0000000000001217.eCollection 2021 Oct.
Beatrice P Concepcion 1, Laura A Binari 1, Heidi Schaefer 1, Scott Rega 2, Irene Feurer 2, Saed Shawar 1, Ruchi Naik 3, Laura Hickman 4, Jasmine Walker 4, Meghan Kapp 5, Kelly A Birdwell 1, Anthony Langone 1, J Harold Helderman 1, Bonnie Ann Sarrell 1, Guneet Kochar 1, Bernard Dubray 4, Kristin Smith 6, Heather O'Dell 6, April DeMers 6, Princess Shelton 6, Roman Perri 7, David Shaffer 4, Rachel C Forbes 4
|
|
|
|
|
|
|
|
|
597. | Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018 |
|
AIDS Patient Care STDS. 2021 Oct;35(10):392-400. doi: 10.1089/apc.2021.0087.
Gina M Simoncini 1, Qingjiang Hou 2, Kimberly Carlson 2, Kate Buchacz 3, Ellen Tedaldi 1, Frank Palella , Jr 4, Marcus Durham 3, Jun Li 3, HIV Outpatient Study (HOPS) Investigators
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
605. | Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly |
|
J Med Chem. 2021 Jul 8;64(13):9431-9443. doi: 10.1021/acs.jmedchem.1c00696.Epub 2021 Jun 29.
Adam Rolt 1, Daniel C Talley 2, Seung Bum Park 1, Zongyi Hu 1, Andrés Dulcey 2, Christopher Ma 1, Parker Irvin 1, Madeleine Leek 1, Amy Q Wang 2, Andrew V Stachulski 3, Xin Xu 2, Noel Southall 2, Marc Ferrer 2, T Jake Liang 1, Juan J Marugan 2
|
|
|
|
|
|
|
|
|
|
|
610. | Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis |
|
Hepatology. 2021 Jul;74(1):72-82. doi: 10.1002/hep.31700. Epub 2021 Jun 15.
Freya Wellhöner 1, Nico Döscher 1, Franziska Woelfl 1, Marius Vital 2, Iris Plumeier 2, Silke Kahl 2, Andrej Potthoff 1, Michael Peter Manns 1 3, Dietmar Helmut Pieper 2 3, Markus Cornberg 1 3, Heiner Wedemeyer 1 3, Benjamin Heidrich 1 2 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
620. | HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago |
|
J Public Health (Oxf). 2021 Jun 22;fdab190. doi: 10.1093/pubmed/fdab190. Online ahead of print.
Sandra Tilmon 1, A Aronsohn 2, B Boodram 3, L Canary 4, S Goel 5, T Hamlish 6, S Kemble 7, D S Lauderdale 8, J Layden 9, K Lee 1, A J Millman 4, N Nelson 4, K Ritger 10, I Rodriguez 1, N Shurupova 11, J Wolf 12, D Johnson 1
|
|
|
|
|
|
|
623. | Is elimination of HCV in 2030 realistic in Central Europe |
|
Liver Int. 2021 Jun;41 Suppl 1:56-60. doi: 10.1111/liv.14834.
Robert Flisiak 1, Dorota Zarebska-Michaluk 2, Sona Frankova 3, Ivica Grgurevic 4, Bela Hunyady 5, Peter Jarcuska 6, Limas Kupcinskas 7, Michael Makara 8, Marieta Simonova 9, Jan Sperl 3, Ieva Tolmane 10, Adriana Vince 11
|
|
|
|
|
625. | Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era |
|
New Microbiol. 2021 Apr;44(2):89-94. Epub 2021 May 21.
Barbara Rossetti 1, Elisabetta Loggi 2 3, Chiara Spertilli Raffaelli 4, Simona Mercinelli 1, Claudia Gandolfo 5, Gianni Gori Savellini 5, Silvia Galli 6, Giovanni Vitale 2 7, Roberto Di Donato 2, Ranka Vukotic 2, Elena Grandini 2, Marzia Margotti 2, Valeria Guarneri 2, Giuliano Furlini 6, Maria Carla Re 6, Andrea De Luca 1 4, Pietro Andreone 2 8, Claudio Galli 9, Maria Grazia Cusi 5
|
|
|
|
|
|
|
|
|
|
|
630. | Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers |
|
J Subst Abuse Treat. 2021 Aug;127:108421. doi: 10.1016/j.jsat.2021.108421. Epub 2021 Apr 21.
Andrew H Talal 1, Urmo Jaanimägi 2, Kathleen Davis 3, Jordan Bailey 4, Barbara M Bauer 2, Arpan Dharia 2, Saliyah George 5, Anthony McLeod 4, Karen Morton 6, Ann Nugent 5, Marija Zeremski 6, Amreen Dinani 5, Don C Des Jarlais 7, Ponni V Perumalswami 8, Jonathan N Tobin 6, Suzanne S Dickerson 9
|
|
|
631. | Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019) |
|
Front Public Health. 2021 May 28;9:568524. doi: 10.3389/fpubh.2021.568524. eCollection 2021.
Ida Sperle 1 2, Stine Nielsen 3, Viviane Bremer 1, Martyna Gassowski 1, Henrikki Brummer-Korvenkontio 4, Roberto Bruni 5, Anna Rita Ciccaglione 5, Elena Kaneva 6, Kirsi Liitsola 4, Zlatina Naneva 6, Tanya Perchemlieva 6, Enea Spada 5, Salla E Toikkanen 4, Andrew J Amato-Gauci 7, Erika Duffell 7, Ruth Zimmermann 1
|
|
|
632. | The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study |
|
Clin Infect Dis. 2021 Jun 14;ciab546. doi: 10.1093/cid/ciab546. Online ahead of print.
Sofia R Bartlett 1 2, Stanley Wong 1, Amanda Yu 1, Margo Pearce 1 3, Julia MacIsaac 4, Susan Nouch 5 6, Prince Adu 1 3, James Wilton 1, Hasina Samji 1 7, Emilia Clementi 1 3, Hector Velasquez 1, Dahn Jeong 1 3, Mawuena Binka 1, Maria Alvarez 1, Jason Wong 1 3, Jane Buxton 1 3, Mel Krajden 1 2, Naveed Z Janjua 1 3
|
|
|
|
|
|
|
|
|
636. | "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era |
|
Transplant Direct. 2021 Jun 8;7(7):e707. doi: 10.1097/TXD.0000000000001154.eCollection 2021 Jul.
Thomas G Cotter 1, Jennifer Wang 1, Sarah R Lieber 2, Matthew A Odenwald 1, Nicole E Rich 2, Jorge A Marrero 2, Amit G Singal 2, Mack C Mitchell 2, Andrew Aronsohn 1, Michael Charlton 1, John Fung 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
646. | The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018 |
|
PLoS One. 2021 Jun 9;16(6):e0251635. doi: 10.1371/journal.pone.0251635. eCollection 2021.
Adriane Wynn 1, Samantha Tweeten 2, Eric McDonald 2, Wilma Wooten 2, Kimberley Lucas 3, Cassandra L Cyr 1, Maricris Hernandez 1, Franchesca Ramirez 4, Corey VanWormer 5, Scott Suckow 6, Christian B Ramers 7, Natasha K Martin 1
|
|
|
647. | Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S |
|
AIDS Behav. 2021 Jun 10;1-12. doi: 10.1007/s10461-021-03332-7. Online ahead of print.
Madeline C Frost 1 2, Elsa W Sweek 1, Elizabeth J Austin 1, Maria A Corcorran 3, Alexa M Juarez 3, Noah D Frank 3, Stephanie M Prohaska 4, Paul A LaKosky 4, Alice K Asher 5, Dita Broz 6, Don C Des Jarlais 7, Emily C Williams 1 2, Sara N Glick 8
|
|
|
|
|
|
|
|
|
651. | Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic |
|
Am J Prev Med. 2021 May 10;S0749-3797(21)00220-8. doi: 10.1016/j.amepre.2021.03.011.Online ahead of print.
Harvey W Kaufman 1, Lara Bull-Otterson 2, William A Meyer 3rd 3, Xiaohua Huang 3, Mona Doshani 4, William W Thompson 4, Ademola Osinubi 4, Mohammed A Khan 4, Aaron M Harris 4, Neil Gupta 4, Michelle Van Handel 4, Carolyn Wester 4, Jonathan Mermin 4, Noele P Nelson 4
|
|
|
|
|
|
|
|
|
|
|
656. | Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience |
|
Am J Gastroenterol. 2021 Jun 1;116(6):1248-1255.doi: 10.14309/ajg.0000000000001147.
Luca Rinaldi 1, Vincenzo Messina 2, Vito Di Marco 3, Vincenzo Iovinella 4, Ernesto Claar 5, Giuseppe Cariti 6, Rodolfo Sacco 7, Massimo De Luca 8, Gaetano Scifo 9, Pietro Gatti 10, Giorgio Barbarini 11, Valeria Pace Palitti 12, Mariano Quartini 13, Paolo Tundo 14, Gianpiero D'Offizi 15, Giustino Parruti 16, Maria Antonietta di Rosolini 17, Giovanni Garrucciu 18, Lucio Cosco 19, Francesco Benanti 20, Giancarlo Gimignani 21, Umberto Vespasiani Gentilucci 22, Francesco Di Lorenzo 23, Maria D'Antò 24, Riccardo Nevola 1, Tommaso Lupia 6, Valerio Rosato 5, Valeria Morbiducci 13, Ilaria Luzzitelli 15, Federica Sozio 16, Marco Di Stefano 9, Emanuela Ciraci 10, Fabio Bulla 19, Riccardo Guarisco 21, Cecilia Cangiano 1, Michele Imparato 25, Paolo Maggi 2, Antonio Ascione 25, Antonio Craxì 3, Antonio Izzi 26
|
|
|
|
|
658. | Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis |
|
JAMA Psychiatry. 2021 Jun 2;e210976. doi: 10.1001/jamapsychiatry.2021.0976.Online ahead of print.
Thomas Santo Jr 1, Brodie Clark 1, Matt Hickman 2, Jason Grebely 3, Gabrielle Campbell 1 4, Luis Sordo 5 6, Aileen Chen 1 7, Lucy Thi Tran 1, Chrianna Bharat 1, Prianka Padmanathan 2, Grainne Cousins 8, Julie Dupouy 9 10, Erin Kelty 11, Roberto Muga 12, Bohdan Nosyk 13 14, Jeong Min 13, Raimondo Pavarin 15 16, Michael Farrell 1, Louisa Degenhardt 1
|
|
|
|
|
|
|
661. | "It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C |
|
Int J Drug Policy. 2021 May 28;97:103280. doi: 10.1016/j.drugpo.2021.103280.Online ahead of print.
Shelley Walker 1, Jack Wallace 2, Ned Latham 2, Freya Saich 2, Alisa Pedrana 3, Margaret Hellard 4, Carla Treloar 5, Tafireyi Marukutira 2, Peter Higgs 6, Joseph Doyle 7, Mark Stoové 3
|
|
|
662. | Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France |
|
Blood Transfus. 2021 May 12. doi: 10.2450/2021.0032-21. Online ahead of print.
Pierre Cappy 1, Laure Boizeau 1, Daniel Candotti 1, Rémi Caparros 1, Quentin Lucas 1, Eliane Garrabe 2, Christophe Martinaud 2, Sophie Le Cam 3, Pierre Gallian 3 4, Pascal Morel 3 5, Josiane Pillonel 6, Syria Laperche 1
|
|
|
663. | Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019 |
|
Infez Med. 2021 Jun 1;29(2):242-251.
Barbara Rossetti 1, Lorenzo Paglicci 2, Velia C Di Maio 3, Chiara Cassol 2, Silvia Barbaliscia 3, Stefania Paolucci 4, Bianca Bruzzone 5, Nicola Coppola 6, Francesca Montagnani 2, Valeria Micheli 7, Laura Monno 8, Giacomo Zanelli 2, Teresa Santantonio 9, Nunzia Cuomo 10, Cinzia Caudai 11, Maurizio Zazzi 12, Francesca Ceccherini-Silberstein 3, C On Behalf Of The Hcv Virology Italian Resistance Network Vironet
|
|
|
664. | Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV) |
|
PLoS Med. 2021 Jun 1;18(6):e1003653. doi: 10.1371/journal.pmed.1003653.eCollection 2021 Jun.
Lars T Fadnes 1 2, Christer Frode Aas 1 2, Jørn Henrik Vold 1 2, Rafael Alexander Leiva 3, Christian Ohldieck 1, Fatemeh Chalabianloo 1 2, Svetlana Skurtveit 4 5, Ole Jørgen Lygren 1 6, Olav Dalgård 7 8, Peter Vickerman 9, Håvard Midgard 7 10, Else-Marie Løberg 1 11 12, Kjell Arne Johansson 1 2, INTRO-HCV Study Group
|
|
|
|
|
|
|
|
|
668. | Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes |
|
Nutr Metab Cardiovasc Dis. 2021 May 1;S0939-4753(21)00186-1.doi: 10.1016/j.numecd.2021.04.016. Online ahead of print.
Ferdinando Carlo Sasso 1, Pia Clara Pafundi 2, Alfredo Caturano 2, Raffaele Galiero 2, Erica Vetrano 2, Riccardo Nevola 2, Salvatore Petta 3, Anna Ludovica Fracanzani 4, Carmine Coppola 5, Vito Di Marco 3, Antonio Solano 6, Rosa Lombardi 4, Mauro Giordano 2, Antonio Craxi 3, Alessandro Perrella 7, Celestino Sardu 2, Raffaele Marfella 2, Teresa Salvatore 8, Luigi Elio Adinolfi 2, Luca Rinaldi 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
675. | Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts |
|
Adv Ther. 2021 Jun;38(6):3409-3426. doi: 10.1007/s12325-021-01753-3. Epub 2021 May 22.
Xavier Forns 1, Jordan J Feld 2, Douglas E Dylla 3, Stanislas Pol 4, Kazuaki Chayama 5, Jinlin Hou 6, Jeong Heo 7, Pietro Lampertico 8 9, Ashley Brown 10, Mark Bondin 3, Fernando Tatsch 3, Margaret Burroughs 3, John Marcinak 3, Zhenzhen Zhang 3, Amanda Emmett 3, Stuart C Gordon 11, Ira M Jacobson 12
|
|
|
|
|
|
|
678. | Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection |
|
J Hepatol. 2021 May 20;S0168-8278(21)00336-6. doi: 10.1016/j.jhep.2021.04.056.Online ahead of print.
Gail V Matthews 1, Sanjay Bhagani 2, Marc Van der Valk 3, Juergen Rockstroh 4, Jordan J Feld 5, Andri Rauch 6, Christine Thurnheer 6, Julie Bruneau 7, Arthur Kim 8, Margaret Hellard 9, David Shaw 10, Ed Gane 11, Mark Nelson 12, Patrick Ingiliz 13, Tanya L Applegate 14, Jason Grebely 14, Phillipa Marks 14, Marianne Martinello 14, Kathy Petoumenos 14, Gregory J Dore 15, REACT study group; Protocol Steering Committee; Marc van der Valk 16, Margaret Hellard 17, Ed Gane 11, Andri Rauch 18, Julie Bruneau 7, Arthur Kim 19, Sanjay Bhagani 20, Greg Dore 21, Pip Marks 22, Gail Matthews 22, Jason Grebely 22, Kathy Petoumenos 22, Marianne Martinello 22, Tanya Applegate 22, Jordan Feld 23, Jürgen Rockstroh 4, Coordinating Centre; Site Principal Investigators
Collaborators
- Gail Matthews 24, Pip Marks 24, Sophia Amjad 24, Elise Tu 24, Kathy Petoumenos 24, Mahshid Tamaddoni 24, Marc van der Valk 16, Margaret Hellard 17, Ed Gane 11, Maria Christine Thurnheer 18, Yvonne Gilleece 25, Julie Bruneau 7, Mark Nelson 26, Chris Fraser 27, Alberto Moriggia 28, Thomas Lutz 29, Juhi Moon 30, Phillip Read 31, Arthur Y Kim 19, Andrew Ustianowski 32, Christiane Cordes 33, David Shaw 10, Sanjay Bhagani 20, Joe Sasadeusz 34, Mark Hull 35, Greg Dore 21, Jordan Feld 23, Jürgen Rockstroh 4, Dominique Braun 36, Patrick Ingiliz 13
|
|
|
679. | Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir |
|
J Hepatol. 2021 May 20;S0168-8278(21)00339-1. doi: 10.1016/j.jhep.2021.04.057.Online ahead of print.
Gary P Wang 1, Gretja L Schnell 2, Jens J Kort 3, Gurjit S Sidhu 4, Layla Schuster 4, Rakesh L Tripathi 2, Lois Larsen 2, Larry C Michael 5, Ken Bergquist 5, Ashley Magee 5, Chandni B Patel 4, Joan A Whitlock 4, Ryan Tamashiro 4, Joy A Peter 6, Michael W Fried 7, David R Nelson 8
|
|
|
|
|
|
|
|
|
683. | Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy |
|
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549. Online ahead of print.
David A Smith 1 2, Daniel Bradshaw 3, Jean Mbisa 3, Carmen F Manso 3, David Bibby 3, Josh Singer 4, Emma Thomson 4, Ana Filipe 4, Elihu Aranday-Cortes 4, M Azim Ansari 1, Anthony Brown 1, Emma Hudson 1, Jennifer Benselin 5, Brendan Healy 6, Phil Troke 7, John McLauchlan 4, Eleanor Barnes 1 2, William L Irving 5
|
|
|
|
|
|
|
|
|
687. | Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease |
|
Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.
Monica Pons 1, Salvador Augustin, Bernhard Scheiner, Maeva Guillaume, Matteo Rosselli, Susana G Rodrigues, Horia Stefanescu, Mang M Ma, Mattias Mandorfer, Mayka Mergeay-Fabre, Bogdan Procopet, Philipp Schwabl, Arnulf Ferlitsch, Georg Semmler, Annalisa Berzigotti, Emmanuel Tsochatzis, Christophe Bureau, Thomas Reiberger, Jaime Bosch, Juan G Abraldes, Joan Genescà
|
|
|
688. | Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018 |
|
Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.
Karen M J Waller 1, Nicole L De La Mata, Brenda M Rosales, James A Hedley, Patrick J Kelly, Imogen K Thomson, Michael J O'Leary, Elena Cavazzoni, Vidiya Ramachandran, William D Rawlinson, Kate R Wyburn, Angela C Webster
|
|
|
|
|
|
|
|
|
692. | Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease |
|
Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.
Monica Pons 1, Salvador Augustin, Bernhard Scheiner, Maeva Guillaume, Matteo Rosselli, Susana G Rodrigues, Horia Stefanescu, Mang M Ma, Mattias Mandorfer, Mayka Mergeay-Fabre, Bogdan Procopet, Philipp Schwabl, Arnulf Ferlitsch, Georg Semmler, Annalisa Berzigotti, Emmanuel Tsochatzis, Christophe Bureau, Thomas Reiberger, Jaime Bosch, Juan G Abraldes, Joan Genescà
|
|
|
693. | Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018 |
|
Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.
Karen M J Waller 1, Nicole L De La Mata, Brenda M Rosales, James A Hedley, Patrick J Kelly, Imogen K Thomson, Michael J O'Leary, Elena Cavazzoni, Vidiya Ramachandran, William D Rawlinson, Kate R Wyburn, Angela C Webster
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
707. | T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy |
|
Open Forum Infect Dis. 2021 Feb 18;8(4):ofab079.doi: 10.1093/ofid/ofab079.eCollection 2021 Apr.
Ann W N Auma 1, Carey Shive 1, Sofi Damjanovska 2, Corinne Kowal 2, Daniel E Cohen 3, Debika Bhattacharya 4, Beverly Alston-Smith 5, Melissa Osborne 2, Robert Kalayjian 2, Ashwin Balagopal 6, Mark Sulkowski 6, David Wyles 7, Donald D Anthony 1 2 8
|
|
|
|
|
|
|
710. | Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial |
|
Lancet Gastroenterol Hepatol. 2021 Apr 15;S2468-1253(21)00031-5.doi: 10.1016/S2468-1253(21)00031-5. Online ahead of print.
Isabelle Andrieux-Meyer 1, Soek-Siam Tan 2, Sombat Thanprasertsuk 3, Nicolas Salvadori 4, Caroline Menétrey 5, François Simon 5, Tim R Cressey 6, Hajjah Rosaida Hj Mohd Said 7, Muhammad Radzi Abu Hassan 8, Haniza Omar 2, Hoi-Poh Tee 9, Wah Kheong Chan 10, Suresh Kumar 11, Satawat Thongsawat 12, Kanawee Thetket 13, Anchalee Avihingsanon 14, Suparat Khemnark 15, Sabine Yerly 16, Nicole Ngo-Giang-Huong 17, Sasikala Siva 18, Alistair Swanson 5, Vishal Goyal 19, Francois Bompart 5, Bernard Pécoul 5, Shahnaz Murad 20
|
|
|
|
|
|
|
|
|
714. | Hepatitis C Virus Testing Among Men With Human Immunodeficiency Virus Who Have Sex With Men: Temporal Trends and Racial/Ethnic Disparities |
|
-
Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa645. doi: 10.1093/ofid/ofaa645.eCollection 2021 Apr.
Jun Li 1, Carl Armon 2, Frank J Palella 3, Ellen Tedaldi 4, Richard M Novak 5, Jack Fuhrer 6, Gina Simoncini 4, Kimberly Carlson 2, Kate Buchacz 1, HIV Outpatient Study (HOPS) Investigators
Collaborators
- HIV Outpatient Study (HOPS) Investigators:
-
Jun Li, Kate Buchacz, Marcus D Durham, Cheryl Akridge, Stacey Purinton, Nabil Rayeed, Selom Agbobil-Nuwoaty, Kalliope Chagaris, Kimberly Carlson, Carl Armon, Linda Battalora, Jonathan Mahnken, Frank J Palella, Saira Jahangir, Conor Daniel Flaherty, Patricia Bustamante, John Hammer, Kenneth S Greenberg, Barbara Widick, Rosa Franklin, Douglas J Ward, Troy Thomas, Cheryl Stewart, Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, Jane Esteves, Ellen M Tedaldi, Ramona A Christian, Faye Ruley, Dania Beadle, Princess Davenport, Richard M Novak, Andrea Wendrow, Stockton Mayer, Mia Scott, Billie Thomas, Loraine Van Slyke, Cynthia Mayer, Terry Beitler, Karen Maroney, Denise Franklin
|
|
|
|
|
716. | Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C) |
|
Harm Reduct J. 2021 Apr 26;18(1):46. doi: 10.1186/s12954-021-00494-4.
Jake Rance 1, Lise Lafferty 2, Carla Treloar 2, SToP-C Study Group
Collaborators
Stuart Loveday, Gregory Dore, Andrew Lloyd, Jason Grebely, Tony Butler, Natasha Martin, Georgina Chambers, Carla Treloar, Marianne Byrne, Roy Donnelly, Colette McGrath, Julia Bowman, Lee Trevethan, Luke Grant, Terry Murrell, Nicky Bath, Mary Harrod, Alison Churchill, Kate Pinnock, Sallie Cairnduff
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
726. | High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California |
|
PLoS One. 2021 Mar 30;16(3):e0249219. doi: 10.1371/journal.pone.0249219. eCollection 2021.
Christopher J Hernandez 1, Dillon Trujillo 1, Sofia Sicro 1, Joaquin Meza 1, Mackie Bella 1, Emperatriz Daza 1, Francisco Torres 1, Willi McFarland 1 2, Caitlin M Turner 1 2, Erin C Wilson 1 2
|
|
|
|
|
728. | Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study |
|
Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841. Online ahead of print.
Maureen M Jonas 1, Susan Rhee 2, Deirdre A Kelly 3, Antonio Del Valle-Segarra 4, Cornelia Feiterna-Sperling 5, Susan Gilmour 6, Regino P Gonzalez-Peralta 7, Loreto Hierro 8, Daniel H Leung 9, Simon C Ling 10, Yuri Lobzin 11, Steven Lobritto 12, Tatsuki Mizuochi 13, Michael R Narkewicz 14, Vishakha Sabharwal 15, Jessica Wen 16, Hoi Kei Lon 2, John Marcinak 2, Andrew Topp 2, Rakesh Tripathi 2, Etienne Sokal 17
|
|
|
|
|
|
|
731. | Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era |
|
Open Forum Infect Dis. 2021 Feb 24;8(3):ofab076. doi: 10.1093/ofid/ofab076.eCollection 2021 Mar.
Shannon Wood 1 2 3 4, Seung Hyun Won 3 5, Hsing-Chuan Hsieh 3 5, Tahaniyat Lalani 3 5 6, Karl Kronmann 3 6, Ryan C Maves 3 7, Gregory Utz 3 7, Christina Schofield 3 4, Rhonda E Colombo 3 5 4, Jason F Okulicz 3 8, Jason Blaylock 2 3, Brian K Agan 3 5, Anuradha Ganesan 2 3 5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
739. | Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women |
|
AIDS. 2021 Mar 11. doi: 10.1097/QAD.0000000000002869. Online ahead of print.
Audrey L French 1, Dara Grennan, Elizabeth Daubert, Eric C Seaberg, Marion Peters, Michael Augenbraun, Margaret Fischl, Seble Kassaye, Ricardo Franco, Mark Kuniholm, Adaora A Adimora, Kimberly Workowski, Kathleen M Weber
|
|
|
|
|
|
|
|
|
743. | Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry |
|
Clin Infect Dis. 2021 Mar 2;ciaa1510. doi: 10.1093/cid/ciaa1510. Online ahead of print.
Fernanda Q Onofrio 1, Curtis Cooper 2, Sergio M Borgia 3, Marie-Louise Vachon 4, Alnoor Ramji 5, Leslie B Lilly 6, Alexander Wong 7, Joshua Booth 1, Izza Sattar 1, Heidy Morales 1, Samuel Lee 8, Brian Conway 9, Jordan J Feld 1
|
|
|
|
|
|
|
|
|
747. | HCV virology and diagnosis |
|
Clin Res Hepatol Gastroenterol. 2021 Feb 23;45(3):101626.doi: 10.1016/j.clinre.2021.101626. Online ahead of print.
Steven Roger 1, Alexandra Ducancelle 1, Hélène Le Guillou-Guillemette 1, Catherine Gaudy 2, Françoise Lunel 3
|
|
|
748. | Willingness to Participate in Research among Black Patients with Liver Disease: A National Cross-Sectional Study |
|
J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13493. Online ahead of print.
F Hunter McGuire 1 2, Kat André 2 3, Minyone L Bradsher 2, Dawn Harrison 4, Richard K Sterling 5, K Rajender Reddy 6, Marina Serper 6, Carol E Golin 1 7, Nancy Reau 8, Joseph K Lim 9, David R Nelson 10, Souvik Sarkar 11, Donna M Evon 2 4
|
|
|
|
|
|
|
|
|
|
|
753. | Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment |
|
J Addict Med. 2021 Feb 5. doi: 10.1097/ADM.0000000000000807. Online ahead of print.
Kristi Hill 1, Laura Nussdorf, Julia D Mount, Rachel Silk, Chloe Gross, David Sternberg, Phyllis Bijole, Miriam Jones, Randy Kier, Dana Mccullough, Poonam Mathur, Shyam Kottilil, Henry Masur, Sarah Kattakuzhy, Elana S Rosenthal
|
|
|
754. | The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017 |
|
Clin Infect Dis. 2021 Feb 9;ciab108. doi: 10.1093/cid/ciab108. Online ahead of print.
Philip R Spradling 1, Yuna Zhong 1, Anne C Moorman 1, Loralee B Rupp 2, Mei Lu 2, Eyasu H Teshale 1, Mark A Schmidt 3, Yihe G Daida 4, Joseph A Boscarino 5, Stuart C Gordon 2 6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
761. | Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study |
|
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):169-184. doi: 10.1016/S2468-1253(20)30359-9.Epub 2021 Jan 28.
Ellen Dugan 1, Sarah Blach 1, Mia Biondi 2, Zongzhen Cai 1, Mindi DePaola 1, Chris Estes 1, Jordan Feld 3, Ivane Gamkrelidze 1, Shyamasundaran Kottilil 4, Siya Ma 1, Poonam Mathur 1, Shauna Montoya 1, Devin Razavi-Shearer 1, Kathryn Razavi-Shearer 1, Sarah Robbins-Scott 1, Jonathan Schmelzer 1, Homie Razavi 5
|
|
|
762. | Outcomes of Hepatitis C Virus Seropositive Donors to Hepatitis C Virus Seronegative Liver Recipients: A Large Single Center Analysis |
|
Ann Hepatol. 2021 Jan 27;100318. doi: 10.1016/j.aohep.2021.100318. Online ahead of print.
Lindsay A Sobotka 1, Khalid Mumtaz 1, Michael R Wellner 1, Sean G Kelly 1, Lanla F Conteh 1, A James Hanje 1, Austin Schenk 2, Ashraf El-Hinnawi 2, Sylvester Black 2, Kenneth Washburn 2, Todd Pesavento 3, Reem Daloul 3, Anthony J Michaels 4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
771. | Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response |
|
Clin Gastroenterol Hepatol. 2021 Jan 22;S1542-3565(21)00076-8.doi:10.1016/j.cgh.2021.01.026. Online ahead of print.
Zobair M Younossi 1, Andrei Racila 2, Andrew Muir 3, Marc Bourliere 4, Alessandra Mangia 5, Rafael Esteban 6, Stefan Zeuzem 7, Massimo Colombo 8, Michael Manns 9, George V Papatheodoridis 10, Maria Buti 6, Anand Chokkalingam 11, Anuj Gaggar 11, Fatema Nader 12, Issah Younossi 12, Linda Henry 12, Maria Stepanova 12
|
|
|
|
|
773. | Hepatitis C Virus Transmission Clusters in Public Health and Correctional Settings, Wisconsin, USA, 2016-2017 1 |
|
Emerg Infect Dis. 2021 Feb;27(2):480-489. doi: 10.3201/eid2702.202957.
Karli R Hochstatter, Damien C Tully, Karen A Power, Ruth Koepke, Wajiha Z Akhtar, Audrey F Prieve, Thomas Whyte, David J Bean, David W Seal, Todd M Allen, Ryan P Westergaard
|
|
|
|
|
775. | Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis |
|
JGH Open. 2020 Dec 10;5(1):133-142. doi: 10.1002/jgh3.12462. eCollection 2021 Jan.
Steven M McPhail 1 2, Samath Amarasena 3, Katherine A Stuart 4, Kelly Hayward 5, Rohit Gupta 6, David Brain 1 2, Gunter Hartel 7, Tony Rahman 6, Paul J Clark 8, Christina M Bernardes 6, Richard Skoien 3, Benjamin Mckillen 3, Andrew Lee 8, Leshni Pillay 9, Lei Lin 6, Myat Myat Khaing 6, Leigh Horsfall 4 5, Elizabeth E Powell 4 5, Patricia C Valery 7
|
|
|
|
|
|
|
|
|
779. | Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives |
|
J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474. Online ahead of print.
Julius M Wilder 1 2, Donna M Evon 3, Rae Jean Proeschold-Bell 4 5, Jia Yao 4 5, Malik Muhammed Sohail 4, Donna Niedzwiecki 6, Christina Makarushka 4 5, Terra Hodge 1, Andrew J Muir 1 2
|
|
|
780. | HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men |
|
Transfusion. 2021 Jan 18. doi: 10.1111/trf.16250. Online ahead of print.
Whitney R Steele 1, Roger Y Dodd 1, Edward P Notari 1, James Haynes 1, Steven A Anderson 2, Alan E Williams 2, Rita Reik 3, Debra Kessler 4, Brian Custer 5, Susan L Stramer 1, Transfusion-Transmissible Infections Monitoring System (TTIMS)
|
|
|
|
|
|
|
783. | Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study |
|
Open Forum Infect Dis. 2020 Nov 19;8(1):ofaa564. doi: 10.1093/ofid/ofaa564.eCollection 2021 Jan.
Kristina M Brooks 1, Jose R Castillo-Mancilla 2, Mary Morrow 3, Samantha MaWhinney 3, Sarah E Rowan 2 4, David Wyles 2 4, Joshua Blum 4, Ryan Huntley 1, Lana M Salah 1, Arya Tehrani 1, Lane R Bushman 1, Peter L Anderson 1, Jennifer J Kiser 1
|
|
|
|
|
|
|
786. | Patient-Reported Outcomes 12 Months After Hepatitis C Treatment with Direct-Acting Antivirals: Results from the PROP UP Study |
|
Liver Int. 2021 Jan 2. doi: 10.1111/liv.14781. Online ahead of print.
Marina Serper 1, Donna M Evon 2, Jipcy Amador 3, Paul W Stewart 3, Souvik Sarkar 4, Anna S Lok 5, Richard K Sterling 6, Bryce B Reeve 7, Carol E Golin 8, K Rajender Reddy 1, Joseph K Lim 9, Nancy Reau 10, David R Nelson 11, Adrian M Di Bisceglie 12, Michael W Fried 2
|
|
|
|
|
|
|
789. | Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond |
|
Chem Rev. 2021 Jan 7. doi: 10.1021/acs.chemrev.0c00648. Online ahead of print.
Ashley N Matthew 1, Florian Leidner 1, Gordon J Lockbaum 1, Mina Henes 1, Jacqueto Zephyr 1, Shurong Hou 1, Desaboini Nageswara Rao 1, Jennifer Timm 1, Linah N Rusere 1, Debra A Ragland 1, Janet L Paulsen 1, Kristina Prachanronarong 1, Djade I Soumana 1, Ellen A Nalivaika 1, Nese Kurt Yilmaz 1, Akbar Ali 1, Celia A Schiffer 1
|
|
|
790. | HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status |
|
Clin Infect Dis. 2020 Dec 21;ciaa1869.doi: 10.1093/cid/ciaa1869. Online ahead of print.
Risha Irvin 1, Theresa Gamble 2, Jowanna Malone 1, Zhe Wang 3, Ethan Wilson 3, James P Hughes 4, Jason Farley 1, Kenneth H Mayer 5, Carlos Del Rio 6, D Scott Batey 7, Vanessa Cummings 1, Robert H Remien 8, Chris Beyrer 1, Chloe L Thio 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
797. | Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy |
|
J Hepatol. 2020 Nov 18;S0168-8278(20)33770-3. doi: 10.1016/j.jhep.2020.11.017.Online ahead of print.
Julia Dietz 1, Velia Chiara Di Maio 2, Adolfo de Salazar 3, Dolores Merino 4, Johannes Vermehren 1, Stefania Paolucci 5, Andreas E Kremer 6, Magdalena Lara 7, Maria Rodriguez Pardo 8, Heinz Zoller 9, Elisabetta Degasperi 10, Kai-Henrik Peiffer 1, Laura Sighinolfi 11, Francisco Téllez 12, Christiana Graf 1, Valeria Ghisetti 13, Jonas Schreiber 14, Elisa Fernández-Fuertes 15, Lucio Boglione 16, Leopoldo Muñoz-Medina 17, Rudolf Stauber 18, William Gennari 19, Blanca Figueruela 20, Jesús Santos 21, Pietro Lampertico 10, Stefan Zeuzem 1, Francesca Ceccherini-Silberstein 2, Federico García 3, Christoph Sarrazin 22
|
|
|
|
|
|
|
800. | Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs |
|
Drug Alcohol Rev. 2020 Nov 8. doi: 10.1111/dar.13198. Online ahead of print.
Vivian D Hope 1, James McVeigh 2, Emma Begley 1, Rachel Glass 3, Claire Edmundson 3, Ellen Heinsbroek 3, Joseph Kean 4, John Campbell 5, Mark Whitfield 1, Gareth Morgan 6, Dean Acreman 7, Josie Smith 7
|
|
|
|
|
|
|
|
|
804. | Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C Treated Liver Transplant Recipients with Residual Fibrosis or Cirrhosis |
|
Liver Transpl. 2020 Nov 8. doi: 10.1002/lt.25934. Online ahead of print.
Ethan W Weinberg 1, Michael P Curry 2, Catherine T Frenette 3, Fredric G Regenstein 4, Eugene R Schiff 5, Zachary D Goodman 6, James Mac Robinson 7, Jean L Chan 7, Joanne C Imperial 7, K Rajender Reddy 1
|
|
|
805. | Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV |
|
J Infect Dis. 2020 Nov 3;jiaa686. doi: 10.1093/infdis/jiaa686. Online ahead of print.
Danielle F Haley 1, Andrew Edmonds 2, Catalina Ramirez 3, Audrey L French 4, Phyllis Tien 5, Chloe L Thio 6, Mallory D Witt 7, Eric C Seaberg 8, Michael W Plankey 9, Mardge H Cohen 10, Adaora A Adimora 11
|
|
|
|
|
|
|
|
|
809. | A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C |
|
BMC Infect Dis. 2020 Oct 29;20(1):802. doi: 10.1186/s12879-020-05531-4.
Jessica Ramsay 1, Julie Marsh 1, Alisa Pedrana 2 3, Nada Andric 4, Richard Norman 5, Wendy Cheng 6 7 8, Steve Webb 3 9, Nikolajs Zeps 10, Matthew Bellgard 11, Todd Graves 12, Margaret Hellard 2 3 13 14 15, Tom Snelling 16 17 18 19 20
|
|
|
810. | Early Outcomes of Multivisceral Transplant using Hepatitis C Positive Donors |
|
Ann Thorac Surg. 2020 Oct 26;S0003-4975(20)31736-7. doi: 10.1016/j.athoracsur.2020.08.044.Online ahead of print.
William G McMaster Jr 1, Zakiur M Rahaman 2, Maren E Shipe 3, Eric N Quintana 4, Emily M Sandhaus 5, Sarah S Smith 6, Jerod E Crockett 7, Rachel C Forbes 8, Kelly H Schlendorf 9, Ashish S Shah 10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
819. | Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV |
|
mSystems. 2020 Oct 13;5(5):e00528-20. doi: 10.1128/mSystems.00528-20.
Bryn C Taylor # 1, Kelly C Weldon # 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Daniel McDonald 7, Gregory Humphrey 7, MacKenzie Bryant 7, Julia Toronczak 7, Tara Schwartz 7, Jennifer Iudicello 6, Robert Heaton 6, Igor Grant 6, Sara Gianella 8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
831. | Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection |
|
J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408. Online ahead of print.
Philip J Johnson 1, Sarah Berhane 1, Alex J Walker 2, Fiona H Gordon 3, Steven D Ryder 4 5, Stuart McPherson 6, Aravamuthan Sreedharan 7, Andrew A Ustianowski 8, Kosh Agarwal 9, David Mutimer 10, Takeshi Kumada 11, Hidenori Toyoda 12, William L Irving 5, HCV Research UK
|
|
|
832. | Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome |
|
mSystems. 2020 Sep 29;5(5):e00465-20. doi: 10.1128/mSystems.00465-20.
Bryn C Taylor 1, Kelly C Weldon 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Tobin Groth 7, Emily C Gentry 2, Anupriya Tripathi 2 7 8, Daniel McDonald 8, Gregory Humphrey 8, MacKenzie Bryant 8, Julia Toronczak 8, Tara Schwartz 8, Michelli F Oliveira 9, Robert Heaton 6, Igor Grant 6, Sara Gianella 10, Scott Letendre 9 11, Austin Swafford 3, Pieter C Dorrestein 2 3 8, Rob Knight 12 8 13 14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
841. | Cholesterol sensing by CD81 is important for hepatitis C virus entry |
|
J Biol Chem. 2020 Sep 8;jbc.RA120.014761. doi: 10.1074/jbc.RA120.014761.Online ahead of print.
Machaela Palor 1, Lenka Stejskal 1, Piya Mandal 1, Annasara Lenman 2, Maria Pia Alberione 3, Jared Kirui 4, Rebecca Moeller 4, Stefan Ebner 5, Felix Meissner 5, Gisa Gerold 6, Adrian J Shepherd 7, Joe Grove 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
850. | Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or |
|
J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393. Online ahead of print.
David Stephen Prince 1 2, Joseph Louis Pipicella 1 3, Melissa Fraser 1, Frank Alvaro 1 4, Michael Maley 1 2 4, Hong Foo 1 4 5, Paul MacConachie Middleton 1 2 3 6 7, Scott Anthony Davison 1 2, Greg John Dore 8, Geoff William McCaughan 7 9, Miriam Tania Levy 1 2 3
|
|
|
851. | Hepatitis C Virus |
|
Ann Intern Med. 2020 Sep 1;173(5):ITC33-ITC48. doi: 10.7326/AITC202009010.
|
|
|
|
|
|
|
854. | Hepatic benefits of HCV cure |
|
J Hepatol. 2020 Aug 7;S0168-8278(20)30530-4. doi: 10.1016/j.jhep.2020.08.006.Online ahead of print.
Vincenza Calvaruso 1, Antonio Craxì 2
|
|
|
855. | Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper |
|
J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):407-417. doi: 10.1097/MPG.0000000000002814.
Daniel H Leung 1, James E Squires 2, Ravi Jhaveri 3, Nanda Kerkar 4, Chuan-Hao Lin 5, Parvathi Mohan 6, Karen F Murray 7, Regino P Gonzalez-Peralta 8, Eve A Roberts 9, Shikha S Sundaram 10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
867. | Global hepatitis C elimination: an investment framework |
|
Lancet Gastroenterol Hepatoldoi: 10.1016/S2468-1253(20)30010-8. Online ahead of print.
Alisa Pedrana 1, Jessica Howell 2, Nick Scott 3, Sophia Schroeder 3, Christian Kuschel 4, Jeffrey V Lazarus 5, Rifat Atun 6, Ricardo Baptista-Leite 7, Ellen 't Hoen 8, Sharon J Hutchinson 9, Lisa Aufegger 10, Raquel Peck 11, Annette H Sohn 12, Tracy Swan 13, Mark Thursz 14, Olufunmilayo Lesi 15, Manik Sharma 16, John Thwaites 17, David P Wilson 3, Margaret Hellard 18
|
|
|
868. | Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020 MMWR |
|
Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.
MMWR Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.
Anne C Moorman, Marie A de Perio, Ronald Goldschmidt, Carolyn Chu, David Kuhar, David K Henderson, Susanna Naggie, Saleem Kamili, Philip R Spradling, Stuart C Gordon, Mark B Russi, Eyasu H Teshale
|
|
|
|
|
|
|
|
|
|
|
|
|
874. | Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience |
|
Transplant Proc. 2020 Jul 4;S0041-1345(20)32581-1. doi:10.1016/j.transproceed.2020.06.005.Online ahead of print.
Eloi Chevallier 1, Matthias Büchler 2, Sophie Caillard 3, Nicolas Bouvier 4, Charlotte Colosio 5, Joseph Rivalan 6, Johnny Sayegh 7, Dominique Bertrand 8, Yannick Le Meur 9, Antoine Thierry 10, Cyril Garrouste 11, Jean-Philippe Rerolle 12, Lionel Rostaing 13, Philippe Gatault 2
|
|
|
|
|
876. | Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions |
|
Liver Int. 2020 Jul 8. doi: 10.1111/liv.14591. Online ahead of print.
Julia Dietz 1, Johannes Vermehren 1, Katrin Matschenz 2, Peter Buggisch 2, Hartwig Klinker 3, Julian Schulze Zur Wiesch 4, Holger Hinrichsen 5, Kai-Henrik Peiffer 1, Christiana Graf 1, Thomas Discher 6, Janina Trauth 6, Jörn M Schattenberg 7, Felix Piecha 4, Stefan Mauss 8, Claus Niederau 9, Tobias Müller 10, Christoph Neumann-Haefelin 11, Christoph P Berg 12, Stefan Zeuzem 1, Christoph Sarrazin 1 13, European HCV Resistance Study Group
|
|
|
877. | Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014 : A Study of Health Care Encounter Data |
|
Public Health Rep. Jul/Aug 2020;135(4):461-471. doi: 10.1177/0033354920937284.Epub 2020 Jul 7.
Mary E Evans 1 2 3, Marissa Person 4, Brigg Reilley 5, Jessica Leston 5, Richard Haverkate 6, Jeffrey T McCollum 6, Andria Apostolou 6 7, Michele K Bohm 1, Michelle Van Handel 8, Danae Bixler 9, Andrew J Mitsch 2, Dana L Haberling 4, Sarah M Hatcher 3 5, Thomas Weiser 10, Kim Elmore 2, Eyasu H Teshale 9, Paul J Weidle 2, Philip J Peters 2, Kate Buchacz 2
|
|
|
|
|
|
|
|
|
881. | Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection |
|
Clin Gastroenterol Hepatol. 2020 Jul 1;S1542-3565(20)30907-1. doi: 10.1016/j.cgh.2020.06.044.Online ahead of print.
Eli Zuckerman 1, Julio A Gutierrez 2, Douglas E Dylla 3, Victor de Ledinghen 4, Andrew J Muir 5, Michael Gschwantler 6, Massimo Puoti 7, Florin Caruntu 8, Jihad Slim 9, Frederik Nevens 10, Samuel Sigal 11, Stanley Cohen 12, Linda M Fredrick 3, Ana Gabriela Pires Dos Santos 3, Lino Rodrigues Jr 3, John F Dillon 13
|
|
|
882. | Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals |
|
Int J Antimicrob Agents. 2020 Jun 26;106067. doi: 10.1016/j.ijantimicag.2020.106067.Online ahead of print.
M Pisaturo 1, M Starace 1, C Minichini 1, S De Pascalis 2, L Occhiello 1, A Di Fraia 1, V Messina 3, V Sangiovanni 4, E Claar 5, N Coppola 6, CampC Network
|
|
|
|
|
|
|
|
|
886. | The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services |
|
PLoS One. 2020 Jun 30;15(6):e0235445.doi: 10.1371/journal.pone.0235445. eCollection 2020.
Michael W Traeger 1 2, Alisa E Pedrana 1 2, Daniela K van Santen 1 2, Joseph S Doyle 1 3, Jessica Howell 1 4, Alexander J Thompson 4, Carol El-Hayek 1, Jason Asselin 1, Victoria Polkinghorne 1, Dean Membrey 5, Fran Bramwell 5, Allison Carter 6, Rebecca Guy 6, Mark A Stoové 1 2 7, Margaret E Hellard 1 2 3, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
|
|
|
|
|
|
|
|
|
890. | Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study |
|
Lancet Gastroenterol Hepatol. 2020 Jun 9;S2468-1253(19)30417-0.doi: 10.1016/S2468-1253(19)30417-0. Online ahead of print.
Eric Lawitz 1, Charles S Landis 2, Steven L Flamm 3, Maurizio Bonacini 4, Grisell Ortiz-Lasanta 5, Jonathan Huang 6, Jie Zhang 7, Brian J Kirby 7, Shampa De-Oertel 7, Robert H Hyland 7, Anu O Osinusi 7, Diana M Brainard 7, Richard Robson 8, Benedict J Maliakkal 6, Stuart C Gordon 9, Edward J Gane 10
|
|
|
|
|
|
|
|
|
894. | Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance |
|
Hepatol Commun. 2020 Apr 6;4(6):904-915. doi: 10.1002/hep4.1496. eCollection 2020 Jun.
Mark W Douglas 1 2 3, Enoch S E Tay 1 4, Dao Sen Wang 1, Adrian T L Ong 1 2, Caroline Wilson 1, Amy Phu 1, Jen Kok 4, Dominic E Dwyer 3 4, Rowena A Bull 5, Andrew R Lloyd 5, Tanya L Applegate 5, Gregory J Dore 5, Anita Y Howe 6, Richard Harrigan 7, Jacob George 1 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
904. | Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a |
|
Adv Ther. 2020 Jul;37(7):3299-3310. doi: 10.1007/s12325-020-01389-9. Epub 2020 May 25.
Philip Rosenthal 1, Michael R Narkewicz 2, Betty B Yao 3, Christopher D Jolley 4, Steven J Lobritto 5, Jessica Wen 6, Jean P Molleston 7, Evelyn K Hsu 8, Maureen M Jonas 9, Jiuhong Zha 3, Li Liu 3, Daniel H Leung 10
|
|
|
|
|
|
|
907. | Public Health Clinic-Based Hepatitis C Treatment |
|
Am J Prev Med. 2020 May 16;S0749-3797(20)30146-X. doi:10.1016/j.amepre.2020.03.006.Online ahead of print.
Amanda M Rosecrans 1, Aneesha Cheedalla 2, Sarah T Rives 3, Lisa A Scotti 3, Robert E Harris 3, Adena H Greenbaum 4, Risha R Irvin 2, Boatemaa A Ntiri-Reid 5, Holly T Brown 3, Karen E Alston 3, Jaeson A Smith 4, Kathleen R Page 3, Oluwaseun O Falade-Nwulia 2
|
|
|
|
|
909. | English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed |
|
Kathryn Drysdale 1 2, Yevedzo Ntuli 1 3, Jonathan Bestwick 4, William Gelson 5, Kosh Agarwal 3, Daniel Forton 6, David Mutimer 7, Ahmed M Elsharkawy 7, Ceri Townley 8, Faizel Mahomed 9, Graham R Foster 1 2
Aliment Pharmacol Ther. 2020 Jul;52(1):168-181. doi: 10.1111/apt.15780. Epub 2020 May 22.
|
|
|
|
|
|
|
|
|
913. | Resistance-associated Substitutions in Patients With Chronic Hepatitis C Virus Genotype 4 Infection |
|
J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322. Online ahead of print.
Julia Dietz 1 2, Olga V Kalinina 3 4, Johannes Vermehren 1 2, Kai-Henrik Peiffer 1 2, Katrin Matschenz 5, Peter Buggisch 5, Claus Niederau 6, Jörn M Schattenberg 7, Beat Müllhaupt 8, Sabine Yerly 9, Marc Ringelhan 10, Roland M Schmid 10, Christoph Antoni 11, Tobias Müller 12, Julian Schulze Zur Wiesch 13 14, Felix Piecha 13, Darius Moradpour 15, Katja Deterding 16 17 18, Heiner Wedemeyer 16 17 18, Christophe Moreno 19, Thomas Berg 20, Christoph P Berg 21, Stefan Zeuzem 1 2, Christoph Welsch 1 2, Christoph Sarrazin 1 2 22, European HCV Resistance Study Group
|
|
|
|
|
915. | HCV DAA Therapy in Persons With HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation |
|
J Infect Dis. 2020 May 15;jiaa254.doi: 10.1093/infdis/jiaa254. Online ahead of print.
Donald D Anthony 1, Mark S Sulkowski 2, Laura M Smeaton 3, Sofi Damjanovska 1, Carey L Shive 1, Corinne M Kowal 1, Daniel E Cohen 4, Debika Bhattacharya 5, Beverly L Alston-Smith 6, Ashwin Balagopal 2, David L Wyles 7
|
|
|
916. | High Prevalence of Hepatitis C Infection Among Adult Patients at Four Urban Emergency Departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017 |
|
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-574 doi: 10.15585/mmwr.mm6919a1.
James W Galbraith, Erik S Anderson, Yu-Hsiang Hsieh, Ricardo A Franco, John P Donnelly, Joel B Rodgers, Elissa M Schechter-Perkins, William W Thompson, Noele P Nelson, Richard E Rothman, Douglas A E White
Free PMC article
|
|
|
917. | Impact of Treatment With Direct Acting Antiviral Drugs on Glycemic Control in Patients With Hepatitis C and Diabetes Mellitus |
|
Int J Hepatol. 2020 Jan 13;2020:6438753. doi: 10.1155/2020/6438753. eCollection 2020.
Pradeep Kumar Mada 1 2, Matthew E Malus 3, Arvin Parvathaneni 4, Bing Chen 3, Gabriel Castano 5, Sharon Adley 2, Maureen Moore 2, Michinari Hieda 6, Mohammed J Alam 2, Mark Feldman 1, John William King 2
|
|
|
|
|
|
|
|
|
|
|
|
|
923. | Eliciting Patient Views on the Allocation of Limited Healthcare Resources: A Deliberation on Hepatitis C Treatment in the Veterans Health Administration |
|
BMC Health Serv Res. 2020 May 1;20(1):369. doi: 10.1186/s12913-020-05211-8.
Akbar K Waljee 1 2 3, Kerry A Ryan 4, Chris D Krenz 4, George N Ioannou 5 6, Lauren A Beste 6 7, Monica A Tincopa 8, Sameer D Saini 9 8 10, Grace L Su 9 8, Maria E Arasim 9, Patti T Roman 9, Brahmajee K Nallamothu 9 10 11, Raymond De Vries 4
|
|
|
|
|
925. | Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model |
|
Open. 2020 May 1;3(5):e204192. doi: 10.1001/jamanetworkopen.2020.4192.
Mawuena Binka 1, Naveed Z Janjua 1 2 3, Jason Grebely 2 4, Chris Estes 5, Dena Schanzer 2, Jisoo A Kwon 4, Naglaa H Shoukry 2 6, Jeffrey C Kwong 2 7, Homie Razavi 5, Jordan J Feld 2 8, Mel Krajden 1 2 3
|
|
|
|
|
|
|
|
|
|
|
930. | Utilization and Effectiveness of elbasvir/grazoprevir and Adoption of Resistance-Associated Substitutions Testing in Real-World Treatment of Hepatitis C Virus Genotype 1A Infection: Results From the German Hepatitis C-Registry |
|
Eur J Gastroenterol Hepatol. 2020 May 15. doi: 10.1097/MEG.0000000000001759.Online ahead of print.
Holger Hinrichsen 1, Albrecht Stoehr 2, Markus Cornberg 3, Hartwig Klinker 4, Renate Heyne 5, Christine John 6, Karl-Georg Simon 7, Veronika Guenther 8, Karen Martin 8, Vanessa Witte 8, Stefan Zeuzem 9
|
|
|
|
|
|
|
933. | Hepatitis C Prevalence and Risk Factors in Georgia, 2015: Setting a Baseline for Elimination |
|
BMC Public Health. 2019 May 10;19(Suppl 3):480. doi: 10.1186/s12889-019-6784-3.
Liesl M Hagan 1, Ana Kasradze 2, Stephanie J Salyer 3, Amiran Gamkrelidze 2, Maia Alkhazashvili 2, Gvantsa Chanturia 2, Nazibrola Chitadze 2, Roena Sukhiashvili 2, Marina Shakhnazarova 2, Steven Russell 3, Curtis Blanton 3, Giorgi Kuchukhidze 2, Davit Baliashvili 2, Susan Hariri 4, Stephen Ko 4 5, Paata Imnadze 2, Jan Drobeniuc 4, Juliette Morgan 3 6, Francisco Averhoff 4
|
|
|
934. | An Evaluation of the Hepatitis C Testing, Care and Treatment Program in the Country of Georgia's Corrections System, December 2013 - April 2015 |
|
BMC Public Health. 2019 May 10;19(Suppl 3):466. doi: 10.1186/s12889-019-6783-4.
Aaron M Harris 1, Otar Chokoshvili 2, Joshua Biddle 3, Kostantine Turashvili 4, Maia Japaridze 5, Irma Burjanadze 6, Tengiz Tsertsvadze 2, Lali Sharvadze 2, Marine Karchava 2, Archil Talakvadze 7, Ketevan Chakhnashvili 4, Tamta Demurishvili 4, Paata Sabelashvili 8, Monique Foster 9 10, Liesl Hagan 9, Maia Butsashvili 11, Juliette Morgan 5 12, Francisco Averhoff 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
942. | Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation |
|
Kidney Int Rep. 2020 Jan 13;5(4):459-467.doi: 10.1016/j.ekir.2020.01.001. eCollection 2020 Apr.
Meghan E Sise 1, Ian A Strohbehn 2, Donald F Chute 2, Jenna Gustafson 2, Vivianna M Van Deerlin 3, Jennifer R Smith 3, Caren Gentile 3, David Wojciechowski 4, Winfred W Williams 1, Nahel Elias 5, Raymond T Chung 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
954. | Simeprevir, Daclatasvir, and Sofosbuvir for Hepatitis C Virus-Infected Patients: Long-term Follow-Up Results From the Open-Label, Phase II IMPACT Study |
|
Health Sci Rep. 2020 Feb 22;3(2):e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun.
Eric Lawitz 1, Fred Poordad 1, Julio A Gutierrez 2, Maria Beumont 3, Greet Beets 3, Ann Vandevoorde 3, Pieter Van Remoortere 4, Donghan Luo 4, Leen Vijgen 3, Veerle Van Eygen 3, Mohamed Gamil 3
|
|
|
955. | Elbasvir and Grazoprevir for Hepatitis C Virus Genotype 1 Infection in People With Recent Injecting Drug Use (DARLO-C): An Open-Label, Single-Arm, Phase 4, Multicentre Trial |
|
Health Sci Rep. 2020 Mar 15;3(2):e151. doi: 10.1002/hsr2.151. eCollection 2020 Jun.
Jason Grebely 1, Phillip Read 2, Evan B Cunningham 1, Martin Weltman 3, Gail V Matthews 1 4, Adrian Dunlop 5, Mark Montebello 6, Marianne Martinello 1 4, Rosie Gilliver 2, Philippa Marks 1, Tanya L Applegate 1, Gregory J Dore 1 4, DARLO-C Study Group
|
|
|
956. | Infective Endocarditis Among Persons Aged 18-64 Years With HIV, Hepatitis C Infection, or Opioid Use Disorder - United States, 2007-2017 |
|
Clin Infect Dis. 2020 Apr 9;ciaa372. doi: 10.1093/cid/ciaa372. Online ahead of print.
Cecillia Y Wong 1, Weiming Zhu 2, Gerard P Aurigemma 1, Nathan Furukawa 2, Eyasu H Teshale 3, Ya-Lin A Huang 2, Philip J Peters 2, Karen W Hoover 2
|
|
|
|
|
958. | Ombitasvir/paritaprevir/ritonavir & Dasabuvir ± Ribavirin Following Protease Inhibitors Failure - A Prospective Multi-Centre Trial |
|
BMC Infect Dis. 2020 Apr 3;20(1):264. doi: 10.1186/s12879-020-4921-3.
Liat Deutsch 1 2, Inbal Houri 1 2, Ziv Ben-Ari 2 3, Amir Shlomai 2 4, Ella Veitsman 2 3, Oranit Cohen-Ezra 2 3, Assaf Issachar 2 4, Orna Mor 5 6, Yael Gozlan 5, Rafael Bruck 1 2, Yoram Menachem 1 2, Shira Zelber-Sagi 1 7, Helena Katchman 1 2, Oren Shibolet 8 9
|
|
|
|
|
|
|
961. | Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017 |
|
J Clin Gastroenterol. 2020 Apr 3. doi: 10.1097/MCG.0000000000001344. Online ahead of print.
Philip R Spradling 1, Jian Xing 1, Loralee B Rupp 2, Anne C Moorman 1, Stuart C Gordon 2 3, Mei Lu 2, Eyasu H Teshale 1, Joseph A Boscarino 4, Mark A Schmidt 5, Yihe G Daida 6, Scott D Holmberg 1, Chronic Hepatitis Cohort Study (CHeCS) Investigators
|
|
|
|
|
963. | Antibody Avidity-Based Approach to Estimate Population-Level Incidence of Hepatitis C |
|
Hepatol. 2020 Mar 30;S0168-8278(20)30190-2. doi: 10.1016/j.jhep.2020.03.028.Online ahead of print.
Denali Boon 1, Veronica Bruce 2, Eshan U Patel 3, Jeffery Quinn 3, Aylur K Srikrishnan 4, Saravanan Shanmugam 4, Syed Iqbal 4, Pachamuthu Balakrishnan 4, Matthew Sievers 3, Gregory D Kirk 3, David L Thomas 3, Thomas C Quinn 5, Andrea L Cox 3, Kimberly A Page 2, Sunil S Solomon 6, Shruti H Mehta 3, Oliver Laeyendecker 5
|
|
|
|
|
965. | Health of Special Immigrant Visa Holders From Iraq and Afghanistan After Arrival Into the United States Using Domestic Medical Examination Data, 2014-2016: A Cross-Sectional Analysis |
|
PLoS Med. 2020 Mar 31;17(3):e1003083. doi: 10.1371/journal.pmed.1003083.eCollection 2020 Mar.
Gayathri S Kumar 1, Clelia Pezzi 1, Simone Wien 1, Blain Mamo 2, Kevin Scott 3, Colleen Payton 3, Kailey Urban 2, Stephen Hughes 4, Lori Kennedy 5, Nuny Cabanting 6, Jessica Montour 7, Melissa Titus 8, Jenny Aguirre 9, Breanna Kawasaki 5, Rebecca Ford 10, Emily S Jentes 1
|
|
|
|
|
|
|
|
|
969. | The Impact of SVR From Direct-Acting Antiviral- And Interferon-Based Treatments for HCV on Hepatocellular Carcinoma Risk |
|
J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295. Online ahead of print.
Naveed Z Janjua 1 2, Stanley Wong 1, Maryam Darvishian 1 2 3, Zahid A Butt 1 2, Amanda Yu 1, Mawuena Binka 1, Maria Alvarez 1, Ryan Woods 3, Eric M Yoshida 4, Alnoor Ramji 4, Jordan Feld 5, Mel Krajden 1 6
|
|
|
|
|
971. | Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Global Federation of International Societies of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN) |
|
J Pediatr Gastroenterol Nutr. 2020 Mar 20.
doi: 10.1097/MPG.0000000000002710.Online ahead of print.
Giuseppe Indolfi 1, Björn Fischler 2, Regino P Gonzalez-Peralta 3, Mirta Ciocca 4, Gilda Porta 5, Mohan Neelam 6, Mohammed El-Guindi 7, Deirdre Kelly 8, Yen-Hsuan Ni 9, Anupan Sibal 10, Daniel H Leung 11, Mei Hwei Chang 12, Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN)
|
|
|
972. | Population Impact of Direct-Acting Antiviral Treatment on New Presentations of Hepatitis C-related Decompensated Cirrhosis: A National Record-Linkage Study |
|
Gut. 2020 Mar 26;gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007. Online ahead of print.
Sharon J Hutchinson 1 2, Heather Valerio 3 2, Scott A McDonald 3 2, Alan Yeung 3 2, Kevin Pollock 3 2, Shanley Smith 3 2, Stephen Barclay 3 4, John F Dillon 5, Raymond Fox 6, Peter Bramley 7, Andrew Fraser 8 9, Nicholas Kennedy 10, Rory N Gunson 11, Kate Templeton 12, Hamish Innes 3 2, Allan McLeod 2, Amanda Weir 2, Peter C Hayes 13, David Goldberg 3 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
981. | Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors |
|
Prasad M1, Saade GR, Sandoval G, Hughes BL, Reddy UM, Mele L, Salazar A, Varner MW, Gyamfi-Bannerman C, Thorp JM Jr, Tita ATN, Swamy GK, Chien EK, Casey BM, Peaceman AM, El-Sayed YY, Iams JD, Gibbs RS, Sibai B, Wiese N, Kamili S, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Obstet Gynecol. 2020 Apr;135(4):778-788. doi: 10.1097/AOG.0000000000003754.
|
|
|
982. | Reinfection following successful direct-acting antiviral therapy for hepatitis Cinfection among people who inject drugs |
|
Cunningham EB1, Hajarizadeh B1, Amin J1,2, Hellard M3,4, Bruneau J5, Feld JJ6, Cooper C7, Powis J8, Litwin AH9, Marks P1, Dalgard O10, Conway B11, Moriggia A12,13, Stedman C14, Read P1,15, Bruggmann P16, Lacombe K17, Dunlop A18, Applegate TL1, Matthews GV1,19, Fraser C20, Dore GJ1,19, Grebely J1. Clin Infect Dis. 2020 Mar 12. pii: ciaa253. doi: 10.1093/cid/ciaa253. [Epub ahead of print]
|
|
|
|
|
984. | A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy |
|
Akiyama MJ1, Lipsey D1, Ganova-Raeva L2, Punkova L2, Agyemang L1, Sue A2, Ramachandran S2, Khudyakov Y2, Litwin AH3. J Infect Dis. 2020 Mar 9. pii: jiaa100. doi: 10.1093/infdis/jiaa100. [Epub ahead of print]
|
|
|
985. | Transplant Outcomes in Older Patients with Nonalcoholic Steatohepatitis Compared to Alcohol-Related Liver Disease and Hepatitis C |
|
Henson JB1, Wilder JM2,3, Kappus MR2, Barbas AS4, Moylan CA2, Niedzwiecki D5, Muir AJ2,3, Berg CL2, Patel YA2. Transplantation. 2020 Mar 6. doi: 10.1097/TP.0000000000003219. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
990. | Examination of using alcohol to cope, depressive symptoms, and perceived social support in persons with HIV and Hepatitis C |
|
Moitra E1, Anderson BJ2, Herman DS1,2, Hayaki J3, Pinkston MM1,4, Kim HN5,6, Stein MD7. AIDS Care. 2020 Feb 25:1-8. doi: 10.1080/09540121.2020.1734177. [Epub ahead of print]
|
|
|
991. | Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care |
|
Roberts K1, Macleod J1,2, Metcalfe C1,3, Hollingworth W1, Williams J4,5, Muir P6, Vickerman P1,2, Clement C2, Gordon F7, Irving W8, Waldron CA9, North P6, Moore P6, Simmons R5,10, Miners A4,5, Horwood J1,2, Hickman M11,2. BMJ. 2020 Feb 26;368:m322. doi: 10.1136/bmj.m322.
|
|
|
992. | Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial |
|
Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]
|
|
|
|
|
994. | Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis CTreatment: A Randomized Controlled Trial |
|
Davis JS1,2, Young M1, Marshall C3, Tate-Baker J3, Madison M3, Sharma S3, Silva C1, Jones T1, Davies J2,3. Open Forum Infect Dis. 2020 Jan 19;7(2):ofaa022. doi: 10.1093/ofid/ofaa022. eCollection 2020 Feb.
|
|
|
|
|
|
|
|
|
998. | Hepatitis C Virus Vaccine: Challenges and Prospects |
|
Duncan JD1,2,3, Urbanowicz RA1,2,3, Tarr AW1,2,3, Ball JK1,2,3. Vaccines (Basel). 2020 Feb 17;8(1). pii: E90. doi: 10.3390/vaccines8010090.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1006. | Hepatitis C Testing Among Perinatally Exposed Infants |
|
Lopata SM1,2, McNeer E3,4, Dudley JA5, Wester C6, Cooper WO7,3,5, Carlucci JG7,8, Espinosa CM9,10, Dupont W4,5, Patrick SW7,2,3,5. Pediatrics. 2020 Mar;145(3). pii: e20192482. doi: 10.1542/peds.2019-2482. Epub 2020 Feb 14.
|
|
|
|
|
1008. | Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R) |
|
Schmitt A1, Günther R2, Mauss S3, Boeker KHW4, Buggisch P5, Hillenbrand H6, John C7, Klinker H8, Pathil A9,10, Simon KG11, Serfert Y12, Niederau C13, Vermehren J10, Wedemeyer H12,14,15, Sarrazin C1,10. Z Gastroenterol. 2020 Feb 10. doi: 10.1055/a-1068-3056. [Epub ahead of print]
|
|
|
|
|
|
|
1011. | A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program |
|
Lee KS1,2, Quintiliani L1,3, Heinz A4, Johnson NL3, Xuan Z3, Truong V2, Lasser KE1,2,3. PLoS One. 2020 Feb 11;15(2):e0228767. doi: 10.1371/journal.pone.0228767. eCollection 2020
|
|
|
1012. | Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment |
|
Kim NJ1, Pearson M1, Vutien P1, Su F1, Moon AM2, Berry K3, Green PK3, Williams EC3,4, Ioannou GN1,5. Hepatol Commun. 2020 Jan 2;4(2):314-324. doi: 10.1002/hep4.1464. eCollection 2020 Feb.
|
|
|
|
|
|
|
|
|
1016. | Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study |
|
Adinolfi LE1, Petta S2, Fracanzani AL3, Coppola C4, Narciso V5, Nevola R6, Rinaldi L6, Calvaruso V2, Staiano L4, Di Marco V2, Marrone A6, Pafundi PC6, Solano A5, Lombardi R3, Sasso FC6, Saturnino M4, Rini F2, Guerrera B6, Troina G2, Giordano M6, Craxì A2. Atherosclerosis. 2020 Jan 21;296:40-47. doi: 10.1016/j.atherosclerosis.2020.01.010. [Epub ahead of print]
|
|
|
1017. | Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs |
|
Rosenthal ES1,2, Silk R1,2, Mathur P1,2, Gross C1,2, Eyasu R1,2, Nussdorf L2,3, Hill K2,3, Brokus C2,3, D'Amore A2,3, Sidique N2,3, Bijole P4, Jones M4, Kier R4, McCullough D4, Sternberg D4, Stafford K1, Sun J3, Masur H2,3, Kottilil S1,2, Kattakuzhy S1,2. Clin Infect Dis. 2020 Feb 3. pii: ciaa105. doi: 10.1093/cid/ciaa105. [Epub ahead of print]
|
|
|
|
|
1019. | Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project |
|
Caven M1, Robinson EM1,2, Eriksen AJ3, Fletcher EH1,3, Dillon JF1,2. J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269. [Epub ahead of print]
|
|
|
1020. | Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection |
|
Scott N1,2, Snell G3, Westall G3, Pilcher D4,5, Raggatt M6,7, Walker RG8,9, Hellard M6,4,7, Peleg AY7,10, Doyle J6,7. Sci Rep. 2020 Jan 29;10(1):1459. doi: 10.1038/s41598-020-58215-z.
|
|
|
|
|
|
|
1023. | Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort |
|
Soria A1, Fava M1,2, Bernasconi DP3, Lapadula G1, Colella E1, Valsecchi MG3, Migliorino GM1, D'Ambrosio R4, Landonio S5, Schiavini M5, Spinetti A6, Carriero C6, Degasperi E4, Cologni G7, Gatti F8, Viganò P8, Hasson H9, Uberti-Foppa C10, Pasulo L7, Baiguera C11, Rossotti R11, Vinci M11, Puoti M11, Giorgini A12, Menzaghi B13, Lombardi A14, Pan A15, Aghemo A16, Grossi PA17, Boldizzoni R18, Colombo S18, Viganò M19, Rumi MG19, Del Poggio P20, Valenti L21, Giglio O22, De Bona A12, d'Arminio Monforte A12, Colombo A22, Spinelli O22, Pigozzi MG6, Molteni C23, Bonfanti P23, Terreni N24, Perini P25, Capretti A26, Bella D27, Liani C27, Polo S27, Aimo G27, Pagnucco L14, Bhoori S28, Centenaro R29, Graffeo M30, Ciaccio A31, Dionigi E32, Lazzaroni S33, Carderi I34, Di Marco M35, Rizzardini G5, Noventa F36, Lampertico P4, Fagiuoli S7. Liver Int. 2020 Jan 22. doi: 10.1111/liv.14386. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1027. | Global prevalence of hepatitis C virus in children in 2018: a modelling study |
|
Schmelzer J1, Dugan E1, Blach S1, Coleman S1, Cai Z1, DePaola M1, Estes C1, Gamkrelidze I1, Jerabek K1, Ma S1, Montoya S1, Razavi-Shearer D1, Razavi-Shearer K1, Robbins-Scott S1, Razavi H2, El Sayed MH3. Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30385-1. doi: 10.1016/S2468-1253(19)30385-1. [Epub ahead of print]
|
|
|
1028. | Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials |
|
Poordad F1, Castro RE2, Asatryan A3, Aguilar H4, Cacoub P5,6, Dieterich D7, Marinho RT8, Carvalho A9, Siddique A10, Hu YB11, Charafeddine M12, Bondin M11, Khan N11, Cohen DE11, Felizarta F13. J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1036. | Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure |
|
Chen Q1, Perales C1, Soria ME2, García-Cehic D1, Gregori J3, Rodríguez-Frías F4, Buti M1, Crespo J5, Calleja JL6, Tabernero D4, Vila M7, Lázaro F8, Rando-Segura A7, Nieto-Aponte L7, Llorens-Revull M1, Cortese MF7, Fernandez-Alonso I2, Castellote J9, Niubó J10, Imaz A11, Xiol X9, Castells L1, Riveiro-Barciela M1, Llaneras J1, Navarro J12, Vargas-Blasco V1, Augustin S1, Conde I13, Rubín Á13, Prieto M13, Torras X14, Margall N15, Forns X16, Mariño Z16, Lens S16, Bonacci M17, Pérez-Del-Pulgar S16, Londoño MC16, García-Buey ML18, Sanz-Cameno P18, Morillas R19, Martró E20, Saludes V20, Masnou-Ridaura H19, Salmerón J21, Quíles R21, Carrión JA22, Forné M23, Rosinach M23, Fernández I24, García-Samaniego J25, Madejón A25, Castillo-Grau P26, López-Núñez C27, Ferri MJ28, Durández R29, Sáez-Royuela F30, Diago M31, Gimeno C32, Medina R32, Buenestado J33, Bernet A34, Turnes J35, Trigo-Daporta M36, Hernández-Guerra M37, Delgado-Blanco M38, Cañizares A39, Arenas JI40, Gomez-Alonso MJ6, Rodríguez M41, Deig E42, Olivé G43, Río OD43, Cabezas J5, Quiñones I44, Roget M45, Montoliu S46, García-Costa J47, Force L48, Blanch S49, Miralbés M50, López-de-Goicoechea MJ51, García-Flores A52, Saumoy M11, Casanovas T9, Baliellas C9, Gilabert P9, Martin-Cardona A9, Roca R9, Barenys M53, Villaverde J9, Salord S9, Camps B9, Silvan di Yacovo M9, Ocaña I12, Sauleda S54, Bes M54, Carbonell J2, Vargas-Accarino E2, Ruzo SP2, Guerrero-Murillo M2, Von Massow G2, Costafreda MI55, López RM7, González-Moreno L18, Real Y18, Acero-Fernández D27, Viroles S27, Pamplona X27, Cairó M23, Ocete MD32, Macías-Sánchez JF43, Estébanez A5, Quer JC46, Mena-de-Cea Á38, Otero A38, Castro-Iglesias Á38, Suárez F38, Vázquez Á38, Vieito D38, López-Calvo S38, Vázquez-Rodríguez P38, Martínez-Cerezo FJ56, Rodríguez R47, Macenlle R47, Cachero A57, Mereish G57, Mora-Moruny C58, Fábregas S58, Sacristán B59, Albillos A60, Sánchez-Ruano JJ61, Baluja-Pino R62, Fernández-Fernández J62, González-Portela C62, García-Martin C63, Sánchez-Antolín G64, Andrade RJ65, Simón MA66, Pascasio JM67, Romero-Gómez M68, Antonio Del-Campo J68, Domingo E69, Esteban R1, Esteban JI70, Quer J71. Antiviral Res. 2019 Dec 16;174:104694. doi: 10.1016/j.antiviral.2019.104694. [Epub ahead of print]
|
|
|
|
|
|
|
1039. | Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C |
|
Schlendorf KH1, Zalawadiya S1, Shah AS1, Perri R1, Wigger M1, Brinkley DM1, Danter MR1, Menachem JN1, Punnoose LR1, Balsara K1, Sacks SB1, Ooi H1, Awad JA1, Sandhaus E1, Schwartz C1, O'Dell H1, Carver AB1, Edmonds CL1, Ruzevich-Scholl S1, Lindenfeld J1. JAMA Cardiol. 2019 Dec 18. doi: 10.1001/jamacardio.2019.4748. [Epub ahead of print]
|
|
|
1040. | Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs |
|
Irvin R1, Chander G1, Ward KM1, Manogue S1, Falade-Nwulia O1, Moon J1, Sutcliffe CG2, Brinkley S1, Haselhuhn T1, Katz S1, Herne K1, Arteaga L1, Thomas DL1, Mehta SH2, Sulkowski MS1. J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251. [Epub ahead of print]
|
|
|
1041. | "Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy |
|
Jessop AB1, Bass SB2, Brajuha J2, Alhajji M2, Burke M3, Gashat MT3, Wellington C2, Ventriglia N2, Coleman J2, D'Avanzo P2. J Subst Abuse Treat. 2020 Feb;109:23-33. doi: 10.1016/j.jsat.2019.11.001. Epub 2019 Nov 6.
|
|
|
1042. | Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study |
|
Ferguson TF1,2, Rosen E1,2, Carr R3, Brashear M1,4, Simon L1,5, Theall KP1,4, Ronis MJ1,6, Welsh DA1,7, Molina PE1,5. Alcohol Alcohol. 2019 Dec 8. pii: agz089. doi: 10.1093/alcalc/agz089. [Epub ahead of print]
|
|
|
|
|
1044. | Securing sustainable funding for viral hepatitis elimination plans |
|
Hatzakis A1, Lazarus JV2, Cholongitas E3, Baptista-Leite R4,5, Boucher C6, Busoi CS7, Deuffic-Burban S8,9, Chhatwal J10, Esmat G11,12, Hutchinson S13,14, Malliori MM15, Maticic M16,17, Mozalevskis A18, Negro F19, Papandreou GA20, Papatheodoridis GV21, Peck-Radosavljevic M22, Razavi H23, Reic T24, Schatz E25, Tozun N26, Younossi Z27, Manns MP28. Liver Int. 2019 Dec 5. doi: 10.1111/liv.14282. [Epub ahead of print]
|
|
|
|
|
|
|
1047. | HCV NAT positive solid organ allografts transplanted into HCV negative recipients: A real-world experience |
|
Kapila N1,2, Menon KVN3, Al-Khalloufi K4, Vanatta JM4, Murgas C4, Reino D4, Ebaid S4, Shaw JJ4, Agrawal N4, Rhazouani S4, Navas V4, Sheffield C4, Rahman AU1, Castillo M5, Miller C3, Quintini C3, Zervos XB4. Hepatology. 2019 Oct 28. doi: 10.1002/hep.31011. [Epub ahead of print]
|
|
|
|
|
1049. | Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections |
|
Dietz J1, Spengler U2, Müllhaupt B3, Schulze Zur Wiesch J4, Piecha F4, Mauss S5, Seegers B6, Hinrichsen H6, Antoni C7, Wietzke-Braun P8, Peiffer KH1, Berger A9, Matschenz K10, Buggisch P10, Backhus J11, Zizer E11, Boettler T12, Neumann-Haefelin C12, Semela D13, Stauber R14, Berg T15, Berg C16, Zeuzem S1, Vermehren J1, Sarrazin C17; European HCV Resistance Study Group. Clin Gastroenterol Hepatol. 2019 Nov 6. pii: S1542-3565(19)31260-1. doi: 10.1016/j.cgh.2019.10.051. [Epub ahead of print]
|
|
|
|
|
1051. | The Elimination of Hepatitis C as a Public Health Threat |
|
Hellard M1,2,3,4, Schroeder SE1,2, Pedrana A1,2, Doyle J1,3, Aitken C1,2. Cold Spring Harb Perspect Med. 2019 Nov 11. pii: a036939. doi: 10.1101/cshperspect.a036939. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1056. | Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis |
|
Boyle A1,2, Marra F1,2, Peters E3, Datta S4, Ritchie T5, Priest M6, Heydtmann M7, Barclay ST8,9. J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239. [Epub ahead of print]
|
|
|
1057. | Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies |
|
Darvishian M1,2,3,4, Wong S1, Binka M1, Yu A1, Ramji A2, Yoshida EM5, Wong J1,2, Rossi C1,2, Butt ZA1,2, Bartlett S1,2, Pearce ME1,2, Samji H1,6, Cook D1, Alvarez M1, Chong M1, Tyndall M1,2, Krajden M1,2, Janjua NZ1,2. J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]
|
|
|
|
|
|
|
1060. | Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis Ctreatment for people who inject drugs: The HERO study |
|
Litwin AH1, Jost J2, Wagner K3, Heo M4, Karasz A5, Feinberg J6, Kim AY7, Lum PJ8, Mehta SH9, Taylor LE10, Tsui JI11, Pericot-Valverde I12, Page K3; HERO Study Group. Contemp Clin Trials. 2019 Dec;87:105859. doi: 10.1016/j.cct.2019.105859. Epub 2019 Oct 24.
|
|
|
|
|
|
|
1063. | Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study |
|
Bajis S1, Grebely J1, Hajarizadeh B1, Applegate T1, Marshall AD1,2, Harrod ME3, Byrne J4, Bath N3, Read P5, Edwards M6, Gorton C7, Hayllar J8, Cock V9, Peterson S10, Thomson C11, Weltman M12, Jefferies M13, Wood W14, Haber P15, Ezard N16,17, Martinello M1, Maher L1,18, Dore GJ1; LiveRLife Study Group. J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1067. | Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation |
|
Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Transplantation. 2019 Oct 18. doi: 10.1097/TP.0000000000003014. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
1073. | Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals |
|
Serper M1, Evon DM2, Stewart PW3, Lok AS4, Amador J3, Reeve BB5, Golin CE6, Fried MW7, Reddy KR1, Sterling RK8, Sarkar S9, Di Bisceglie AM10, Lim JK11, Nelson DR12, Reau N13. J Gen Intern Med. 2019 Oct 28. doi: 10.1007/s11606-019-05394-9. [Epub ahead of print]
|
|
|
1074. | Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy |
|
Cunningham EB1, Hajarizadeh B1, Amin J1,2, Litwin AH3,4,5, Gane E6, Cooper C7, Lacombe K8, Hellard M9,10, Read P1,11, Powis J12, Dalgard O13,14, Bruneau J15, Matthews GV1,16, Feld JJ17, Dillon JF18, Shaw D19, Bruggmann P20, Conway B21, Fraser C22, Marks P1, Dore GJ1,16, Grebely J1. Clin Infect Dis. 2019 Nov 2. pii: ciz1089. doi: 10.1093/cid/ciz1089. [Epub ahead of print]
|
|
|
|
|
1076. | Glecaprevir/pibrentasvir for 8?weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial |
|
Brown RS Jr1, Buti M2, Rodrigues L3, Chulanov V4, Chuang WL5, Aguilar H6, Horváth G7, Zuckerman E8, Carrion BR9, Rodriguez-Perez F10, Urbánek P11, Abergel A12, Cohen E3, Lovell SS3, Schnell G3, Lin CW3, Zha J3, Wang S3, Trinh R3, Mensa FJ3, Burroughs M3, Felizarta F13. J Hepatol. 2019 Nov 2. pii: S0168-8278(19)30647-6. doi: 10.1016/j.jhep.2019.10.020. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1081. | Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI?=?1 in a Single-Arm, Open-Label, Multicenter Study. |
|
Fontana RJ1, Lens S2, McPherson S3, Elkhashab M4, Ankoma-Sey V5, Bondin M6, Dos Santos AGP6, Xue Z6, Trinh R6, Porcalla A6, Zeuzem S7. Adv Ther. 2019 Oct 23. doi: 10.1007/s12325-019-01123-0. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
1087. | Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol) |
|
Hickman M1, Dillon JF2, Elliott L3, De Angelis D4, Vickerman P5, Foster G6,7, Donnan P8, Eriksen A9, Flowers P3, Goldberg D3,10, Hollingworth W5, Ijaz S11, Liddell D12, Mandal S11, Martin N13, Beer LJZ14, Drysdale K6,7, Fraser H5, Glass R11, Graham L15, Gunson RN16, Hamilton E17, Harris H11, Harris M18, Harris R11, Heinsbroek E11, Hope V19, Horwood J5, Inglis SK14, Innes H3,10, Lane A5, Meadows J5, McAuley A3,10, Metcalfe C5, Migchelsen S11, Murray A17, Myring G5, Palmateer NE3,10, Presanis A4, Radley A2,20, Ramsay M11, Samartsidis P4, Simmons R11, Sinka K11, Vojt G3, Ward Z5, Whiteley D21, Yeung A3,10, Hutchinson SJ3,10. BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.
|
|
|
1088. | Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016 |
|
Zou B1, Yeo YH1, Le MH1, Henry L1, Chang ET2,3, Lok AS4, Cheung R1,5, Nguyen MH1. J Infect Dis. 2019 Sep 27. pii: jiz479. doi: 10.1093/infdis/jiz479. [Epub ahead of print]
|
|
|
1089. | Eradicating hepatitis C virus: The APRN |
|
Pozza R1, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Nurse Pract. 2019 Nov;44(11):16-27. doi: 10.1097/01.NPR.0000586008.23422.2c.
|
|
|
1090. | Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials |
|
Brown A1, Welzel TM2, Conway B3, Negro F4, Bräu N5, Grebely J6, Puoti M7, Aghemo A8, Kleine H9, Pugatch D10, Mensa FJ10, Chen YJ10, Lei Y10, Lawitz E11, Asselah T12. Liver Int. 2019 Sep 30. doi: 10.1111/liv.14266. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
1096. | Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline |
|
Gordon CE1, Berenguer MC2, Doss W3, Fabrizi F4, Izopet J5, Jha V6, Kamar N7, Kasiske BL8, Lai CL9, Morales JM10, Patel PR11, Pol S12, Silva MO13, Balk EM14, Earley A15, Di M16, Cheung M15, Jadoul M17, Martin P18. Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539. [Epub ahead of print]
|
|
|
1097. | The case for a universal hepatitis C vaccine to achieve hepatitis C elimination |
|
Scott N1,2, Wilson DP3,4, Thompson AJ5,6, Barnes E7,8, El-Sayed M9, Benzaken AS10, Drummer HE3,11,12, Hellard ME3,4,12,13. BMC Med. 2019 Sep 18;17(1):175. doi: 10.1186/s12916-019-1411-9.
|
|
|
|
|
|
|
|
|
|
|
1102. | Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-?G and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy |
|
Emmanuel B1, El-Kamary SS2, Magder LS2, Stafford KA1,2, Charurat ME3, Chairez C4, McLaughlin M4, Hadigan C4, Prokunina-Olsson L5, O'Brien TR5, Masur H6, Kottilil S1. J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1106. | HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study |
|
Cooper CL1,2,3, Galanakis C4, Donelle J5, Kwong J5,6,7, Boyd R8, Boucher L9, Kendall CE4,5,9,10,11. BMC Infect Dis. 2019 Aug 23;19(1):712. doi: 10.1186/s12879-019-4315-6.
|
|
|
|
|
1108. | Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care |
|
McMahon BJ1,2, Townshend-Bulson L1, Homan C1, Gounder P2, Barbour Y1, Hewitt A1, Bruden D2, Espera H1, Plotnik J1, Gove J1, Stevenson TJ1, Luna SV1, Simons BC1,2. Clin Infect Dis. 2019 Aug 28. pii: ciz832. doi: 10.1093/cid/ciz832. [Epub ahead of print]
|
|
|
|
|
|
|
1111. | Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV |
|
Saeed S1,2, Strumpf E1,3, Moodie EEM1, Wong L2, Cox J1,2, Walmsley S4,5, Tyndall M6, Cooper C5,7, Conway B8, Hull M5,9, Martel-Laferriere V10, Gill J11, Wong A12, Vachon ML13, Klein MB2,5; Canadian Co-Infection Cohort Study Investigators. Clin Infect Dis. 2019 Aug 28. pii: ciz833. doi: 10.1093/cid/ciz833. [Epub ahead of print]
|
|
|
|
|
|
|
1114. | Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C? |
|
Ferrari SM1, Fallahi P2, Ruffilli I1, Elia G1, Ragusa F1, Paparo SR1, Patrizio A1, Mazzi V1, Colaci M3, Giuggioli D4, Ferri C4, Antonelli A1. J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019.
|
|
|
1115. | Hepatitis C Core-Antigen Testing from Dried Blood Spots |
|
Biondi MJ1,2,3, van Tilborg M4,5, Smookler D6,7, Heymann G8, Aquino A9, Perusini S10, Mandel E11,12, Kozak RA13, Cherepanov V14, Kowgier M15, Hansen B16,17, Goneau LW18, Janssen HLA19,20, Mazzulli T21,22, Cloherty G23, de Knegt RJ24, Feld JJ25,26,27. Viruses. 2019 Sep 6;11(9). pii: E830. doi: 10.3390/v11090830.
|
|
|
|
|
|
|
1118. | Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study |
|
Trickey A1,2, Fraser H1, Lim AG1, Walker JG1, Peacock A3, Colledge S3, Leung J3,4,5, Grebely J5,6, Larney S3, Martin NK1,7, Degenhardt L3, Hickman M1,2, May MT1,2,8, Vickerman P1,2. J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187. [Epub ahead of print]
|
|
|
|
|
1120. | Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities |
|
Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
|
|
|
1121. | Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study |
|
Lee KK1, Stelzle D2, Bing R1, Anwar M1, Strachan F1, Bashir S1, Newby DE1, Shah JS3, Chung MH3, Bloomfield GS4, Longenecker CT5, Bagchi S6, Kottilil S6, Blach S7, Razavi H7, Mills PR8, Mills NL9, McAllister DA10, Shah ASV11. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804. doi: 10.1016/S2468-1253(19)30227-4. Epub 2019 Jul 31.
|
|
|
1122. | We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade |
|
Lazarus JV1, Pericàs JM2, Picchio C1, Cernosa J3, Hoekstra M1, Luhmann N4, Maticic M5,6, Read P7, Robinson EM8, Dillon JF8. J Intern Med. 2019 Aug 31. doi: 10.1111/joim.12972. [Epub ahead of print]
|
|
|
1123. | Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities |
|
Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
|
|
|
|
|
|
|
1126. | Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study |
|
Weinstein AA1, Estep JM2, de Avila L2, Curry M3, Golabi P2, Escheik C2, Birerdinc A2, Stepanova M4, Price JK2, Gerber L5, Younossi ZM6. J Neuroimmunol. 2019 Oct 15;335:577022. doi: 10.1016/j.jneuroim.2019.577022. Epub 2019 Aug 14.
|
|
|
|
|
|
|
|
|
1130. | Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities |
|
Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
|
|
|
|
|
1132. | Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population |
|
Stevens ER1,2, Nucifora KA1, Hagan H2,3, Jordan AE3,4, Uyei J1, Khan B5, Dombrowski K5, des Jarlais D2, Braithwaite RS1,3. Clin Infect Dis. 2019 Aug 11. pii: ciz726. doi: 10.1093/cid/ciz726. [Epub ahead of print]
|
|
|
|
|
|
|
1135. | Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy |
|
Lok AS1, Sulkowski MS2, Kort JJ3, Willner I4, Reddy KR5, Shiffman ML6, Hassan MA7, Pearlman BL8, Hinestrosa F9, Jacobson IM10, Morelli G11, Peter JA12, Vainorius M13, Michael LC14, Fried MW15, Wang GP16, Lu W17, Larsen L18, Nelson DR19. Gastroenterology. 2019 Aug 8. pii: S0016-5085(19)41199-2. doi: 10.1053/j.gastro.2019.08.008. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1140. | Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department |
|
Hutton J1, Doyle J2, Zordan R3, Weiland T3, Cocco A4, Howell J5, Iser S6, Snell J7, Fry S8, New K8, Sloane R8, Jarman M7, Phan D7, Tran S7, Pedrana A9, Williams B9, Johnson J10, Glasgow S8, Thompson A7. Int J Drug Policy. 2019 Jul 24. pii: S0955-3959(19)30176-8. doi: 10.1016/j.drugpo.2019.06.021. [Epub ahead of print]
|
|
|
1141. | The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination |
|
Safreed-Harmon K1, Blach S2, Aleman S3,4, Boe Kielland K5, Bollerup S6, Cooke G7, Dalgard O8,9, Dillon JF10, Dore GJ11, Duberg AS12, Grebely J11, Midgard H13, Porter K14, Razavi H2, Tyndall M15, Weis N6,16, Lazarus JV1,17. Clin Infect Dis. 2019 Jul 28. pii: ciz714. doi: 10.1093/cid/ciz714. [Epub ahead of print]
|
|
|
1142. | Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort |
|
Macken L1,2, Gelson W3, Priest M4, Abouda G5, Barclay S4,6, Fraser A7, Healy B8, Irving W9, Verma S1,2. J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552. [Epub ahead of print]
|
|
|
1143. | Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study |
|
Rentsch CT1,2, Edelman EJ3,4, Justice AC5,3,4, Marshall BDL6, Xu K7, Smith AH7, Crystal S8, Gaither JR9,10, Gordon AJ11, Smith RV12, Kember RL13,14, Polimanti R7, Gelernter J7,15, Fiellin DA3,4, Tate JP5,3, Kranzler HR14,16, Becker WC3,10; VACS Project Team. AIDS Behav. 2019 Jul 17. doi: 10.1007/s10461-019-02608-3. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1147. | Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs |
|
Barbosa C1, Fraser H2, Hoerger TJ1, Leib A3, Havens JR4, Young A4, Kral A1, Page K5, Evans J6, Zibbell J1, Hariri S7, Vellozzi C8, Nerlander L7, Ward JW7, Vickerman P2. Addiction. 2019 Jul 15. doi: 10.1111/add.14731. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1154. | Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study |
|
Lanini S1, Bartolini B1, Taibi C1, Agresta A1, Garbuglia AR1, Montaldo C1, Pisapia R1, D'Offizi G1, Scognamiglio P1, Capobianchi MR1, Zumla A2, Ippolito G1. New Microbiol. 2019 Jul 15;42(2). [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1158. | Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners |
|
Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
|
|
|
1159. | HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center |
|
Calner P1, Sperring H2, Ruiz-Mercado G3, Miller NS4, Andry C4, Battisti L5, Scrudder K3, Shea F3, Chan A3, Schechter-Perkins EM1. PLoS One. 2019 Jul 10;14(7):e0218388. doi: 10.1371/journal.pone.0218388. eCollection 2019.
|
|
|
|
|
|
|
1162. | Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners |
|
Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
|
|
|
1163. | Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016 |
|
Nolen LD1, Gustin C2, Seeman S1, Murphy N2, Truitt S2, Schillie S3, Bruce MG1, Bruden D1, Tiesinga J4, McMahon B4. Can J Gastroenterol Hepatol. 2019 Jun 2;2019:8654741. doi: 10.1155/2019/8654741. eCollection 2019.
|
|
|
|
|
|
|
1166. | Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection |
|
Stevenson TJ1, Barbour Y1, McMahon BJ1, Townshend-Bulson L1, Hewitt AM1, Espera HGF1, Homan C1, Holck P1, Luna SV1, Knall C2, Simons BC1,2. Open Forum Infect Dis. 2019 May 17;6(6):ofz223. doi: 10.1093/ofid/ofz223. eCollection 2019 Jun.
|
|
|
|
|
|
|
1169. | Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C |
|
Schwarz KB1, Rosenthal P2, Murray KF3, Honegger JR4, Hardikar W5, Hague R6, Mittal N7, Massetto B8, Brainard DM8, Hsueh CH8, Shao J8, Parhy B8, Narkewicz MR9, Rao GS10, Whitworth S11, Bansal S12, Balistreri WF13. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830. [Epub ahead of print]
|
|
|
|
|
|
|
1172. | Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs |
|
Llaneras J1, Riveiro-Barciela M2, Lens S3, Diago M4, Cachero A5, García-Samaniego J6, Conde I7, Arencibia A8, Arenas J9, Gea F10, Torras X11, Luis Calleja J12, Antonio Carrión J13, Fernández I14, María Morillas R15, Miguel Rosales J16, Carmona I17, Fernández-Rodríguez C18, Hernández-Guerra M19, Llerena S20, Bernal V21, Turnes J22, González-Santiago JM23, Montoliu S24, Figueruela B25, Badia E26, Delgado M27, Fernández-Bermejo M28, Iñarrairaegui M29, Manuel Pascasio J30, Esteban R2, Mariño Z3, Buti M31. J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345-9. doi: 10.1016/j.jhep.2019.06.002. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
1178. | A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY) |
|
Wilson E1, Covert E2, Hoffmann J1, Comstock E1, Emmanuel B1, Tang L1, Husson J1, Chua J1, Price A1, Mathur P1, Rosenthal E1, Kattakuzhy S1, Masur H3, Kottilil S1. J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307-1. doi: 10.1016/j.jhep.2019.05.021. [Epub ahead of print]
|
|
|
|
|
|
|
1181. | Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study |
|
Persico M1, Aglitti A1, Milella M2, Coppola C3, Messina V4, Claar E5, Gentile I6, Sogari F7, Pierri P8, Surace LA9, Morisco F10, Tundo P11, Brancaccio G12, Serviddio G13, Gatti P14, Termite AP15, Di Costanzo GG16, Caroleo B17, Cozzolongo R18, Coppola N19, Longo A20, Fontanella L21, Federico A22, Rosato V1,5, Terrenato I23, Masarone M1. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14170. [Epub ahead of print]
|
|
|
1182. | The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance |
|
Stopka TJ1, Jacque E2, Kelso P3, Guhn-Knight H4, Nolte K5, Hoskinson R Jr4, Jones A3, Harding J6, Drew A7, VanDonsel A3, Friedmann PD4. Prev Med. 2019 May 31:105740. doi: 10.1016/j.ypmed.2019.05.028. [Epub ahead of print]
|
|
|
1183. | Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs |
|
Coffin PO1,2, Santos GM1,2, Behar E1, Hern J1, Walker J1, Matheson T1, Kinnard EN1,3, Silvis J1, Vittinghoff E2, Fox R2, Page K2. PLoS One. 2019 Jun 3;14(6):e0217471. doi: 10.1371/journal.pone.0217471. eCollection 2019.
|
|
|
|
|
1185. | Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States - a Rural and Urban Comparison |
|
Fraser H1, Vellozzi C2, Hoerger TJ3, Evans JL4, Kral AH3, Havens J5, Young AM5,6, Stone J1, Handanagic S7, Hariri S8, Barbosa C3, Hickman M1, Leib A9, Martin NK1,10, Nerlander L7, Raymond HF11, Page K12, Zibbell J3, Ward JW8,13, Vickerman P1. Am J Epidemiol. 2019 May 31. pii: kwz097. doi: 10.1093/aje/kwz097. [Epub ahead of print]
|
|
|
1186. | Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study |
|
Williams B1, Howell J2, Doyle J3, Thompson AJ4, Draper B5, Layton C6, Latham N7, Bramwell F6, Membrey D6, Mcpherson M8, Roney J9, Stoové M5, Hellard ME10, Pedrana A11. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30134-3. doi: 10.1016/j.drugpo.2019.05.012. [Epub ahead of print]
|
|
|
1187. | Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs |
|
Latham NH1,2, Doyle JS1,3, Palmer AY1, Vanhommerig JW1, Agius P1,4, Goutzamanis S1,4, Li Z1, Pedrana A1,5, Gottfredsson M6,7,8, Bouscaillou J9, Luhmann N9, Mazhnaya A10,11, Altice FL12,13, Saeed S14, Klein M15, Falade-Nwulia OO16, Aspinall E17,18, Hutchinson S17,18, Hellard ME1,3,5,19, Sacks-Davis R1,4,20. Liver Int. 2019 May 24. doi: 10.1111/liv.14152. [Epub ahead of print]
|
|
|
|
|
1189. | Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project |
|
Rojas Rojas T1, Di Beo V1, Delorme J2, Barre T1, Mathurin P3, Protopopescu C1, Bailly F4, Coste M1, Authier N2, Carrieri MP5, Rolland B6, Marcellin F1. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30135-5. doi: 10.1016/j.drugpo.2019.05.013. [Epub ahead of print]
|
|
|
|
|
1191. | Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs |
|
Gutkind S1, Schackman BR1, Morgan JR2, Leff JA1, Agyemang L3, Murphy SM1, Akiyama MJ3, Norton BL3, Litwin AH4,5, Linas BP2,6. Clin Infect Dis. 2019 May 16. pii: ciz384. doi: 10.1093/cid/ciz384. [Epub ahead of print]
|
|
|
1192. | Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons |
|
Assoumou SA1,2, Tasillo A1, Vellozzi C3, Yazdi GE1, Wang J1, Nolen S1, Hagan L4, Thompson W4, Randall LM5, Strick L6,7, Salomon JA8, Linas BP1,2,9.
|
|
|
1193. | Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE |
|
Teixeira PA1, Bresnahan MP2, Laraque F2, Litwin AH3, Shukla SJ3, Schwartz JM3, Reynoso S3, Perumalswami PV4, Weiss JM4, Wyatt B4, Schackman BR1. Learn Health Syst. 2018 Jul;2(3). pii: e10056. doi: 10.1002/lrh2.10056. Epub 2018 May 10.
|
|
|
|
|
|
|
|
|
1197. | Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort) |
|
Costa M1,2, Rojas Rojas T1,2, Lacoste D3, Villes V1,2, Aumaitre H4, Protopopescu C1,2, Yaya I1,2, Wittkop L5,6, Krause J7, Salmon-Céron D8,9, Marcellin F1,2, Sogni P8,10,11, Carrieri MP1,2; ANRS CO13 HEPAVIH Study Group. Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1207. | The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration |
|
Gidwani-Marszowski R1,2,3, Owens DK4,5, Lo J6, Goldhaber-Fiebert JD5, Asch SM4,7, Barnett PG6,4,5. Appl Health Econ Health Policy. 2019 Apr 27. doi: 10.1007/s40258-019-00468-5. [Epub ahead of print]
|
|
|
|
|
|
|
1210. | Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment |
|
Voils CI1,2, King HA3,4,5, Thorpe CT6,7, Blalock DV3,8, Kronish IM9, Reeve BB4, Boatright C3, Gellad ZF3,10. Dig Dis Sci. 2019 Apr 29. doi: 10.1007/s10620-019-05621-7. [Epub ahead of print]
|
|
|
1211. | The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study |
|
Trickey A1, Fraser H2, Lim AG2, Peacock A3, Colledge S3, Walker JG2, Leung J4, Grebely J5, Larney S3, Martin NK6, Hickman M7, Degenhardt L3, May MT8, Vickerman P7. Lancet Gastroenterol Hepatol. 2019 Apr 10. pii: S2468-1253(19)30085-8. doi: 10.1016/S2468-1253(19)30085-8. [Epub ahead of print]
|
|
|
|
|
1213. | Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study |
|
Bajis S1, Grebely J1, Cooper L2, Smith J2, Owen G2, Chudleigh A2, Hajarizadeh B1, Martinello M1, Adey S3, Read P4, Gilliver R4, Applegate T1, Treloar C5, Maher L1, Dore GJ1. J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112. [Epub ahead of print]
|
|
|
|
|
1215. | Liver Fibrosis Determination |
|
Lai M1, Afdhal NH2. Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.
|
|
|
|
|
1217. | Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis |
|
Back D1, Belperio P2, Bondin M3, Negro F4, Talal AH5, Park C3, Zhang Z3, Pinsky B3, Crown E3, Mensa FJ3, Marra F1. J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1221. | HIV and HCV screening among trauma patients |
|
Simoncini GM1, Oyola-Jimenez J1, Singleton D1, Volgraf J2, Ramsey FV3, Goldberg A4. Int J STD AIDS. 2019 Apr 8:956462419829590. doi: 10.1177/0956462419829590. [Epub ahead of print]
|
|
|
1222. | Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2 |
|
Rogal SS1,2,3, Yakovchenko V4, Waltz TJ5,6, Powell BJ7, Gonzalez R8, Park A9, Chartier M10, Ross D10, Morgan TR8, Kirchner JE11, Proctor EK12, Chinman MJ13,14. Implement Sci. 2019 Apr 8;14(1):36. doi: 10.1186/s13012-019-0881-7.
|
|
|
1223. | Health implications of sex trading characteristics in Long Beach, California, USA |
|
Clingan SE1, Fisher DG2,3, Hardan-Khalil K4, Reynolds GL3,5, Huckabay L4, Costa C4, Pedersen WC2, Johnson ME6. Int J STD AIDS. 2019 Apr 8:956462419828138. doi: 10.1177/0956462419828138. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1227. | Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois |
|
McLuckie C1,2, Pho MT3,4, Ellis K5, Navon L6,7, Walblay K8, Jenkins WD9, Rodriguez C10, Kolak MA11, Chen YT12, Schneider JA13, Zahnd WE14,15. Int J Environ Res Public Health. 2019 Mar 19;16(6). pii: E989. doi: 10.3390/ijerph16060989.
|
|
|
|
|
|
|
|
|
|
|
1232. | Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015 |
|
Abara WE1, Trujillo L2, Broz D2, Finlayson T2, Teshale E1, Paz-Bailey G2, Glick S3, Al-Tayyib AA4, Robinson WT5, Masiello-Schuette S6, Sey EK7, Anderson BJ8, Poe J Infect Dis. 2019 Mar 27. pii: jiz142. doi: 10.1093/infdis/jiz142. [Epub ahead of print]
J9, Braunstein S10.
|
|
|
|
|
|
|
1235. | Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia |
|
Doyle JS1,2, Scott N2,3, Sacks-Davis R2, Pedrana AE2,3, Thompson AJ4,5, Hellard ME1,2,3; Eliminate Hepatitis C Partnership. Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15210. [Epub ahead of print]
Collaborators (10)
|
|
|
1236. | Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy |
|
Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.
Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
|
|
|
|
|
|
|
1239. | The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment |
|
Woodward EN1,2, Matthieu MM3,4, Uchendu US5, Rogal S6,7,8, Kirchner JE3,9,10. Implement Sci. 2019 Mar 12;14(1):26. doi: 10.1186/s13012-019-0861-y.
|
|
|
|
|
|
|
1242. | Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy |
|
Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.
Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
|
|
|
|
|
1244. | Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017 |
|
Bixler D1, Annambholta P2, Abara WE1, Collier MG1, Jones J2, Mixson-Hayden T1, Basavaraju SV2, Ramachandran S1, Kamili S1, Moorman A1. Am J Transplant. 2019 Mar 12. doi: 10.1111/ajt.15352. [Epub ahead of print]
|
|
|
|
|
|
|
1247. | Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review |
|
Francis-Graham S1,2,3, Ekeke NA4, Nelson CA5, Lee TY5, Haj SE4, Rhodes T6, Vindrola C7, Colbourn T8, Rosenberg W9,4,10. BMC Health Serv Res. 2019 Mar 8;19(1):152. doi: 10.1186/s12913-019-3970-z.
|
|
|
|
|
1249. | Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers |
|
Sandmann L1,2, Dörge P1,2, Wranke A1,2, Vermehren J3,2, Welzel TM3,2, Berg CP4,2, Grottenthaler JM4,2, Weiss KH5,2, Langel J5,2, Sterneck M6,2, von Wulffen M6,2, Manns MP1,2, Wedemeyer H1,7,2, Hardtke S1,2, von Hahn T1,2. Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386. [Epub ahead of print]
|
|
|
|
|
1251. | Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study |
|
Ide T1, Koga H2, Nakano M1, Hashimoto S3, Yatsuhashi H3, Higuchi N4, Nakamuta M4, Oeda S5, Eguchi Y5, Shakado S6, Sakisaka S6, Yoshimaru Y7, Sasaki Y7, Honma Y8, Harada M8, Seike M9, Maeshiro T10, Miuma S11, Nakao K11, Mawatari S12, Ido A12, Nagata K13, Matsumoto S14, Takami Y15, Sohda T16, Kakuma T17, Torimura T1. Hepatol Int. 2019 Feb 28. doi: 10.1007/s12072-019-09939-2. [Epub ahead of print]
|
|
|
1252. | Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection |
|
Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
|
|
|
1253. | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease |
|
Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
|
|
|
|
|
1255. | Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease |
|
Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
|
|
|
|
|
|
|
1258. | Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection |
|
Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
|
|
|
1259. | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease |
|
Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
|
|
|
1260. | Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease |
|
Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
|
|
|
1261. | Vitamin D deficiency and health-related quality of life in chronic hepatitis C |
|
Palazzo D1, Biliotti E1, Esvan R1, Volpicelli L1, Franchi C1, Fontanelli Sulekova L1, Spaziante M1, Santori M1, Rugova A1, Rucci P2, Taliani G1. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076. [Epub ahead of print]
|
|
|
1262. | Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs |
|
Day E1, Broder T2, Bruneau J3, Cruse S1, Dickie M4, Fish S4, Grillon C5, Luhmann N5, Mason K6, McLean E7, Trooskin S8, Treloar C9, Grebely J10. Int J Drug Policy. 2019 Feb 8;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. [Epub ahead of print]
|
|
|
1263. | Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs |
|
Childs E1, Assoumou SA2, Biello KB3,4,5, Biancarelli DL1,6, Drainoni ML1,2,6,7, Edeza A3,4, Salhaney P3, Mimiaga MJ3,4,5,8, Bazzi AR9. Harm Reduct J. 2019 Feb 11;16(1):14. doi: 10.1186/s12954-019-0286-6.
|
|
|
1264. | Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis |
|
Kumthekar A1, Shull S2, Lovejoy TI2,3, Morasco BJ2,3, Chang M2,3, Barton J2,3. Int J Rheum Dis. 2019 Feb 6. doi: 10.1111/1756-185X.13479. [Epub ahead of print]
|
|
|
1265. | Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries |
|
Ferenci P1, Bourgeois S2, Buggisch P3, Norris S4, Curescu M5, Larrey D6, Marra F7, Kleine H8, Dorr P9, Charafeddine M9, Crown E9, Bondin M9, Back D7, Flisiak R10. J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080. [Epub ahead of print]
|
|
|
|
|
1267. | Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project |
|
Kempf MC1, Ott C2, Wise JM2, Footman AP3, Araya BY3, Hardy CM4, Walker C4, Latham C5, Stockett R5, Daniels G5, Alexander M5, Lanzi RG3. Am J Prev Med. 2018 Nov;55(5S1):S112-S121. doi: 10.1016/j.amepre.2018.05.015.
|
|
|
1268. | Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection |
|
Lawitz E1, Poordad F1, Anderson LJ2, Vesay M2, Kelly MM2, Liu H2, Gao W2, Fernsler D2, Asante-Appiah E2, Robertson MN2, Hanna GJ2, Barr E2, Butterton J2, Kowdley KV3, Hassanein T4, Sahota A5, Gordon SC6, Yeh WW2. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079. [Epub ahead of print]
|
|
|
1269. | Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy |
|
Grebely J1, Dore GJ2, Alami NN3, Conway B4, Dillon JF5, Gschwantler M6, Felizarta F7, Hézode C8, Tomasiewicz K9, Fredrick LM3, Dumas EO3, Mensa FJ3. Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1274. | JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1 |
|
Shah ND1, Ventura-Cots M2, Abraldes JG3, Alboraie M4, Alfadhli A5, Argemi J6, Badia-Aranda E7, Soler EA8, Barritt AS 4th1, Bessone F9, Biryukova M10, Carrilho FJ11, Fernández MC8, Guiridi ZD10, El Kassas M12, Eng-Kiong T13, Farias A11, George J14, Gui W15, Thurairajah PH13, Hsiang JC13, Husic-Selimovic A16, Isakov V10, Karoney M17, Kim W18, Kluwe J19, Kochhar R20, Dhaka N20, Costa PM21, Nabeshima MA11, Ono SK11, Reis D21, Rodil A11, Domech CR8, Sáez-Royuela F7, Scheurich C19, Siow W14, Sivac-Burina N16, Dos Santos Traquino ES8, Some F17, Spreckic S16, Tan S22, Vorobioff J9, Wandera A17, Wu P22, Yakoub M12, Yang L15, Yu Y22, Zahiragic N16, Zhang C22, Cortez-Pinto H21, Bataller R23. Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30073-4. doi: 10.1016/j.cgh.2019.01.026. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1284. | Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients |
|
Shoreibah M1, Romano J2, Sims OT3,4,5, Guo Y6, Jones D7, Venkata K2, Kommineni V2, Orr J8, Fitzmorris P1, Massoud OI1. J Clin Transl Hepatol. 2018 Dec 28;6(4):391-395. doi: 10.14218/JCTH.2018.00026. Epub 2018 Jul 11. |
|
|
|
|
1286. | Machine learning models to predict disease progression among veterans with hepatitis C virus |
|
Konerman MA1, Beste LA2, Van T3, Liu B4, Zhang X4, Zhu J4, Saini SD1,3, Su GL1,3, Nallamothu BK5,6, Ioannou GN7,8, Waljee AK1,3,6. PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019. |
|
|
1287. | HCV therapy: no one to let behind |
|
Bourlière M1, Pietri O2. Int J Antimicrob Agents. 2018 Dec 31. pii: S0924-8579(18)30380-7. doi: 10.1016/j.ijantimicag.2018.12.010. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1293. | Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure |
|
Lim TR1,2, Hazlehurst JM3, Oprescu AI1, Armstrong MJ1,2, Abdullah SF4, Davies NP5, Flintham R5, Balfe P1, Mutimer DJ1,2, McKeating JA6, Tomlinson JW7. Clin Endocrinol (Oxf). 2018 Dec 26. doi: 10.1111/cen.13924. [Epub ahead of print] |
|
|
|
|
|
|
1296. | Sustained virological response does not improve long-term glycemic control in patients with type 2 diabetes and chronic hepatitis C |
|
Li J1, Gordon SC2, Rupp LB3, Zhang T1, Trudeau S1, Holmberg SD4, Moorman AC4, Spradling PR4, Teshale EH4, Boscarino JA5, Schmidt MA6, Daida YG7, Lu M1; CHeCS Investigators. Liver Int. 2018 Dec 20. doi: 10.1111/liv.14031. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1301. | Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective |
|
Crowley D1,2,3, Van Hout MC4,5, Lambert JS6,7, Kelly E8, Murphy C5,8, Cullen W6. Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z. |
|
|
|
|
|
|
|
|
|
|
|
|
1307. | Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C |
|
D'Ambrosio R1, Pasulo L2, Puoti M3, Vinci M4, Schiavini M5, Lazzaroni S2, Soria A6, Gatti F7, Menzaghi B8, Aghemo A9, Capelli F10, Rumi MG11, Morini L12, Giorgini A13, Pigozzi MG14, Rossini A14, Maggiolo F2, Pan A15, Memoli M16, Spinelli O17, Del Poggio P2, Saladino V18, Spinetti A14, De Bona A13, Capretti A13, Uberti-Foppa C19, Bonfanti P20, Terreni N21, Menozzi F22, Colombo AE17, Giglio O17, Centenaro R23, Borghi M24, Baiguera C3, Picciotto V4, Landonio S5, Gori A25, Magnani C26, Noventa F27, Paolucci S28, Lampertico P24, Fagiuoli S2; NAVIGATORE-Lombardia Study Group. J Hepatol. 2018 Nov 23. pii: S0168-8278(18)32543-1. doi: 10.1016/j.jhep.2018.11.011. [Epub ahead of print] |
|
|
1308. | Hepatitis C: is eradication possible? |
|
Lombardi A1,2, Mondelli MU1,2; ESCMID Study Group for Viral Hepatitis (ESGVH). Liver Int. 2018 Nov 25. doi: 10.1111/liv.14011. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1317. | Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis |
|
Stone J1, Fraser H2, Lim AG2, Walker JG2, Ward Z2, MacGregor L2, Trickey A2, Abbott S2, Strathdee SA3, Abramovitz D3, Maher L4, Iversen J4, Bruneau J5, Zang G6, Garfein RS3, Yen YF7, Azim T8, Mehta SH9, Milloy MJ10, Hellard ME11, Sacks-Davis R12, Dietze PM13, Aitken C13, Aladashvili M14, Tsertsvadze T15, Mrav?ík V16, Alary M17, Roy E18, Smyrnov P19, Sazonova Y19, Young AM20, Havens JR21, Hope VD22, Desai M23, Heinsbroek E23, Hutchinson SJ24, Palmateer NE24, McAuley A25, Platt L26, Martin NK27, Altice FL28, Hickman M2, Vickerman P2. Lancet Infect Dis. 2018 Dec;18(12):1397-1409. doi: 10.1016/S1473-3099(18)30469-9. Epub 2018 Oct 29. |
|
|
|
|
1319. | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials |
|
Grebely J1, Puoti M2, Wedemeyer H3, Cooper C4, Sulkowski MS5, Foster GR6, Berg T7, Villa E8, Rodriguez-Perez F9, Wyles DL10, Schnell G11, Alami NN11, Zhang Z11, Dumas E11, Dore GJ1. Open Forum Infect Dis. 2018 Sep 27;5(11):ofy248. doi: 10.1093/ofid/ofy248. eCollection 2018 Nov. |
|
|
1320. | Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C) |
|
Poordad F1, Shiffman ML2, Ghesquiere W3, Wong A4, Huhn GD5, Wong F6, Ramji A7, Shafran SD8, McPhee F9, Yang R9, Noviello S10, Linaberry M10; ALLY-3C study team. Antivir Ther. 2018 Nov 1. doi: 10.3851/IMP3278. [Epub ahead of print] |
|
|
1321. | Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program |
|
Talal AH1,2, McLeod A2, Andrews P2, Nieves-McGrath H1, Chen Y3, Reynolds A4, Sylvester C2, Dickerson SS5, Markatou M3, Brown LS2. Telemed J E Health. 2018 Oct 16. doi: 10.1089/tmj.2018.0161. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1334. | Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis |
|
Flamm S1, Mutimer D2, Asatryan A3, Wang S3, Rockstroh J4, Horsmans Y5, Kwo PY6, Weiland O7, Villa E8, Heo J9, Gane E10, Ryder SD11, Welzel TM12, Ruane PJ13, Agarwal K14, Ng TI3, Xue Z3, Lovell SS3, Krishnan P3, Kopecky-Bromberg S3, Trinh R3, Mensa FJ3, Wyles DL15. J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1338. | Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine |
|
Morey S1,2, Hamoodi A3, Jones D4, Young T1, Thompson C4, Dhuny J5, Buchanan E1, Miller C1, Hewett M1, Valappil M1, Hunter E6, McPherson S1,7. J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017. [Epub ahead of print] |
|
|
1339. | Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus |
|
Saab S1,2,3,4, Ahn T1,2,3,4, McDaniel T1,2,3,4, Yanny B1,2,3,4, Tong MJ1,2,3,4. Gastroenterol Hepatol (N Y). 2018 Aug;14(8):459-462. |
|
|
|
|
|
|
|
|
1343. | Elimination of Hepatitis C in Liver Transplant Recipients |
|
Saab S1,2, Challita Y1, Chen PH2, Jimenez MA2, Lee AD2, Saab EG2, Ahn T2, Choi G1,2, Durazo FA1,2, El-Kabany MM1,2, Han SB1,2, Grotts J1, Agopian VG2, Busuttil RW2. J Clin Transl Hepatol. 2018 Sep 28;6(3):247-250. doi: 10.14218/JCTH.2017.00079. Epub 2018 Jun 8. |
|
|
|
|
1345. | Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) |
|
Minutolo R1, Aghemo A2,3, Chirianni A4, Fabrizi F5, Gesualdo L6, Giannini EG7, Maggi P8, Montinaro V6, Paoletti E9, Persico M10, Perticone F11, Petta S12, Puoti M13, Raimondo G14, Rendina M15, Zignego AL16; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Infection. 2018 Sep 25. doi: 10.1007/s15010-018-1209-2. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1351. | Race and Hepatitis C Care Continuum in an Underserved Birth Cohort |
|
Kim NJ1,2, Locke CJ1,2, Park H1,2, Magee C2, Bacchetti P3, Khalili M4,5,6. J Gen Intern Med. 2018 Sep 20. doi: 10.1007/s11606-018-4649-6. [Epub ahead of print] |
|
|
1352. | Hepatitis C care cascade among persons born 1945-1965: 3 medical centers |
|
Brady JE1, Vellozzi C, Hariri S, Kruger DL, Nerenz DR, Brown KA, Federman AD, Krauskopf K, Kil N, Massoud OI, Wise JM, Seay TA, Smith BD, Yartel AK, Rein DB. Am J Manag Care. 2018 Sep;24(9):421-427. |
|
|
|
|
|
|
1355. | Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance |
|
Rosenberg BR1,2, Depla M3, Freije CA2, Gaucher D3, Mazouz S3,4, Boisvert M3, Bédard N3, Bruneau J3,5, Rice CM6,7, Shoukry NH3,8. PLoS Pathog. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290. eCollection 2018 Sep. |
|
|
1356. | Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C |
|
Lynch SM1, Wilson SM2,3, DeRycke EC4, Driscoll MA4,5, Becker WC4,6, Goulet JL4,7, Kerns RD6, Mattocks KM8,9, Brandt CA4,7, Bathulapalli H4, Skanderson M4, Haskell SG4,6, Bastian LA4,6. Pain Med. 2018 Sep 1;19(suppl_1):S5-S11. doi: 10.1093/pm/pny146. |
|
|
|
|
|
|
1359. | The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial |
|
Lawitz E1, Bidair M2, Marbury T3, Jones CT4, Barve A5, Magnusson B6, Barkan DT4, Bodendorf U6, Bracken K7, Canino E4, Chen D4, Dabovic K5, Heimbach T5, Ison M4, Jones CL4, Kovacs SJ7, Lakshman JP5, Li B7, Raman P5, Steiner-Swiat R5, Thohan S7, Wong KA4, Zhong W4, Colvin RA8. Clin Ther. 2018 Sep;40(9):1567-1581.e4. doi: 10.1016/j.clinthera.2018.07.019. Epub 2018 Sep 2. |
|
|
1360. | Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection |
|
Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Fontana RJ, Gordon SC, Heller T, Holmberg SD, Jhaveri R, Jonas MM, Kiser JJ, Linas BP, Lo Re V 3rd, Morgan TR, Nahass RG, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Swan T, Terrault NA, Trooskin SB, Wong JB, Workowski KA. Clin Infect Dis. 2018 Sep 12. doi: 10.1093/cid/ciy585. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1364. | Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort |
|
Rossi C1, Butt ZA2, Wong S3, Buxton JA2, Islam N4, Yu A3, Darvishian M2, Gilbert M2, Wong J2, Chapinal N3, Binka M1, Alvarez M3, Tyndall MW2, Krajden M1, Janjua NZ5; BC Hepatitis Testers Cohort Team. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32288-8. doi: 10.1016/j.jhep.2018.07.025. [Epub ahead of print] |
|
|
|
|
1366. | A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study |
|
Evon DM1, Stewart PW2, Amador J2, Serper M3, Lok AS4, Sterling RK5, Sarkar S6, Golin CE7,8, Reeve BB9, Nelson DR10, Reau N11, Lim JK12, Reddy KR3, Di Bisceglie AM13, Fried MW1. PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018. |
|
|
|
|
|
|
|
|
1370. | Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis Cin Children Ages 6-11 |
|
Murray KF1, Balistreri WF2, Bansal S3, Whitworth S4, Evans HM5, Gonzalez-Peralta RP6, Wen J7, Massetto B8, Kersey K8, Shao J8, Garrison KL8, Parhy B8, Brainard DM8, Arnon R9, Gillis LA10, Jonas MM11, Chuan-Hao L12, Narkewicz MR13, Schwarz K14, Rosenthal P15. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1382. | Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings |
|
Scott N1,2, Sacks-Davis R1,2, Pedrana A1,2, Doyle J1,3, Thompson A4,5, Hellard M1,2,3. J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1386. | Changes in Practice and Perception of Hepatitis C and Liver Transplantation: Results of a National Survey |
|
Shaffer AA1,2, Thomas AG1, Bowring MG1, Van Pilsum Rasmussen SE1, Cash A1, Kucirka L1,2, Alqahtani S3, Gurakar A3, Sulkowski M3,4, Cameron AM1, Segev DL1,2, Durand CM4. Transpl Infect Dis. 2018 Aug 24:e12982. doi: 10.1111/tid.12982. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1392. | Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs |
|
Grebely J1, Larney S2, Peacock A1, Colledge S1, Leung J3, Hickman M4, Vickerman P4, Blach S5, Cunningham E1, Dumchev K6, Lynskey M7, Stone J4, Trickey A4, Razavi H5, Mattick RP2, Farrell M2, Dore GJ1, Degenhardt L2. Addiction. 2018 Jul 23. doi: 10.1111/add.14393. [Epub ahead of print] |
|
|
|
|
1394. | Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection |
|
Suda G1, Kurosaki M2, Itakura J2, Izumi N2, Uchida Y3, Mochida S3, Hasebe C4, Abe M4, Haga H5, Ueno Y5, Masakane I6, Abe K7, Takahashi A7, Ohira H7, Furuya K8, Baba M8, Yamamoto Y9, Kobayashi T10, Kawakami A11, Kumagai K12, Terasita K1, Ohara M1, Kawagishi N1, Umemura M1, Nakai M1, Sho T1, Natsuizaka M1, Morikawa K1, Ogawa K1, Sakamoto N13; NORTE Study Group. J Gastroenterol. 2018 Jul 17. doi: 10.1007/s00535-018-1495-6. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1398. | Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City |
|
Tieu HV1,2, Laeyendecker O3,4, Nandi V5, Rose R6, Fernandez R4, Lynch B3, Hoover DR7, Frye V8, Koblin BA1. PLoS One. 2018 Jul 18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018. |
|
|
|
|
|
|
|
|
|
|
1403. | Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection |
|
Flamm S1, Reddy KR2, Zadeikis N3, Hassanein T4, Bacon BR5, Maieron A6, Zeuzem S7, Bourliere M8, Calleja JL9, Kosloski MP3, Oberoi RK3, Lin CW3, Yu Y3, Lovell S3, Semizarov D3, Mensa FJ3. Clin Gastroenterol Hepatol. 2018 Jul 13. pii: S1542-3565(18)30702-X. doi: 10.1016/j.cgh.2018.07.003. [Epub ahead of print] |
|
|
|
|
1405. | Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system |
|
Sessa M1,2, Bernardi FF1, Vitale A3, Schiavone B3, Gritti G1, Mascolo A1, Bertini M1, Scavone C1, Sportiello L1, Rossi F1, Capuano A1. J Clin Pharm Ther. 2018 Jul 16. doi: 10.1111/jcpt.12744. [Epub ahead of print] |
|
|
1406. | Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users |
|
Major M1, Gutfraind A2,3, Shekhtman L2,4, Cui Q5, Kachko A5, Cotler SJ2, Hajarizadeh B6, Sacks-Davis R7,8, Page K9, Boodram B3, Dahari H10. Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1414. | Incidence and prevalence of antibody to hepatitis C virus in FDNY first responders before and after work at the World Trade Center disaster site |
|
Webber MP1,2, Liu Y2, Cohen HW1, Schwartz T2, Weiden MD2, Kelly K2, Ortiz V2, Zeig-Owens R1,2, Jaber N2, Colbeth HL2, Prezant DJ2,3. Am J Ind Med. 2018 Jun 20. doi: 10.1002/ajim.22871. [Epub ahead of print] |
|
|
|
|
1416. | Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C |
|
Younossi ZM1,2, Stepanova M3, Reddy R4, Manns MP5, Bourliere M6, Gordon SC7, Schiff E8, Tran T9, Younossi I3, Racila A3. Liver Int. 2018 Jun 12. doi: 10.1111/liv.13900. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1422. | Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1 |
|
Bourlière M1, Gordon SC2, Schiff ER3, Tran TT4, Ravendhran N5, Landis CS6, Hyland RH7, Stamm LM7, Zhang J7, Dvory-Sobol H7, Subramanian GM7, Brainard DM7, McHutchison JG7, Serfaty L8, Thompson AJ9, Sepe TE10, Curry MP11, Reddy KR12, Manns MP13. Lancet Gastroenterol Hepatol. 2018 May 30. pii: S2468-1253(18)30118-3. doi: 10.1016/S2468-1253(18)30118-3. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1427. | Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005-2015 |
|
Reilley B1, Leston J2, Doshani M3, Haberling DL4, Persvon M4, Weiser T5, Collier M3, Iralu J6, Mera J7, Haverkate R8. J Community Health. 2018 May 28. doi: 10.1007/s10900-018-0528-7. [Epub ahead of print] |
|
|
|
|
|
|
1430. | Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis |
|
Ascione A1, De Luca M2, Melazzini M3, Montilla S3, Trotta MP3, Petta S4, Puoti M5, Sangiovanni V6, Messina V7, Bruno S8, Izzi A9, Villa E10, Aghemo A11, Zignego AL12, Orlandini A13, Fontvanella L14, Gasbarrini A15, Marzioni M16, Giannini EG17, Craxì A4; ABACUS Study Group. Infection. 2018 May 28. doi: 10.1007/s15010-018-1157-x. [Epub ahead of print] |
|
|
|
|
1432. | Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study |
|
Butt AA1,2,3,4, Ren Y1, Puenpatom A5, Arduino JM5, Kumar R5, Abou-Samra AB2,3,4. Aliment Pharmacol Ther. 2018 Jul;48(1):35-43. doi: 10.1111/apt.14799. Epub 2018 May 24. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1443. | Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings |
|
Moorman AC1, Rupp LB2, Gordon SC2, Zhong Y3, Xing J3, Lu M4, Boscarino JA5, Schmidt MA6, Daida YG7, Teshale EH3, Spradling PR3, Holmberg SD3; CHeCS Investigators. Infect Dis Clin North Am. 2018 Jun;32(2):253-268. doi: 10.1016/j.idc.2018.02.002. |
|
|
1444. | Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? |
|
Ward Z1, Platt L2, Sweeney S2, Hope VD3,4, Maher L5, Hutchinson S6,7, Palmateer N6,7, Smith J8, Craine N8, Taylor A9, Martin N10, Ayres R11, Dillon J12, Hickman M1, Vickerman P1. Addiction. 2018 May 17. doi: 10.1111/add.14217. [Epub ahead of print] |
|
|
1445. | Localized US Efforts to Eliminate Hepatitis C |
|
Gaudino A1, Gay B1, Garmon C2, Selick M3, Vreeland R4, Burk K5, Huriaux E6, Facente SN7, Luetkemeyer A8, Waters P9, Graham CS10. Infect Dis Clin North Am. 2018 Jun;32(2):293-311. doi: 10.1016/j.idc.2018.02.009. |
|
|
|
|
|
|
1448. | Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician |
|
Alroy-Preis S1, Daly ER1, Adamski C1, Dionne-Odom J1,2, Talbot EA1,2, Gao F1, Cavallo SJ1, Hansen K1, Mahoney JC1, Metcalf E1, Loring C1, Bean C1, Drobeniuc J3, Xia GL3, Kamili S3, Montero JT1; New Hampshire and Centers for Disease Control and Prevention Investigation Teams. Clin Infect Dis. 2018 May 14. doi: 10.1093/cid/ciy193. [Epub ahead of print] |
|
|
|
|
|
|
1451. | Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approach |
|
Deming R1, Ford MM1, Moore MS1, Lim S1, Perumalswami P2, Weiss J3, Wyatt B2, Shukla S4, Litwin A4, Reynoso S4, Laraque F1. J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1461. | Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care |
|
Martin SA1,2,3, Bosse J4, Wilson A5, Losikoff P6,7, Chiodo L5,4. Addict Sci Clin Pract. 2018 Apr 25;13(1):10. doi: 10.1186/s13722-018-0111-7. |
|
|
1462. | Hepatitis C in Pregnancy |
|
Dibba P1, Cholankeril R2, Li AA3, Patel M4, Fayek M5, Dibble C6, Okpara N7, Hines A8, Ahmed A9. Diseases. 2018 Apr 27;6(2). pii: E31. doi: 10.3390/diseases6020031. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1470. | Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection |
|
Reau N1, Kwo PY2, Rhee S3, Brown RS Jr.4, Agarwal K5, Angus P6, Gane E7, Kao JH8, Mantry PS9, Mutimer D10, Reddy KR11, Tran TT12, Hu YB3, Gulati A3, Krishnan P3, Dumas EO3, Porcalla A3, Shulman NS3, Liu W3, Samanta S3, Trinh R3, Forns X13. Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046. [Epub ahead of print] |
|
|
1471. | Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C |
|
Wade AJ1,2,3, McCormack A4, Roder C4, McDonald K5, Davies M5,6, Scott N2, Wardrop M1, Athan E1,4, Hellard ME2,3. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910. [Epub ahead of print] |
|
|
1472. | Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection |
|
Martinello M1,2, Bhagani S3, Gane E4, Orkin C5, Cooke G6, Dore GJ1,2, Petoumenos K1, Applegate TL1, Tu E1, Marks P1, Pagani N7, Grebely J1, Nelson M7, Matthews GV1,2. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917. [Epub ahead of print] |
|
|
1473. | Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination |
|
Facente SN1,2, Grebe E3, Burk K4, Morris MD2, Murphy EL2,5, Mirzazadeh A2, Smith AA4, Sanchez MA4, Evans JL2, Nishimura A4, Raymond HF2,6; End Hep C SF. PLoS One. 2018 Apr 11;13(4):e0195575. doi: 10.1371/journal.pone.0195575. eCollection 2018. |
|
|
|
|
|
|
1476. | Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era |
|
Sacks-Davis R1,2, Doyle JS1,3, Rauch A4, Beguelin C4, Pedrana AE1,5, Matthews GV6, Prins M7, van der Valk M8, Klein MB9, Saeed S10, Lacombe K11, Chkhartishvili N12, Altice FL13,14,15, Hellard ME1,5. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051. |
|
|
|
|
1478. | HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities |
|
Bosh KA1, Coyle JR2, Hansen V3, Kim EM3, Speers S4, Comer M5, Maddox LM5, Khuwaja S6, Zhou W6, Jatta A7, Mayer R7, Brantley AD8, Muriithi NW8, Bhattacharjee R9, Flynn C9, Bouton L10, John B10, Keusch J2, Barber CA11, Sweet K11, Ramaswamy C12, Westheimer EF12, VanderBusch L13, Nishimura A14, Vu A14, Hoffman-Arriaga L15, Rowlinson E15, Carter AO16, Yerkes LE16, Li W17, Reuer JR17, Stockman LJ18, Tang T19, Brooks JT1, Teshale EH20, Hall HI1. Epidemiol Infect. 2018 Apr 11:1-11. doi: 10.1017/S0950268818000766. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1482. | Mother-to-child transmission of hepatitis C virus |
|
Pott H Junior1, Theodoro M2, de Almeida Vespoli J2, Senise JF3, Castelo A3. Eur J Obstet Gynecol Reprod Biol. 2018 Mar 20;224:125-130. doi: 10.1016/j.ejogrb.2018.03.034. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1486. | Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015 |
|
Kasting ML1,2, Giuliano AR2,3, Reich RR4, Roetzheim RG1,5, Nelson DR6, Shenkman E7,8, Vadaparampil ST9,2. Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):503-513. doi: 10.1158/1055-9965.EPI-17-0855. Epub 2018 Mar 27. |
|
|
|
|
1488. | Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis |
|
Wang H1, Swann R2, Thomas E3, Innes HA4,5, Valerio H4,5, Hayes PC6, Allen S7, Barclay ST8, Wilks D9, Fox R10, Bhattacharyya D11, Kennedy N12, Morris J13, Fraser A14, Stanley AJ8, Gunson R15, Mclntyre PG16, Hunt A17, Hutchinson SJ4,5, Mills PR2, Dillon JF18. J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1493. | Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis |
|
McLinden T1, Moodie EEM1, Hamelin AM1, Harper S1, Rossi C1, Walmsley SL2, Rourke SB3, Cooper C4, Klein MB5, Cox J6. Drug Alcohol Depend. 2018 Feb 20;185:374-380. doi: 10.1016/j.drugalcdep.2017.12.031. [Epub ahead of print] |
|
|
|
|
1495. | The Role of Aging, Drug Dependence, and Hepatitis C Comorbidity in Alcoholism Cortical Compromise |
|
Sullivan EV1, Zahr NM1,2, Sassoon SA2, Thompson WK3, Kwon D1,2, Pohl KM2, Pfefferbaum A1,2. JAMA Psychiatry. 2018 Mar 14. doi: 10.1001/jamapsychiatry.2018.0021. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1502. | Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis CVirus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial |
|
Durand CM1, Bowring MG1, Brown DM1, Chattergoon MA1, Massaccesi G1, Bair N1, Wesson R1, Reyad A1, Naqvi FF1, Ostrander D1, Sugarman J2, Segev DL1, Sulkowski M1, Desai NM1. Ann Intern Med. 2018 Mar 6. doi: 10.7326/M17-2871. [Epub ahead of print] |
|
|
|
|
|
|
1505. | Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis |
|
Petta S1, Adinolfi LE2, Fracanzani AL3, Rini F4, Caldarella R5, Calvaruso V4, Cammà C4, Ciaccio M5, Di Marco V4, Grimaudo S4, Licata A4, Marrone A2, Nevola R2, Pipitone RM4, Pinto A6, Rinaldi L2, Torres D6, Tuttolomondo A6, Valenti L3, Fargion S3, Craxì A4. J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30132-6. doi: 10.1016/j.jhep.2018.02.015. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1510. | A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection |
|
Sims OT: 1,: 2,: 3,: 4, Hong BA: 5, Ji S: 6, Pollio DE: 7,: 8,: 9, North CS: 10,: 11. J Relig Health. 2018 Feb 6. doi: 10.1007/s10943-018-0565-7. [Epub ahead of print] |
|
|
|
|
|
|
1513. | Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial |
|
Foster GR1, Agarwal K2, Cramp ME3, Moreea S4, Barclay S5, Collier J6, Brown AS7, Ryder SD8, Ustianowski A9, Forton DM10, Fox R11, Gordon F12, Rosenberg WM13, Mutimer DJ14, Du J15, Gilbert CL15, Asante-Appiah E15, Wahl J15, Robertson MN15, Barr E15, Haber B15. Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852. [Epub ahead of print] |
|
|
1514. | Efficacy of Elbasvir and Grazoprevir in Participants with Hepatitis C Virus Genotype 4 Infection: A Pooled Analysis |
|
Asselah T1, Reesink H2, Gerstoft J3, de Ledinghen V4, Pockros PJ5, Robertson M6, Hwang P6, Asante-Appiah E6, Wahl J6, Nguyen BY6, Barr E6, Talwani R6, Serfaty L7. Liver Int. 2018 Feb 20. doi: 10.1111/liv.13727. [Epub ahead of print] |
|
|
1515. | Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia: a multicentre open-label study |
|
Mazzaro C1, Dal Maso L2, Quartuccio L3, Ghersetti M4, Lenzi M5, Mauro E4, Bond M3, Casarin P4, Gattei V6, Crosato IM7, De Vita S3, Pozzato G8. Clin Exp Rheumatol. 2018 Feb 13. [Epub ahead of print] |
|
|
|
|
1517. | Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies |
|
Grebely J1, Feld JJ2, Wyles D3, Sulkowski M4, Ni L5, Llewellyn J5, Mir HM5, Sajed N5, Stamm LM5, Hyland RH5, McNally J5, Brainard DM5, Jacobson I6, Zeuzem S7, Bourlière M8, Foster G9, Afdhal N10, Dore GJ1. Open Forum Infect Dis. 2018 Feb 9;5(2):ofy001. doi: 10.1093/ofid/ofy001. eCollection 2018 Feb. |
|
|
1518. | Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population |
|
Fill MA1, Sizemore LA2, Rickles M2, Cooper KC3, Buecker CM4, Mullins HL5, Hofmeister MG1, Abara WE1, Foster MA6, Asher AK6, Schaffner W7, Dunn JR2, Jones TF2, Wester C2. Epidemiol Infect. 2018 Feb 12:1-7. doi: 10.1017/S0950268818000080. [Epub ahead of print] |
|
|
|
|
1520. | Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study |
|
Kelly ML1,2,3, Riordan SM4,5, Bopage R2, Lloyd AR1,3,6, Post JJ1,2,3,4. PLoS One. 2018 Feb 13;13(2):e0192763. doi: 10.1371/journal.pone.0192763. eCollection 2018. |
|
|
|
|
1522. | The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities |
|
Cortesi PA1, Belli LS2,3, Facchetti R1, Mazzarelli C2, Perricone G2, De Nicola S2, Cesana G1, Duvoux C4, Mantovani LG1,3, Strazzabosco M3,5; European Liver and Intestine Transplant Association (ELITA). J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1526. | Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA |
|
Chhatwal J1,2,3, Chen Q1,2, Ayer T4, Bethea ED1,2,3, Kanwal F5,6, Kowdley KV7, Wang X8, Roberts MS9, Gordon SC10. Aliment Pharmacol Ther. 2018 Jan 29. doi: 10.1111/apt.14527. [Epub ahead of print] |
|
|
|
|
1528. | Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis Cinfection |
|
Reau N1, Robertson MN2, Feng HP2, Caro L2, Yeh WW2, Nguyen BT2, Wahl J2, Barr E2, Hwang P2, Klopfer SO2. Hepatol Commun. 2017 Aug 22;1(8):757-764. doi: 10.1002/hep4.1081. eCollection 2017 Oct. |
|
|
|
|
|
|
1531. | Vertical transmission of hepatitis C: Testing and health-care engagement |
|
Reid S1,2, Day CA3, Bowen DG4, Minnis J2, Ludlow J5,6, Jacobs S5,6, Gordon A5,6, Haber PS2,3. J Paediatr Child Health. 2018 Jan 2. doi: 10.1111/jpc.13832. [Epub ahead of print] |
|
|
|
|
1533. | Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection |
|
Collins LF1, Chan A2, Zheng J3, Chow SC3,4, Wilder JM4,5, Muir AJ4,5, Naggie S2,4. Open Forum Infect Dis. 2017 Dec 9;5(1):ofx264. doi: 10.1093/ofid/ofx264. eCollection 2018 Jan. |
|
|
|
|
|
|
|
|
1537. | Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition |
|
Indolfi G1, Hierro L2, Dezsofi A3, Jahnel J4, Debray D5, Hadzic N6, Czubowski P7, Gupte G8, Mozer-Glassberg Y9, van der Woerd W10, Smets F11, Verkade HJ12, Fischler B12,13. J Pediatr Gastroenterol Nutr. 2017 Dec 28. doi: 10.1097/MPG.0000000000001872. [Epub ahead of print] |
|
|
1538. | Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis |
|
McDonald SA1,2, Innes HA1,2, Aspinall EJ1,2, Hayes PC3, Alavi M2, Valerio H1,2, Goldberg DJ1,2, Hutchinson SJ1,2. Liver Int. 2017 Dec 30. doi: 10.1111/liv.13681. [Epub ahead of print] |
|
|
|
|
1540. | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection |
|
Mark S. Sulkowski, M.D., David F. Gardiner, M.D., Maribel Rodriguez-Torres, M.D., K. Rajender Reddy, M.D., Tarek Hassanein, M.D., Ira Jacobson, M.D., Eric Lawitz, M.D., Anna S. Lok, M.D., Federico Hinestrosa, M.D., Paul J. Thuluvath, M.D., Howard Schwartz, M.D., David R. Nelson, M.D., Gregory T. Everson, M.D., Timothy Eley, Ph.D., Megan Wind-Rotolo, Ph.D., Shu-Pang Huang, Ph.D., Min Gao, Ph.D., Dennis Hernandez, Ph.D., Fiona McPhee, Ph.D., Diane Sherman, M.S., Robert Hindes, M.D., William Symonds, Pharm.D., Claudio Pasquinelli, M.D., Ph.D., and Dennis M. Grasela, Pharm.D., Ph.D. for the AI444040 Study Group N Engl J Med 2014; 370:211-221January 16, 2014DOI: 10.1056/NEJMoa1306218 |
|
|
|
|
|
|
|
|
1544. | Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes |
|
Younossi ZM1,2, Stepanova M3, Asselah T4, Foster G5, Patel K6, Brau N7, Swain M8, Tran T9, Esteban R10, Colombo M11, Pianko S12, Henry L3, Bourliere M13. Clin Infect Dis. 2017 Dec 20. doi: 10.1093/cid/cix1106. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1549. | GHOST: global hepatitis outbreak and surveillance technology |
|
Longmire AG1,2, Sims S1,3,2, Rytsareva I1, Campo DS4, Skums P1,3, Dimitrova Z1, Ramachandran S1, Medrzycki M1, Thai H1, Ganova-Raeva L1, Lin Y1, Punkova LT1, Sue A1, Mirabito M5,2, Wang S5,2, Tracy R5,2, Bolet V6, Sukalac T5, Lynberg C7, Khudyakov Y1. BMC Genomics. 2017 Dec 6;18(Suppl 10):916. doi: 10.1186/s12864-017-4268-3. |
|
|
1550. | Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment |
|
Marshall WL1, Feng HP2, Wenning L1, Garrett G1, Huang X1, Liu F1, Panebianco D1, Caro L1, Fandozzi C1, Lasseter KC3, Preston RA4, Marbury T5, Butterton JR1, Iwamoto M1, Yeh WW1. Eur J Drug Metab Pharmacokinet. 2017 Dec 15. doi: 10.1007/s13318-017-0451-9. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1555. | Hepatitis C virus genotyping of organ donor samples to aid in transplantation of HCV-positive organs |
|
Gentile C1, Van Deerlin VM1, Goldberg DS2,3,4, Reese PP3,4,5, Hasz RD6, Abt P7, Blumberg E8, Farooqi MS9. Clin Transplant. 2017 Dec 8. doi: 10.1111/ctr.13172. [Epub ahead of print] |
|
|
1556. | Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study) |
|
Rosenthal E1, Fougerou-Leurent C2,3, Renault A3,4, Carrieri MP5,6, Marcellin F5,6, Garraffo R7, Teicher E8, Aumaitre H9, Lacombe K10, Bailly F11, Billaud E12, Chevaliez S13, Dominguez S14, Valantin MA15, Reynes J16, Naqvi A17, Cotte L18, Metivier S19, Leroy V20, Dupon M21, Allegre T22, De Truchis P23, Jeantils V24, Chas J25, Salmon-Ceron D26, Morlat P27, Neau D28, Perré P29, Piroth L30, Pol S31, Bourlière M32, Pageaux GP33, Alric L34, Zucman D35, Girard PM10, Poizot-Martin I36,37, Yazdanpanah Y38, Raffi F12, Pabic EL2,3, Tual C2,3, Pailhé A39, Amri I39, Bellissant E2,3,4, Molina JM40; ANRS HC31 SOFTRIH Study Group. Collaborators (17) HIV Med. 2017 Dec 7. doi: 10.1111/hiv.12571. [Epub ahead of print] |
|
|
|
|
|
|
1559. | Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ? 15) |
|
McCaughan GW1, Thwaites PA2, Roberts SK3, Strasser SI1, Mitchell J3, Morales B2, Mason S1, Gow P2, Wigg A4, Tallis C5, Jeffrey G6, George J7, Thompson AJ8, Parker FC2, Angus PW2; Australian Liver Association Clinical Research Network. Aliment Pharmacol Ther. 2017 Dec 5. doi: 10.1111/apt.14404. [Epub ahead of print] |
|
|
1560. | The Effect of Interferon-Free Regimens on Health-Related Quality of Life in East Asian Patients with Chronic Hepatitis C |
|
Younossi ZM1,2, Stepanova M3, Henry L3, Han KH4, Ahn SH4, Lim YS5, Chuang WL6, Kao JH7, Kinh N8, Lai CL9, Yuen MF9, Chan HL10, Lai W11. Liver Int. 2017 Dec 2. doi: 10.1111/liv.13650. [Epub ahead of print] |
|
|
|
|
|
|
1563. | Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3 |
|
Younossi ZM1, Stepanova M2, Jacobson IM3, Asselah T4, Gane EJ5, Lawitz E6, Foster GR7, Roberts SK8, Thompson AJ8, Willems BE9, Welzel TM10, Pearlman B11, Younossi I2, Racila A1, Henry L2. Aliment Pharmacol Ther. 2018 Jan;47(2):259-267. doi: 10.1111/apt.14423. Epub 2017 Nov 27. |
|
|
|
|
|
|
1566. | Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals |
|
Zhu J, Hazen RJ, Joyce C, Delpino A, Kirkham HS, Strickland CD, Markes-Wilson S, Kim T, Kang M, Rubin RA, Stein LL.AbstractJ Am Pharm Assoc (2003). 2017 Nov 16. pii: S1544-3191(17)30967-6. doi: 10.1016/j.japh.2017.10.011. [Epub ahead of print] |
|
|
|
|
1568. | Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir |
|
Younossi ZM1, Stepanova M2, Gordon S3, Zeuzem S4, Mann MP5, Jacobson I6, Bourliere M7, Cooper C8, Flamm S9, Reddy KR10, Kowdley K11, Younossi I2, Hunt S2. Clin Gastroenterol Hepatol. 2017 Nov 16. pii: S1542-3565(17)31360-5. doi: 10.1016/j.cgh.2017.11.023. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1573. | Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems |
|
Camus G1, Xu S2, Han B2, Lu J2, Dvory-Sobol H2, Yu M2, Cheng G2, Miller MD2, Doehle BP2, Mo H2. Virology. 2017 Nov 22;514:134-141. doi: 10.1016/j.virol.2017.11.003. [Epub ahead of print] |
|
|
1574. | Improving patient access to hepatitis C virus treatment |
|
McLaughlin MM, Marx KT, Terriff C; American Academy of HIV Medicine Pharmacists Committee. AbstractJ Am Pharm Assoc (2003). 2017 Nov 16. pii: S1544-3191(17)30969-X. doi: 10.1016/j.japh.2017.10.013. [Epub ahead of print] |
|
|
1575. | No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV |
|
Chaudhury CS1, Sheehan J1, Chairez C1, Akoth E2, Gross C2, Silk R2, Kattakuzhy S2, Rosenthal E2, Kottilil S2, Masur H3, Hadigan C1. J Infect Dis. 2017 Nov 17. doi: 10.1093/infdis/jix517. [Epub ahead of print] |
|
|
|
|
|
|
1578. | Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure |
|
Poordad F1, Pol S2, Asatryan A3, Buti M4, Shaw D5, Hézode C6, Felizarta F7, Reindollar RW8, Gordon SC9, Pianko S10, Fried MW11, Bernstein DE12, Gallant J13, Lin CW3, Lei Y3, Ng TI3, Krishnan P3, Kopecky-Bromberg S3, Kort J3, Mensa F3. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671. [Epub ahead of print] |
|
|
|
|
1580. | Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study |
|
Brown A1, Hézode C2, Zuckerman E3, Foster GR4, Zekry A5, Roberts SK6, Lahser F7, Durkan C7, Badshah C7, Zhang B7, Robertson M7, Wahl J7, Barr E7, Haber B7; C-SCAPE Study Investigators. J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801. [Epub ahead of print] |
|
|
1581. | Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C |
|
Konerman MA1, Lu D1, Zhang Y1, Thomson M1, Zhu J1, Verma A2, Liu B1, Talaat N1, Balis U3, Higgins PDR1, Lok ASF1, Waljee AK1,4. PLoS One. 2017 Nov 6;12(11):e0187344. doi: 10.1371/journal.pone.0187344. eCollection 2017. |
|
|
1582. | Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world |
|
Tempestilli M1, Fabbri G2, Mastrorosa I2, Timelli L2, Notari S1, Bellagamba R2, Libertone R2, Lupi F2, Zaccarelli M2, Antinori A2, Agrati C1, Ammassari A2. J Antimicrob Chemother. 2017 Nov 2. doi: 10.1093/jac/dkx348. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1586. | Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe |
|
Fraser H1, Martin NK2, Brummer-Korvenkontio H3, Carrieri P4, Dalgard O5, Dillon J6, Goldberg D7, Hutchinson S8, Jauffret-Roustide M9, Kåberg M10, Matser AA11, Mati?i? M12, Midgard H13, Mravcik V14, Øvrehus A15, Prins M16, Reimer J17, Robaeys G18, Schulte B19, van Santen DK20, Zimmermann R21, Vickerman P22, Hickman M22. J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387-5. doi: 10.1016/j.jhep.2017.10.010. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1591. | Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV) |
|
Brown AN1, Liu L2, Rodriquez JL3, Zhao L2, Schuster L2, Li E2, Wang GP2,4, Neely MN5, Yamada W5, Drusano GL3. Sci Rep. 2017 Oct 31;7(1):14421. doi: 10.1038/s41598-017-15007-2. |
|
|
|
|
1593. | Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review |
|
Larney S1, Peacock A2, Leung J3, Colledge S2, Hickman M4, Vickerman P4, Grebely J5, Dumchev KV6, Griffiths P7, Hines L8, Cunningham EB5, Mattick RP2, Lynskey M8, Marsden J8, Strang J8, Degenhardt L2. Lancet Glob Health. 2017 Dec;5(12):e1208-e1220. doi: 10.1016/S2214-109X(17)30373-X. Epub 2017 Oct 23. |
|
|
|
|
|
|
|
|
|
|
|
|
1599. | Should we treat acute hepatitis C? A decision and cost-effectiveness analysis |
|
Bethea E1,2,3, Chen Q1,2, Hur C1,2,3, Chung RT2,3, Chhatwal J1,2,3. Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611. [Epub ahead of print] |
|
|
|
|
1601. | Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women |
|
Sarkar M1, Dodge JL2, Greenblatt RM3, Kuniholm MH4, DeHovitz J5, Plankey M6, Kovacs A7, French AL8, Seaberg EC9, Ofotokun I10, Fischl M11, Overton E12, Kelly E13, Bacchetti P14, Peters MG1; Women?s Interagency HIV Study. Clin Infect Dis. 2017 Jul 26. doi: 10.1093/cid/cix643. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1606. | Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-naïve Hepatitis C virus Genotype 1-infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen |
|
Bourgeois S1, Horsmans Y2, Nevens F3, van Vlierberghe H4, Moreno C5, Beumont M6, Vijgen L6, van Eygen V6, Luo D7, Hillewaert V6, Van Remoortere P7, van de Logt J8, Ouwerkerk-Mahadevan S6. Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01217-17. doi: 10.1128/AAC.01217-17. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1610. | Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies |
|
Origa R1, Ponti ML2, Filosa A3, Galeota Lanza A3, Piga A4, Saracco GM4, Pinto V5, Picciotto A6, Rigano P7, Madonia S7, Rosso R8, D'Ascola D9, Cappellini MD10, D'Ambrosio R10, Tartaglione I11, De Franceschi L12, Gianesin B5, Di Marco V13, Forni GL5; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24911. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1619. | Hepatitis C Virus Prevalence in Egyptian Americans in Southern California |
|
Saab S1, Viramontes MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG, Saab EG, Saab CE, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M. J Clin Gastroenterol. 2017 Jun 14. doi: 10.1097/MCG.0000000000000858. [Epub ahead of print] |
|
|
|
|
1621. | The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience |
|
Martini S1, Donato MF2, Mazzarelli C3, Rendina M4, Visco-Comandini U5, Filì D6, Gianstefani A7, Fagiuoli S8, Melazzini M9, Montilla S9, Pani L9, Petraglia S9, Russo P9, Trotta MP9, Carrai P10, Caraceni P7; ITACOPS study group. Liver Int. 2017 Sep 16. doi: 10.1111/liv.13588. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1626. | Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model |
|
Wright N1, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B. Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962. [Epub ahead of print] |
|
|
1627. | Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial |
|
Wyles D1, Poordad F2, Wang S3, Alric L4, Felizarta F5, Kwo PY6, Maliakkal B7, Agarwal K8, Hassanein T9, Weilert F10, Lee SS11, Kort J3, Lovell SS3, Liu R3, Lin CW3, Pilot-Matias T3, Krishnan P3, Mensa FJ3. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1631. | Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis |
|
Platt L1, Minozzi S2, Reed J3, Vickerman P4, Hagan H3, French C4, Jordan A3, Degenhardt L5, Hope V6, Hutchinson S7, Maher L8, Palmateer N7, Taylor A9, Bruneau J10, Hickman M4. Addiction. 2017 Sep 11. doi: 10.1111/add.14012. [Epub ahead of print] |
|
|
|
|
|
|
1634. | A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus |
|
Kanwal F1, Pyne JM2,3, Tavakoli-Tabasi S4, Nicholson S5, Dieckgraefe B6, Storay E7, Goetz MB8, Kramer JR9, Smith D10, Sansgiry S11, Tansel A12, Gifford AL13,14, Asch SM15. Health Serv Res. 2017 Sep 11. doi: 10.1111/1475-6773.12758. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1638. | Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s |
|
Garvey P1, Murphy N2, Flanagan P2, Brennan A2, Courtney G3, Crosbie O4, Crowe J5, Hegarty J6, Lee J7, McIver M2, McNulty C6, Murray F8, Nolan N6, O'Farrelly C9, Stewart S5, Tait M10, Norris S11, Thornton L2. J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249-3. doi: 10.1016/j.jhep.2017.07.034. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1650. | Chronic hepatitis C virus infection and neurocognitive function in adult survivors of childhood cancer |
|
Studaway A1, Ojha RP2, Brinkman TM1,3, Zhang N4, Baassiri M5, Banerjee P1, Ehrhardt MJ1,5, Srivastava D4, Robison LL1, Hudson MM1,5, Krull KR1,3. Cancer. 2017 Jul 25. doi: 10.1002/cncr.30913. [Epub ahead of print] |
|
|
1651. | Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study |
|
Wiessing L1, Ferri M2, B?lá?ková V3,4,5, Carrieri P6,7, Friedman SR8, Folch C9,10, Dolan K11, Galvin B12, Vickerman P13, Lazarus JV14,15, Mrav?ík V3,4,16, Kretzschmar M17,18, Sypsa V19, Sarasa-Renedo A10,20, Uusküla A21, Paraskevis D19, Mendão L22, Rossi D23, van Gelder N2, Mitcheson L24, Paoli L25,26, Gomez CD27, Milhet M27, Dascalu N28, Knight J29, Hay G30, Kalamara E2, Simon R2; EUBEST working group, Comiskey C31, Rossi C32, Griffiths P2. Harm Reduct J. 2017 Apr 22;14(1):19. doi: 10.1186/s12954-017-0141-6. |
|
|
|
|
|
|
|
|
|
|
1656. | The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease |
|
Young J1, Weis N2, Hofer H3, Irving W4, Weiland O5, Giostra E6, Pascasio JM7, Castells L8, Prieto M9, Postema R10, Lefevre C11, Evans D11, Bucher HC12, Calleja JL13. BMC Infect Dis. 2017 Jan 7;17(1):45. doi: 10.1186/s12879-016-2106-x. |
|
|
1657. | Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial |
|
van der Ree MH1, de Vree JM2, Stelma F1, Willemse S3, van der Valk M4, Rietdijk S5, Molenkamp R6, Schinkel J6, van Nuenen AC7, Beuers U3, Hadi S8, Harbers M8, van der Veer E9, Liu K10, Grundy J10, Patick AK10, Pavlicek A10, Blem J10, Huang M10, Grint P10, Neben S10, Gibson NW10, Kootstra NA7, Reesink HW11. Lancet. 2017 Jan 10. pii: S0140-6736(16)31715-9. doi: 10.1016/S0140-6736(16)31715-9. [Epub ahead of print] |
|
|
|
|
|
|
1660. | Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study |
|
Foster MA1, Xing J2, Moorman AC2, Boscarino J3, Gordon SC4, Lu M4, Rupp L4, Schmidt MA5, Trinacty CM6, Xu F2, Holmberg SD2, Spradling PR2. Dig Dis Sci. 2016 Aug 10. [Epub ahead of print] |
|
|
1661. | Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras |
|
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R; North American AIDS Cohort Collaboration on Research and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Clin Infect Dis. 2016 Aug 9. pii: ciw531. [Epub ahead of print] |
|
|
1662. | Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening |
|
Irvin R1, McAdams-Mahmoud A1, Hickman D2, Wilson J2, Fenwick W2, Chen I3, Irvin N4, Falade-Nwulia O1, Sulkowski M1, Chaisson R1, Thomas DL1, Mehta SH5. J Community Med Health Educ. 2016 Jun;6(3). pii: 431. Epub 2016 May 30. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1674. | Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort |
|
Foster GR1, Coppola C2, Derbala M3, Ferenci P4, Orlandini A5, Reddy KR6, Tallarico L7, Shiffman ML8, Ahlers S9, Bakalos G10, Hassanein T11; GUARD-C Study Group. PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016. |
|
|
|
|
1676. | GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study |
|
Rodriguez-Torres M1, Glass S2, Hill J3, Freilich B4, Hassman D5, Di Bisceglie AM6, Taylor JG7, Kirby BJ7, Dvory-Sobol H7, Yang JC7, An D7, Stamm LM7, Brainard DM7, Kim S8, Krefetz D9, Smith W10, Marbury T11, Lawitz E12. J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527. [Epub ahead of print] |
|
|
|
|
1678. | Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals |
|
Chhatwal J1,2,3, Wang X4,5, Ayer T4, Kabiri M6, Chung RT2,3, Hur C1,2,3, Donohue JM6, Roberts MS6, Kanwal F7,8. Hepatology. 2016 Mar 25. doi: 10.1002/hep.28571. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1684. | Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies |
|
Martinello M1, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV. Antivir Ther. 2016 Feb 11. doi: 10.3851/IMP3035. [Epub ahead of print] |
|
|
|
|
1686. | Is increased HCV case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis |
|
Martin NK1,2, Vickerman P2, Brew IF3, Williamson J3, Miners A4, Irving WL5, Saksena S6, Hutchinson SJ7, Mandal S8, O'Moore E8, Hickman M2. Hepatology. 2016 Feb 10. doi: 10.1002/hep.28497. [Epub ahead of print] |
|
|
|
|
1688. | Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C |
|
Valcour VG1, Rubin LH, Obasi MU, Maki PM, Peters MG, Levin S, Crystal HA, Young MA, Mack WJ, Cohen MH, Pierce CB, Adimora AA, Tien PC; Women?s Interagency HIV Study protocol team. J Acquir Immune Defic Syndr. 2016 Feb 16. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1695. | Synergistic activity of combined NS5A inhibitors |
|
O'Boyle DR 2nd1, Nower PT2, Gao M2, Fridell R2, Wang C2, Hewawasam P2, Lopez O2, Tu Y2, Meanwell NA2, Belema M2, Roberts SB2, Cockett M2, Sun JH2. Antimicrob Agents Chemother. 2015 Dec 28. pii: AAC.02639-15. [Epub ahead of print] |
|
|
|
|
|
|
1698. | Potent Antiviral Activity of Direct-Acting Antivirals, ABT-493 and ABT-530, With 3-day Monotherapy for Hepatitis C Genotype 1 Infection |
|
Lawitz EJ1, O'Riordan WD2, Asatryan A3, Freilich BL4, Box TD5, Overcash JS2, Lovell S3, Ng TI3, Liu W3, Campbell A3, Lin CW3, Yao B3, Kort J3. Antimicrob Agents Chemother. 2015 Dec 28. pii: AAC.02264-15. [Epub ahead of print] |
|
|
|
|
1700. | Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial |
|
Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK. Ann Intern Med. 2015 Dec 1;163(11):809-17. doi: 10.7326/M15-1014. Epub 2015 Nov 10. |
|
|
|
|
|
|
1703. | Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers |
|
Patel K1,2,3, Tillmann HL1,2, Matta B2, Sheridan MJ4, Gardner SD5, Shackel NA3, McHutchison JG6, Goodman ZD7. Aliment Pharmacol Ther. 2015 Nov 11. doi: 10.1111/apt.13471. [Epub ahead of print] |
|
|
|
|
1705. | Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET |
|
Brown RS Jr1, O'Leary JG2, Reddy KR3, Kuo A4, Morelli GJ5, Burton JR Jr6, Stravitz RT7, Durand C8, Di Bisceglie AM9, Kwo P10, Frenette CT11, Stewart TG12, Nelson DR5, Fried MW12, Terrault NA13; HCV-TARGET Study Group. Liver Transpl. 2015 Oct 31. doi: 10.1002/lt.24366. [Epub ahead of print] |
|
|
|
|
1707. | Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study |
|
Jensen DM1, Brunda M2, Elston R3, Gane EJ4, George J5, Glavini K6, Hammond JM6, Le Pogam S7, Nájera I6, Passe S2, Piekarska A8, Rodriguez I2, Zeuzem S9, Chu T2; ANNAPURNA study investigators. Liver Int. 2015 Oct 31. doi: 10.1111/liv.12997. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1714. | Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE |
|
Buti M1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Forns X8. Clin Infect Dis. 2015 Sep 14. pii: civ722. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1721. | The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial) |
|
Poordad F1, Rustgi V2, Brown RS Jr3, Patel V4, Kugelmas M5, Regenstein F6, Balart L7, LaBrecque D8, Brown K9, Avila M10, Biederman M11, Freed G12, Smith R13, Bernstein M14, Arnold H15, Cahan J16, Fink S17, Katkov W18, Massoumi H19, Harrison S20. Therap Adv Gastroenterol. 2015 Sep;8(5):263-9. doi: 10.1177/1756283X15588876. |
|
|
|
|
|
|
1724. | Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV |
|
Susanna Naggie, M.D., M.H.S., Curtis Cooper, M.D., Michael Saag, M.D., Kimberly Workowski, M.D., Peter Ruane, M.D., William J. Towner, M.D., Kristen Marks, M.D., Anne Luetkemeyer, M.D., Rachel P. Baden, M.D., Paul E. Sax, M.D., Edward Gane, M.D., Jorge Santana-Bagur, M.D., Luisa M. Stamm, M.D., Ph.D., Jenny C. Yang, Pharm.D., Polina German, Pharm.D., Hadas Dvory-Sobol, Ph.D., Liyun Ni, M.A., Phillip S. Pang, M.D., Ph.D., John G. McHutchison, M.D., Catherine A.M. Stedman, M.B., Ch.B., Ph.D., Javier O. Morales-Ramirez, M.D., Norbert Bräu, M.D., Dushyantha Jayaweera, M.D., Amy E. Colson, M.D., Pablo Tebas, M.D., David K. Wong, M.D., Douglas Dieterich, M.D., and Mark Sulkowski, M.D. for the ION-4 Investigators |
|
|
|
|
1726. | Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 |
|
David L. Wyles, M.D., Peter J. Ruane, M.D., Mark S. Sulkowski, M.D., Douglas Dieterich, M.D., Anne Luetkemeyer, M.D., Timothy R. Morgan, M.D., Kenneth E. Sherman, M.D., Ph.D., Robin Dretler, M.D., Dawn Fishbein, M.D., Joseph C. Gathe, Jr., M.D., Sarah Henn, M.D., Federico Hinestrosa, M.D., Charles Huynh, D.O., Cheryl McDonald, M.D., Anthony Mills, M.D., Edgar Turner Overton, M.D., Moti Ramgopal, M.D., Bruce Rashbaum, M.D., Graham Ray, M.S.N., A.N.P., Anthony Scarsella, M.D., Joseph Yozviak, D.O., Fiona McPhee, Ph.D., Zhaohui Liu, Ph.D., Eric Hughes, M.D., Ph.D., Philip D. Yin, M.D., Ph.D., Stephanie Noviello, M.D., and Peter Ackerman, M.D. for the ALLY-2 Investigators |
|
|
|
|
1728. | Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study |
|
Gordon SC1, Lamerato LE2, Rupp LB3, Holmberg SD4, Moorman AC4, Spradling PR4, Teshale E4, Xu F4, Boscarino JA5, Vijayadeva V6, Schmidt MA7, Oja-Tebbe N2, Lu M2. Am J Gastroenterol. 2015 Aug;110(8):1169-77. doi: 10.1038/ajg.2015.203. Epub 2015 Jul 28. |
|
|
|
|
|
|
1731. | Development of sofosbuvir for the treatment of hepatitis C virus infection |
|
Lawitz E1, Jacobson IM2, Nelson DR3, Zeuzem S4, Sulkowski MS5, Esteban R6, Brainard D7, McNally J7, Symonds WT7, McHutchison JG7, Dieterich D8, Gane E9. Ann N Y Acad Sci. 2015 Jul 31. doi: 10.1111/nyas.12832. [Epub ahead of print] |
|
|
|
|
1733. | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) |
|
Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4. |
|
|
1734. | Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial |
|
Shiffman ML1, Cheinquer H2, Berg CP3, Berg T4, de Figueiredo-Mendes C5, Dore GJ6, Ferraz ML7, Mendes-Corrêa MC8, Lima MP9, Parise ER10, Rios AM11, Reuter T12, Sanyal AJ13, Shafran SD14, Hohmann M15, Tatsch F16,17, Bakalos G18, Zeuzem S1 Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24. |
|
|
1735. | Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 |
|
Naggie S1, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21. |
|
|
|
|
|
|
|
|
|
|
1740. | Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-label Study of Patients With Genotype 1b Chronic Hepatitis C Virus, With and Without Cirrhosis |
|
Lawitz E1, Makara M2, Akarca US3, Thuluvath PJ4, Preotescu LL5, Varunok P6, Morillas RM7, Hall C8, Mobashery N8, Redman R8, Pilot-Matias T8, Vilchez RA8, Hézode C9. Gastroenterology. 2015 Jul 10. pii: S0016-5085(15)00936-1. doi: 10.1053/j.gastro.2015.07.001. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1744. | Treating Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin: A Matched Analysis |
|
Saab S1,2, Jimenez M3, Bau S2, Goo T1, Zhao D3, Durazo F1,2, Han S1,2, El Kabany M1,2, Kaldas F2, Tong MJ2,4, Busuttil RW2. Clin Transplant. 2015 Jul 4. doi: 10.1111/ctr.12584. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1750. | The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study |
|
Fortier E1, Alavi M2, Micallef M2, Dunlop AJ3, Balcomb AC4, Day CA5, Treloar C6, Bath N7, Haber PS8, Dore GJ2, Bruneau J9, Grebely J10; ETHOS Study Group. Int J Drug Policy. 2015 Jun 11. pii: S0955-3959(15)00181-4. doi: 10.1016/j.drugpo.2015.06.001. [Epub ahead of print] |
|
|
1751. | A phase II, randomized, controlled trial of S-adenosylmethionine in reducing serum alpha-fetoprotein (AFP) in patients with hepatitis C cirrhosis and elevated AFP |
|
Morgan TR1, Osann K2, Bottiglieri T3, Pimstone N4, Hoefs JC5, Hu KQ6, Hassanein T7, Boyer T8, Kong L9, Chen WP10, Richmond E11, Gonzalez R12, Rodriguez LM13, Meyskens FL14. Cancer Prev Res (Phila). 2015 Jun 30. pii: canprevres.0029.2015. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1755. | Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review |
|
Onofrey S, Aneja J, Haney GA, Nagami EH, Jr AD, Lauer GM, Hills-Evans K, Barton K, Kulaga S, Bowen MJ, Cocoros N, McGovern BH, Church DR, Kim AY. Ann Intern Med. 2015 Jun 30. doi: 10.7326/M14-2939. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1762. | Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent |
|
Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print] |
|
|
|
|
1764. | Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study |
|
Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1773. | Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013 |
|
Wandeler G1, Schlauri M2, Jaquier ME2, Rohrbach J2, Metzner KJ3, Fehr J3, Ambrosioni J4, Cavassini M5, Stöckle M6, Schmid P7, Bernasconi E8, Keiser O9, Salazar-Vizcaya L9, Furrer H2, Rauch A2; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. Open Forum Infect Dis. 2015 Mar 25;2(1):ofv026. doi: 10.1093/ofid/ofv026. eCollection |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1786. | Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin |
|
Rower JE1, Meissner EG2, Jimmerson LC1, Osinusi A3, Sims Z2, Petersen T2, Bushman LR1, Wolfe P4, McHutchison JG5, Kottilil S2, Kiser JJ6. J Antimicrob Chemother. 2015 May 13. pii: dkv122. [Epub ahead of print] |
|
|
1787. | Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study |
|
Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, Cooper C, Cox J, Gill J, Hull M, Walmsley S, Klein MB. HIV Clin Trials. 2015 May-Jun;16(3):100-10. doi: 10.1179/501100000024. Epub 2015 May 14. |
|
|
|
|
1789. | Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease |
|
Charlton M1, Everson GT2, Flamm SL3, Kumar P4, Landis C5, Brown RS Jr6, Fried MW7, Terrault NA8, O'Leary JG9, Vargas HE10, Kuo A11, Schiff E12, Sulkowski MS13, Gilroy R14, Watt KD15, Brown K16, Kwo P17, Pungpapong S18, Korenblat KM19, Muir AJ20, Teperman L21, Fontana RJ22, Denning J23, Arterburn S23, Dvory-Sobol H23, Brandt-Sarif T23, Pang PS23, McHutchison JG23, Reddy KR24, Afdhal N25; SOLAR-1 Investigators. Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682-4. doi: 10.1053/j.gastro.2015.05.010. [Epub ahead of print] |
|
|
1790. | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis |
|
Muir AJ1, Poordad F2, Lalezari J3, Everson G4, Dore GJ5, Herring R6, Sheikh A7, Kwo P8, Hézode C9, Pockros PJ10, Tran A11, Yozviak J12, Reau N13, Ramji A14, Stuart K15, Thompson AJ16, Vierling J17, Freilich B18, Cooper J19, Ghesquiere W20, Yang R21, McPhee F22, Hughes EA21, Swenson ES22, Yin PD22. JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868. |
|
|
1791. | Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection |
|
Poordad F1, Sievert W2, Mollison L3, Bennett M4, Tse E5, Bräu N6, Levin J7, Sepe T8, Lee SS9, Angus P10, Conway B11, Pol S12, Boyer N13, Bronowicki JP14, Jacobson I15, Muir AJ16, Reddy KR17, Tam E18, Ortiz-Lasanta G19, de Lédinghen V20, Sulkowski M21, Boparai N22, McPhee F23, Hughes E22, Swenson ES23, Yin PD23; UNITY-1 Study Group. JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860. |
|
|
1792. | Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials |
|
Alqahtani SA1, Afdhal N2, Zeuzem S3, Gordon S4, Mangia A5, Kwo P6, Fried M7, Yang JC8, Ding X8, Pang PS8, McHutchison JG8, Pound D9, Reddy KR10, Marcellin P11, Kowdley KV12, Sulkowski M1. Hepatology. 2015 May 11. doi: 10.1002/hep.27890. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1797. | Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients with Hepatitis C, Regardless of Response to Antiviral Therapy |
|
Lens S1, Rincón D2, García-Retortillo M3, Albillos A4, Calleja JL5, Bañares R2, González-Abraldes J6, Bosch J7, Sanchez-Tapias JM1, Forns X1, García-Pagán JC8. Clin Gastroenterol Hepatol. 2015 Apr 22. pii: S1542-3565(15)00415-2. doi: 10.1016/j.cgh.2015.04.013. [Epub ahead of print] |
|
|
|
|
1799. | Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic HCV Genotype 1, 4, or 6 Infection: A Randomized Trial |
|
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Ann Intern Med. 2015 Apr 24. doi: 10.7326/M15-0785. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1803. | Telaprevir- and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study |
|
Verna EC1, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA; for the CRUSH-C Consortium. Transplantation. 2015 Feb 24. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1808. | Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent |
|
Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print] |
|
|
|
|
1810. | Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study |
|
Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1823. | A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China |
|
Wu E1, Chen X, Guan Z, Cao C, Rao H, Feng B, Chan M, Fu S, Lin A, Wei L, Lok AS. Hepatol Int. 2015 Jan;9(1):58-66. doi: 10.1007/s12072-014-9559-z. Epub 2014 Jul 31. |
|
|
|
|
|
|
1826. | |
|
Sep 9;10(3):164-71. doi: 10.1108/IJPH-11-2013-0051. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1837. | Integrated Care Increases Treatment and Improves Outcomes of Patients with Chronic HCV Infection and Psychiatric Illness or Substance Abuse |
|
Ho SB1, Bräu N2, Cheung R3, Liu L4, Sanchez C5, Sklar M4, Phelps TE6, Marcus SG7, Wasil MM5, Tisi A7, Huynh L6, Robinson SK4, Gifford A8, Asch SM3, Groessl EJ4. Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00161-5. doi: 10.1016/j.cgh.2015.02.022. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1842. | Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection |
|
Osinusi A1, Townsend K2, Kohli A3, Nelson A4, Seamon C5, Meissner EG6, Bon D7, Silk R8, Gross C8, Price A8, Sajadi M9, Sidharthan S5, Sims Z5, Herrmann E7, Hogan J10, Teferi G10, Talwani R9, Proschan M11, Jenkins V12, Kleiner DE13, Wood BJ14, Subramanian GM15, Pang PS15, McHutchison JG15, Polis MA2, Fauci AS2, Masur H5, Kottilil S4. JAMA. 2015 Feb 23. doi: 10.1001/jama.2015.1373. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1848. | Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders |
|
Jensen D1, Sherman KE2, Hézode C3, Pol S4, Zeuzem S5, Ledinghen V6, Tran A7, Elkhashab M8, Younes ZH9, Kugelmas M10, Mauss S11, Everson G12, Luketic V13, Vierling J14, Serfaty L15, Brunetto M16, Heo J17, Bernstein D18, McPhee F19, Hennicken D20, Mendez P21, Hughes E21, Noviello S21; on behalf of the HALLMARK-QUAD Study Team. J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00125-7. doi: 10.1016/j.jhep.2015.02.018. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1854. | Findings from Integrated Behavioral and Biologic Survey among Males Who Inject Drugs (MWID) - Vietnam, 2009-2010: Evidence of the Need for an Integrated Response to HIV, Hepatitis B Virus, and Hepatitis C Virus |
|
Nadol P1, O'connor S2, Duong H3, Le LV3, Thang PH4, Tram TH4, Ha HT4, Mcconnell MS3, Partridge J5, Kaldor J6, Law M6, Nguyen TA4. PLoS One. 2015 Feb 18;10(2):e0118304. doi: 10.1371/journal.pone.0118304. eCollection 2015. |
|
|
1855. | Hepatitis C |
|
Webster DP1, Klenerman P2, Dusheiko GM3. Lancet. 2015 Feb 13. pii: S0140-6736(14)62401-6. doi: 10.1016/S0140-6736(14)62401-6. [Epub ahead of print] |
|
|
1856. | Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis |
|
Maan R1, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. J Gastroenterol Hepatol. 2015 Feb 13. doi: 10.1111/jgh.12929. [Epub ahead of print] |
|
|
|
|
|
|
1859. | Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study |
|
Molina JM1, Orkin C2, Iser DM3, Zamora FX4, Nelson M5, Stephan C6, Massetto B7, Gaggar A7, Ni L7, Svarovskaia E7, Brainard D7, Subramanian GM7, McHutchison JG7, Puoti M8, Rockstroh JK9; for the PHOTON-2 study team. Lancet. 2015 Feb 3. pii: S0140-6736(14)62483-1. doi: 10.1016/S0140-6736(14)62483-1. [Epub ahead of print] |
|
|
1860. | Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir |
|
Menon R1, Badri P2, Wang T2, Polepally A2, Zha J2, Khatri A2, Wang H2, Hu B2, Coakley E2, Podsadecki T2, Awni W2, Dutta S2. J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00057-4. doi: 10.1016/j.jhep.2015.01.026. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1865. | All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study |
|
Nelson DR1, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; on behalf of the ALLY-3 Study Team. Hepatology. 2015 Jan 23. doi: 10.1002/hep.27726. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1870. | Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study |
|
Kohli A1, Osinusi A2, Sims Z3, Nelson A4, Meissner EG4, Barrett LL5, Bon D6, Marti MM4, Silk R7, Kotb C7, Gross C7, Jolley TA4, Sidharthan S3, Petersen T3, Townsend K4, Egerson D7, Kapoor R7, Spurlin E4, Sneller M4, Proschan M8, Herrmann E6, Kwan R4, Teferi G9, Talwani R10, Diaz G11, Kleiner DE12, Wood BJ13, Chavez J9, Abbott S9, Symonds WT14, Subramanian GM14, Pang PS14, McHutchison J14, Polis MA4, Fauci AS4, Masur H3, Kottilil S15. Lancet. 2015 Jan 12. pii: S0140-6736(14)61228-9. doi: 10.1016/S0140-6736(14)61228-9. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1875. | Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term |
|
Macías J1, Mancebo M, Márquez M, Merino D, Téllez F, Rivero A, von Wichmann MA, López-Cortés LF, Merchante N, Santos J, Raffo M, Pérez-Pérez M, Camacho Á, Iribarren JA, Pineda JA. Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1885. | Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies |
|
Lenz O1, Verbinnen T2, Fevery B2, Tambuyzer L2, Vijgen L2, Peeters M2, Buelens A2, Ceulemans H2, Beumont M2, Picchio G3, Meyer SD2. J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00881-2. doi: 10.1016/j.jhep.2014.11.032. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1890. | An Interferon-free Antiviral Regimen for HCV after Liver Transplantation |
|
Kwo PY1, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X N Engl J Med. 2014 Nov 11. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1894. | Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study |
|
Wu T1, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ. Dig Dis. 2014;32(6):791-9. doi: 10.1159/000368024. Epub 2014 Oct 29. |
|
|
|
|
|
|
1897. | Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation |
|
Charlton M1, Gane E2, Manns MP3, Brown RS Jr4, Curry MP5, Kwo PY6, Fontana RJ7, Gilroy R8, Teperman L9, Muir AJ10, McHutchison JG11, Symonds WT11, Brainard D11, Kirby B11, Dvory-Sobol H11, Denning J11, Arterburn S11, Samuel D12, Forns X13, Terrault NA14. Gastroenterology. 2014 Oct 7. pii: S0016-5085(14)01194-9. doi: 10.1053/j.gastro.2014.10.001. [Epub ahead of print] |
|
|
1898. | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies |
|
Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print] |
|
|
1899. | Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus |
|
Yoshida EM1, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E. Hepatology. 2014 Oct 14. doi: 10.1002/hep.27366. [Epub ahead |
|
|
|
|
|
|
|
|
|
|
1904. | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies |
|
Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1908. | Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials |
|
Svarovskaia ES1, Dvory-Sobol H1, Parkin N2, Hebner C1, Gontcharova V1, Martin R1, Ouyang W1, Han B1, Xu S1, Ku K1, Chiu S1, Gane E3, Jacobson IM4, Nelson DR5, Lawitz E6, Wyles DL7, Bekele N1, Brainard D1, Symonds WT1, McHutchison JG1, Miller MD1, Mo H1. Clin Infect Dis. 2014 Sep 28. pii: ciu697. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1916. | What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? |
|
McDonald SA1, Innes HA2, Hayes PC3, Dillon JF4, Mills PR5, Goldberg DJ6, Barclay S7, Allen S8, Fox R5, Fraser A9, Kennedy N10, Bhattacharyya D11, Hutchinson SJ2. J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00635-7. doi: 10.1016/j.jhep.2014.08.046. [Epub ahead of print] |
|
|
1917. | Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients |
|
Meissner EG1, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Hepatology. 2014 Sep 9. doi: 10.1002/hep.27424. [Epub ahead of print] |
|
|
1918. | Simeprevir (TMC435) with Peginterferon/Ribavirin in Patients Coinfected with HCV Genotype-1 and HIV-1: A Phase III Study |
|
Dieterich D1, Rockstroh JK2, Orkin C3, Gutiérrez F4, Klein MB5, Reynes J6, Shukla U7, Jenkins A8, Lenz O9, Ouwerkerk-Mahadevan S10, Peeters M9, De La Rosa G7, Tambuyzer L9, Jessner W9. Clin Infect Dis. 2014 Sep 5. pii: ciu675. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1922. | Current Practices of Screening for Incident Hepatitis C Virus Infection among HIV- Infected, HCV-Uninfected Individuals in Primary Care |
|
Freiman JM1, Huang W1, White L2, Geng EH3, Hurt CB4, Taylor LE5, Overton ET6, Cachay ER7, Kitahata MM8, Moore RD9, Rodriguez B10, Mayer KH11, Linas BP12. Clin Infect Dis. 2014 Sep 3. pii: ciu698. [Epub ahead of print] |
|
|
1923. | Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C |
|
Younossi ZM1, Stepanova M2, Henry L3, Gane E4, Jacobson IM5, Lawitz E6, Nelson D7, Gerber L2, Nader F8, Hunt S2. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1942. | Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance |
|
Chang ML1, Tsou YK2, Hu TH3, Lin CH2, Lin WR2, Sung CM2, Chen TH2, Cheng ML4, Chang KC3, Chiu CT2, Yeh CT2, Pang JH5, Shiao MS4. PLoS One. 2014 Aug 14;9(8):e104783. doi: 10.1371/journal.pone.0104783. eCollection 2014. |
|
|
|
|
|
|
|
|
1946. | Hepatitis C in African Americans |
|
Saab S1, Jackson Md Facg C2, Nieto DO Facg Facp J3, Francois Md MSc Facg F4. Am J Gastroenterol. 2014 Sep 2. doi: 10.1038/ajg.2014.243. [Epub ahead of print] |
|
|
|
|
1948. | Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C |
|
Lawitz E1, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M. Antivir Ther. 2014 Aug 8. doi: 10.3851/IMP2845. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1954. | Modeling viral evolutionary dynamics after telaprevir-based treatment |
|
Haseltine EL1, De Meyer S2, Dierynck I2, Bartels DJ1, Ghys A2, Davis A1, Zhang EZ1, Tigges AM1, Spanks J1, Picchio G3, Kieffer TL1, Sullivan JC1. PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014. |
|
|
|
|
|
|
|
|
|
|
1959. | Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir |
|
Sabo JP1, Kort J1, Ballow C2, Haschke M3, Battegay M3, Fuhr R4, Girlich B5, Schobelock M6, Feifel U7, Lang B8, Li Y1, Elgadi M9. Clin Infect Dis. 2014 Aug 4. pii: ciu616. [Epub ahead of print] |
|
|
1960. | Clinical outcomes of compensated and decompensated cirrhosis: A long term study |
|
Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. World J Hepatol. 2014 Jul 27;6(7):504-12. doi: 10.4254/wjh.v6.i7.504. |
|
|
|
|
1962. | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study |
|
Lawitz E1, Sulkowski MS2, Ghalib R3, Rodriguez-Torres M4, Younossi ZM5, Corregidor A6, DeJesus E7, Pearlman B8, Rabinovitz M9, Gitlin N10, Lim JK11, Pockros PJ12, Scott JD13, Fevery B14, Lambrecht T15, Ouwerkerk-Mahadevan S14, Callewaert K14, Symonds WT16, Picchio G17, Lindsay KL17, Beumont M14, Jacobson IM18. Lancet. 2014 Jul 26. pii: S0140-6736(14)61036-9. doi: 10.1016/S0140-6736(14)61036-9. [Epub ahead of print] |
|
|
1963. | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study |
|
Manns M1, Pol S2, Jacobson IM3, Marcellin P4, Gordon SC5, Peng CY6, Chang TT7, Everson GT8, Heo J9, Gerken G10, Yoffe B11, Towner WJ12, Bourliere M13, Metivier S14, Chu CJ15, Sievert W16, Bronowicki JP17, Thabut D18, Lee YJ19, Kao JH20, McPhee F21, Kopit J21, Mendez P22, Linaberry M22, Hughes E22, Noviello S22; on behalf of the HALLMARK-DUAL Study Team. Lancet. 2014 Jul 26. pii: S0140-6736(14)61059-X. doi: 10.1016/S0140-6736(14)61059-X. [Epub ahead of print] |
|
|
|
|
|
|
1966. | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study |
|
Hézode C1, Hirschfield GM2, Ghesquiere W3, Sievert W4, Rodriguez-Torres M5, Shafran SD6, Thuluvath PJ7, Tatum HA8, Waked I9, Esmat G10, Lawitz EJ11, Rustgi VK12, Pol S13, Weis N14, Pockros PJ15, Bourlière M16, Serfaty L17, Vierling JM18, Fried MW19, Weiland O20, Brunetto MR21, Everson GT22, Zeuzem S23, Kwo PY24, Sulkowski M25, Bräu N26, Hernandez D27, McPhee F27, Wind-Rotolo M28, Liu Z29, Noviello S28, Hughes EA28, Yin PD27, Schnittman S27. Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print] |
|
|
|
|
1968. | Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3) |
|
Loras C1, Gisbert JP2, Saro MC3, Piqueras M4, Sánchez-Montes C5, Barrio J6, Ordás I7, Montserrat A8, Ferreiro R9, Zabana Y1, Chaparro M2, Fernández-Bañares F1, Esteve M10; for the REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). J Crohns Colitis. 2014 Jul 19. pii: S1873-9946(14)00206-2. doi: 10.1016/j.crohns.2014.06.009. [Epub ahead of print] |
|
|
1969. | Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per Sustained Virologic Response |
|
Bichoupan K1, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Hepatology. 2014 Jul 28. doi: 10.1002/hep.27340. [Epub ahead of print] |
|
|
1970. | Delivery of treatment for hepatitis C virus infection in the primary care setting |
|
Baker D1, Alavi M, Erratt A, Hill S, Balcomb A, Hallinan R, Siriragavan S, Richmond D, Smart J, Keats J, Doong N, Marks P, Grebely J, Dore GJ. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1003-9. doi: 10.1097/MEG.0000000000000150. |
|
|
|
|
1972. | Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection |
|
Sulkowski MS1, Naggie S2, Lalezari J3, Fessel WJ4, Mounzer K5, Shuhart M6, Luetkemeyer AF7, Asmuth D8, Gaggar A9, Ni L9, Svarovskaia E9, Brainard DM9, Symonds WT9, Subramanian GM9, McHutchison JG9, Rodriguez-Torres M10, Dieterich D11; PHOTON-1 Investigators. JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734. |
|
|
|
|
|
|
|
|
|
|
1977. | Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C |
|
Bronowicki JP1, Ratziu V2, Gadano A3, Thuluvath PJ4, Bessone F5, Martorell CT6, Pol S7, Terg R8, Younes Z9, He B10, Eley T10, Cohen D11, Yu F11, Hernandez D11, McPhee F11, Mendez P10, Hughes E10. J Hepatol. 2014 Jul 16. pii: S0168-8278(14)00480-2. doi: 10.1016/j.jhep.2014.07.011. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1992. | Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study |
|
Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print] |
|
|
|
|
1994. | Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program |
|
Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print] |
|
|
|
|
|
|
1997. | Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study |
|
Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print] |
|
|
|
|
1999. | Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program |
|
Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2004. | Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model |
|
Ikeda K1, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Oncology. 2014 Jun 7;86(5-6):295-302. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2008. | IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response |
|
Lin JC1, Habersetzer F2, Rodriguez-Torres M3, Afdhal N4, Lawitz EJ5, Paulson MS6, Zhu Y6, Subramanian GM6, McHutchison JG6, Sulkowski M7, Wyles DL1, Schooley RT1. J Infect Dis. 2014 Jun 6. pii: jiu325. [Epub ahead of print] |
|
|
|
|
|
|
2011. | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial |
|
Manns M1, Marcellin P2, Poordad F3, de Araujo ES4, Buti M5, Horsmans Y6, Janczewska E7, Villamil F8, Scott J9, Peeters M10, Lenz O10, Ouwerkerk-Mahadevan S11, De La Rosa G12, Kalmeijer R12, Sinha R10, Beumont-Mauviel M10. Lancet. 2014 Jun 3. pii: S0140-6736(14)60538-9. doi: 10.1016/S0140-6736(14)60538-9. [Epub ahead of print] |
|
|
|
|
|
|
2014. | Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial |
|
Jacobson IM1, Dore GJ2, Foster GR3, Fried MW4, Radu M5, Rafalsky VV6, Moroz L7, Craxi A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, De La Rosa G11, Kalmeijer R11, Scott J12, Sinha R9, Beumont-Mauviel M9. Lancet. 2014 Jun 3. pii: S0140-6736(14)60494-3. doi: 10.1016/S0140-6736(14)60494-3. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2021. | Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C |
|
Elkrief L1, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Hepatology. 2014 May 20. doi: 10.1002/hep.27228. [Epub ahead of print] |
|
|
|
|
2023. | Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity |
|
Flamm SL1, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2031. | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters |
|
van der Meer AJ1, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HL. Gut. 2014 May 9. doi: 10.1136/gutjnl-2013-305357. [Epub ahead of print] |
|
|
2032. | ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection |
|
Andreone P1, Colombo MG2, Enejosa JV3, Koksal I4, Ferenci P5, Maieron A6, Müllhaupt B7, Horsmans Y8, Weiland O9, Reesink HW10, Rodrigues L Jr3, Hu YB3, Podsadecki T3, Bernstein B3. Gastroenterology. 2014 May 9. pii: S0016-5085(14)00603-9. doi: 10.1053/j.gastro.2014.04.045. [Epub ahead of print] |
|
|
2033. | Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 |
|
Zeuzem S1, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; the VALENCE Investigators. N Engl J Med. 2014 May 4. [Epub ahead of print] |
|
|
|
|
|
|
2036. | A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy |
|
Burton JR Jr1, O'Leary JG2, Verna EC3, Saxena V4, Dodge JL4, Stravitz RT5, Levitsky J6, Trotter JF2, Everson GT1, Brown RS Jr3, Terrault NA7. J Hepatol. 2014 May 3. pii: S0168-8278(14)00300-6. doi: 10.1016/j.jhep.2014.04.037. [Epub ahead of print] |
|
|
2037. | Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model - Arizona and utah, 2012-2014 |
|
Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, Box T, Carroll C, Holtzman D, Ward JW; Division of Viral Hepatitis, National Center for National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):393-8. |
|
|
|
|
|
|
2040. | All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection |
|
Wyles DL1, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS. Hepatology. 2014 Feb 5. doi: 10.1002/hep.27053. [Epub ahead of print] |
|
|
|
|
|
|
2043. | ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type |
|
Matsuura K1, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M. J Viral Hepat. 2013 Sep 3. doi: 10.1111/jvh.12171. [Epub ahead of print] |
|
|
2044. | Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy |
|
Miller MH1, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF. Aliment Pharmacol Ther. 2014 Apr 22. doi: 10.1111/apt.12764. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
2050. | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection |
|
Afdhal N1, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; the ION-1 Investigators. N Engl J Med. 2014 Apr 11. [Epub ahead of print] |
|
|
|
|
2052. | Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection |
|
Afdhal N1, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11. |
|
|
2053. | Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis |
|
Kowdley KV1, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; the ION-3 Investigators. N Engl J Med. 2014 Apr 10. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2064. | Boceprevir In Liver Transplant Recipients |
|
Saab S1, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M, Han S, Busuttil RW. Liver Int. 2014 Mar 26. doi: 10.1111/liv.12548. [Epub ahead of print] |
|
|
|
|
2066. | The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine |
|
Haznedar J1, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Drug Dev Res. 2013 Dec 26. doi: 10.1002/ddr.21166. [Epub ahead of print] |
|
|
2067. | Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188) |
|
Deuffic-Burban S1, Schwarzinger M2, Obach D3, Mallet V4, Pol S5, Pageaux GP6, Canva V7, Deltenre P8, Roudot-Thoraval F9, Larrey D10, Dhumeaux D11, Mathurin P12, Yazdanpanah Y13. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155-X. doi: 10.1016/j.jhep.2014.03.011. [Epub ahead of print] |
|
|
|
|
2069. | Barriers to HCV treatment in the era of triple therapy: A prospective multi-centered study in clinical practice |
|
Crespo J1, Cabezas J, Sacristán B, Olcoz JL, Pérez R, de la Vega J, García R, García-Pajares F, Sáez-Royuela F, González JM, Jiménez F, Rodríguez S, Cuadrado A, López-Arias MJ, García I, Milla A, García-Riesco E, Muñoz M, Sánchez-Antolín G, Jorquera F. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12536. [Epub ahead of print] |
|
|
|
|
2071. | Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C |
|
Ponziani FR1, Viganò R2, Iemmolo RM3, Donato MF4, Rendina M5, Toniutto P6, Pasulo L7, Morelli MC8, Burra P9, Miglioresi L10, Merli M11, Di Paolo D12, Fagiuoli S7, Gasbarrini A13, Pompili M13; on behalf of AISF RECOLT-C Group, Belli L, Gerunda GE, Marino M, Montalti R, Di Benedetto F, De Ruvo N, Rigamonti C, Colombo M, Rossi G, Di Leo A, Lupo L, Memeo V, Bringiotti R, Zappimbulso M, Bitetto D, Vero V, Colpani M, Fornasiere E, Pinna AD, Morelli MC, Bertuzzo V, De Martin E, Senzolo M, Ettorre GM, Visco-Comandini U, Antonucci G, Angelico M, Tisone G, Giannelli V, Giusto M. Dig Liver Dis. 2014 Mar 10. pii: S1590-8658(14)00207-2. doi: 10.1016/j.dld.2014.01.157. [Epub ahead of print] |
|
|
|
|
2073. | Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients |
|
Terrault N1, Reddy KR, Poordad F, Curry M, Schiano T, Johl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P; for the HIVTR Investigators. Am J Transplant. 2014 Mar 17. doi: 10.1111/ajt.12668. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2078. | Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection |
|
Kumada H1, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Hepatology. 2014 Mar 6. doi: 10.1002/hep.27113. [Epub ahead of print] |
|
|
2079. | Simeprevir with Peginterferon and Ribavirin Leads to High Rates of SVR in Patients with HCV Genotype 1 Who Relapsed After Previous Therapy: a Phase 3 Trial |
|
Forns X1, Lawitz E2, Zeuzem S3, Gane E4, Bronowicki JP5, Andreone P6, Horban A7, Brown A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, Scott J11, De La Rosa G12, Kalmeijer R12, Sinha R9, Beumont-Mauviel M9. Gastroenterology. 2014 Mar 3. pii: S0016-5085(14)00293-5. doi: 10.1053/j.gastro.2014.02.051. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2103. | Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection |
|
Picchio G1, De Meyer S2, Dierynck I2, Ghys A2, Gritz L3, Kieffer TL3, Bartels DJ3, Witek J4, Bengtsson L3, Luo D4, Kauffman RS3, Adda N5, Sarrazin C6. J Clin Virol. 2014 Jan 6. pii: S1386-6532(13)00542-8. doi: 10.1016/j.jcv.2013.12.011. [Epub ahead of print] |
|
|
|
|
2105. | Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders |
|
Lok AS1, Gardiner DF2, Hézode C3, Lawitz EJ4, Bourlière M5, Everson GT6, Marcellin P7, Rodriguez-Torres M8, Pol S9, Serfaty L10, Eley T2, Huang SP11, Li J11, Wind-Rotolo M11, Yu F12, McPhee F12, Grasela DM2, Pasquinelli C2. J Hepatol. 2013 Oct 26. pii: S0168-8278(13)00744-7. doi: 10.1016/j.jhep.2013.10.019. [Epub ahead of print] |
|
|
2106. | Acute hepatitis C: A 24 week-course of Peg-Interferon alpha-2b versus a 12 week-course of Peg-Interferon alpha-2b alone or with ribavirin |
|
Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Perri GD, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Hepatology. 2014 Jan 18. doi: 10.1002/hep.26991. [Epub ahead of print] |
|
|
|
|
|
|
2109. | A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4 |
|
Vince B1, Hill JM2, Lawitz EJ3, O'Riordan W4, Webster LR5, Gruener DM6, Mofsen RS7, Murillo A8, Donovan E9, Chen J9, McCarville JF9, Sullivan-Bólyai JZ9, Mayers D9, Zhou XJ10. J Hepatol. 2014 Jan 13. pii: S0168-8278(14)00014-2. doi: 10.1016/j.jhep.2014.01.003. [Epub ahead of print] |
|
|
2110. | Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 |
|
Kris V. Kowdley, M.D., Eric Lawitz, M.D., Fred Poordad, M.D., Daniel E. Cohen, M.D., David R. Nelson, M.D., Stefan Zeuzem, M.D., Gregory T. Everson, M.D., Paul Kwo, M.D., Graham R. Foster, F.C.R.P., Mark S. Sulkowski, M.D., Wangang Xie, Ph.D., Tami Pilot-Matias, Ph.D., George Liossis, B.A., Lois Larsen, Ph.D., Amit Khatri, Ph.D., Thomas Podsadecki, M.D., and Barry Bernstein, M.D. |
|
|
|
|
|
|
2113. | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection |
|
Mark S. Sulkowski, M.D., David F. Gardiner, M.D., Maribel Rodriguez-Torres, M.D., K. Rajender Reddy, M.D., Tarek Hassanein, M.D., Ira Jacobson, M.D., Eric Lawitz, M.D., Anna S. Lok, M.D., Federico Hinestrosa, M.D., Paul J. Thuluvath, M.D., Howard Schwartz, M.D., David R. Nelson, M.D., Gregory T. Everson, M.D., Timothy Eley, Ph.D., Megan Wind-Rotolo, Ph.D., Shu-Pang Huang, Ph.D., Min Gao, Ph.D., Dennis Hernandez, Ph.D., Fiona McPhee, Ph.D., Diane Sherman, M.S., Robert Hindes, M.D., William Symonds, Pharm.D., Claudio Pasquinelli, M.D., Ph.D., and Dennis M. Grasela, Pharm.D., Ph.D. for the AI444040 Study Group |
|
|
|
|
|
|
2116. | Hepatitis C virus and type 1 diabetes |
|
Fallahi P, Di Domenicantonio A, Mazzi V, Santini F, Fabiani S, Sebastiani M, Zignego AL, Ferri C, Antonelli A. Clin Ter. 2013;164(5):e437-44. doi: 10.7417/CT.2013.1624. |
|
|
|
|
|
|
|
|
2120. | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial |
|
Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Lancet. 2013 Nov 1. pii: S0140-6736(13)62121-2. doi: 10.1016/S0140-6736(13)62121-2. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
2126. | Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies |
|
Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network. J Gastroenterol Hepatol. 2014 Jan;29(1):179-84. doi: 10.1111/jgh.12424. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2133. | Hepatitis C and alcohol exacerbate liver injury by suppression of FOXO3 |
|
Tumurbaatar B, Tikhanovich I, Li Z, Ren J, Ralston R, Kuravi S, Campbell R, Chaturvedi G, Huang TT, Zhao J, Hao J, O'Neil M, Weinman SA. Am J Pathol. 2013 Dec;183(6):1803-14. doi: 10.1016/j.ajpath.2013.08.013. Epub 2013 Nov 11. |
|
|
|
|
|
|
2136. | Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of Sustained Viral Response in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis |
|
Rodriguez-Torres M1, Stoehr A2, Gane EJ3, Serfaty L4, Lawitz E5, Zhou A6, Bourque M6, Bhanja S6, Strizki J6, Barnard RJ6, Hwang PM6, Dinubile MJ6, Mobashery N7. Clin Gastroenterol Hepatol. 2013 Oct 10. pii: S1542-3565(13)01519-X. doi: 10.1016/j.cgh.2013.09.067. [Epub ahead of print] |
|
|
2137. | α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype |
|
Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. J Med Virol. 2013 Oct 28. doi: 10.1002/jmv.23824. [Epub ahead of print] |
|
|
|
|
2139. | Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy |
|
Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD. Liver Int. 2013 Oct 1. doi: 10.1111/liv.12342. [Epub ahead of print] |
|
|
2140. | Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial |
|
Zeuzem S1, Berg T2, Gane E3, Ferenci P4, Foster GR5, Fried MW6, Hezode C7, Hirschfield GM8, Jacobson I9, Nikitin I10, Pockros PJ11, Poordad F12, Scott J13, Lenz O14, Peeters M14, Sekar V15, De Smedt G14, Sinha R14, Beumont-Mauviel M14. Gastroenterology. 2013 Nov 1. pii: S0016-5085(13)01576-X. doi: 10.1053/j.gastro.2013.10.058. [Epub ahead of print] |
|
|
|
|
|
|
2143. | The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection |
|
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. J Viral Hepat. 2013 Oct 10. doi: 10.1111/jvh.12185. [Epub ahead of print] |
|
|
|
|
|
|
2146. | Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy |
|
Afdhal NH1, Dusheiko GM2, Giannini EG3, Chen PJ4, Han KH5, Mohsin A6, Rodriguez-Torres M7, Rugina S8, Bakulin I9, Lawitz E10, Shiffman ML11, Tayyab GU12, Poordad F10, Kamel YM13, Brainsky A14, Geib J14, Vasey SY14, Patwardhan R14, Campbell FM13, Theodore D15. Gastroenterology. 2013 Oct 12. pii: S0016-5085(13)01436-4. doi: 10.1053/j.gastro.2013.10.012. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2150. | Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials |
|
Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Liver Int. 2013 Aug 2. doi: 10.1111/liv.12300. [Epub ahead of print] |
|
|
|
|
2152. | α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype |
|
Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. J Med Virol. 2013 Oct 28. doi: 10.1002/jmv.23824. [Epub ahead of print] |
|
|
|
|
2154. | Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C |
|
Arase Y, Kobayashi M, Kawamura Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T. J Med Virol. 2014 Jan;86(1):169-75. doi: 10.1002/jmv.23777. Epub 2013 Oct 24. |
|
|
|
|
|
|
|
|
2158. | The new paradigm of hepatitis C therapy: integration of oral therapies into best practices |
|
Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants. J Viral Hepat. 2013 Nov;20(11):745-60. doi: 10.1111/jvh.12173. |
|
|
2159. | Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor |
|
de Bruijne J, Thomas XV, Rebers SP, Weegink CJ, Treitel MA, Hughes E, Bergmann JF, de Knegt RJ, Janssen HL, Reesink HW, Molenkamp R, Schinkel J. J Viral Hepat. 2013 Nov;20(11):779-89. doi: 10.1111/jvh.12104. Epub 2013 Jun 27. |
|
|
|
|
2161. | Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy |
|
Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. J Viral Hepat. 2013 Nov;20(11):761-9. doi: 10.1111/jvh.12097. Epub 2013 Apr 7. |
|
|
|
|
|
|
|
|
2165. | Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis |
|
Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxì A; Multicenter Italian Group for the Study of Hepatitis C. J Viral Hepat. 2013 Nov;20(11):790-800. doi: 10.1111/jvh.12106. Epub 2013 Sep 15. |
|
|
|
|
2167. | Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response |
|
Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ. J Clin Gastroenterol. 2013 Oct 30. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2176. | Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14. |
|
Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14. |
|
|
2177. | Variation of transaminases, HCV-RNA levels and Th1/Th2 cytokine production during the post-partum period in pregnant women with chronic hepatitis C |
|
Ruiz-Extremera A, Muñoz-Gámez JA, Abril-Molina A, Salmerón-Ruiz MA, Muñoz-de-Rueda P, Pavón-Castillero EJ, Quiles-Pérez R, Carazo A, Gila A, Jimenez-Ruiz SM, Casado J, Martín AB, Sanjuán-Núñez L, Ocete-Hita E, Viota JL, León J, Salmerón J. PLoS One. 2013 Oct 10;8(10):e75613. doi: 10.1371/journal.pone.0075613. |
|
|
|
|
2179. | Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease |
|
García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez de Cía J, Sáez A, Porrero JL, Vargas-Castrillón J, Chávez-Jiménez E, Soto-Fernández S, Díaz A, Gallego-Durán R, Madejón A, Miquilena-Colina ME. Eur J Clin Invest. 2014 Jan;44(1):65-73. doi: 10.1111/eci.12192. Epub 2013 Nov 23. |
|
|
|
|
|
|
2182. | A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers |
|
Real LM, Caruz A, Rivero-Juarez A, Soriano V, Neukam K, Rivero A, Cifuentes C, Mira JA, Macías J, Pineda JA. Liver Int. 2013 Sep 25. doi: 10.1111/liv.12330. [Epub ahead of print] |
|
|
|
|
2184. | Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy |
|
Afdhal NH1, Dusheiko GM2, Giannini EG3, Chen PJ4, Han KH5, Mohsin A6, Rodriguez-Torres M7, Rugina S8, Bakulin I9, Lawitz E10, Shiffman ML11, Tayyab GU12, Poordad F10, Kamel YM13, Brainsky A14, Geib J14, Vasey SY14, Patwardhan R14, Campbell FM13, Theodore D15. Gastroenterology. 2013 Oct 12. pii: S0016-5085(13)01436-4. doi: 10.1053/j.gastro.2013.10.012. [Epub ahead of print] |
|
|
|
|
2186. | Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents |
|
Kittner JM, Weiss NM, Wiltink J, Schattenberg JM, Grambihler A, Thieringer F, Weinmann A, Zimmermann T, Koch S, Schuchmann M, Galle PR. Dig Liver Dis. 2013 Oct 11. pii: S1590-8658(13)00424-6. doi: 10.1016/j.dld.2013.08.139. [Epub ahead of print] |
|
|
2187. | Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort |
|
Aronsohn A, Ancuta I, Caruntu F, Coppola C, Delic D, Digiacomo A, Dusheiko GM, Lengyel G, Marcellin P, Orlandini A, Pruthi J, Silva GF, Tallarico L, Schmitz M, Tatsch F, Korner E, Cheinquer H. J Viral Hepat. 2013 Oct 17. doi: 10.1111/jvh.12179. [Epub ahead of print] |
|
|
|
|
2189. | Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study |
|
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Aliment Pharmacol Ther. 2013 Nov;38(9):1076-85. doi: 10.1111/apt.12494. Epub 2013 Sep 17. |
|
|
2190. | Liver stiffness predicts hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy |
|
Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12401. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2197. | A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects |
|
Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, Rodriguez-Torres M, Hong Z. Liver Int. 2013 Sep 25. doi: 10.1111/liv.12334. [Epub ahead of print] |
|
|
|
|
2199. | Emerging treatments for hepatitis C |
|
Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Expert Opin Emerg Drugs. 2013 Dec;18(4):461-75. doi: 10.1517/14728214.2013.847089. Epub 2013 Oct 8. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2209. | Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response |
|
Furusyo N, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Kainuma M, Okada K, Hayashi J. J Antimicrob Chemother. 2013 Oct 3. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
2215. | Optimizing treatment in HIV/HCV coinfection |
|
Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, Cocca G, Orso M, Moioli MC. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S355-62. doi: 10.1016/j.dld.2013.09.001. |
|
|
|
|
2217. | Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy |
|
Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Br J Cancer. 2013 Oct 29;109(9):2481-8. doi: 10.1038/bjc.2013.564. Epub 2013 Oct 1. |
|
|
|
|
|
|
|
|
|
|
|
|
2223. | High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients |
|
Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, Kuo HT, Huang JF, Chang JM, Chen HC, Juo SH, Hwang SJ, Chuang WL; FORMOSA-LIKE group. J Hepatol. 2013 Oct 2. pii: S0168-8278(13)00683-1. doi: 10.1016/j.jhep.2013.09.023. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2227. | Less-established risk factors are common in asian americans with hepatitis C virus: a case-controlled study |
|
Kin KC, Lin B, Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Levitt BS, da Silveira EB, Nguyen MH. Dig Dis Sci. 2013 Nov;58(11):3342-7. doi: 10.1007/s10620-013-2884-6. Epub 2013 Oct 1. |
|
|
|
|
2229. | Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment |
|
Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF. Antimicrob Agents Chemother. 2013 Dec;57(12):6097-105. doi: 10.1128/AAC.00608-13. Epub 2013 Sep 30. |
|
|
2230. | Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B |
|
Schoenfeld RC, Bourdet DL, Brameld KA, Chin E, de Vicente J, Fung A, Harris SF, Lee EK, Le Pogam S, Leveque V, Li J, Lui AS, Najera I, Rajyaguru S, Sangi M, Steiner S, Talamas FX, Taygerly JP, Zhao J. J Med Chem. 2013 Oct 10. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2239. | Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C |
|
Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H, Iijima H, Nishiguchi S. J Gastroenterol. 2013 Sep 25. [Epub ahead of print] |
|
|
2240. | Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor |
|
Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J. Antimicrob Agents Chemother. 2013 Dec;57(12):6034-49. doi: 10.1128/AAC.01176-13. Epub 2013 Sep 23. |
|
|
|
|
|
|
|
|
2244. | Predictors of consent to pharmacogenomics testing in the IDEAL study |
|
Jazwinski AB, Clark PJ, Thompson AJ, Gordon SC, Lawitz EJ, Noviello S, Brass CA, Pedicone LD, Albrecht JK, Sulkowski MS, Muir AJ. Pharmacogenet Genomics. 2013 Nov;23(11):619-23. doi: 10.1097/FPC.0000000000000002. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2254. | Targeted hepatitis C screening among ex-injection drug users in the community |
|
Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, Szeto KJ, Tsang S, Wu SH, Yan KK, Hui AY, Yiu DC, Wu BB, Cheung D, Chung CS, Lai CW, Chan HL. J Gastroenterol Hepatol. 2013 Aug 22. doi: 10.1111/jgh.12355. [Epub ahead of print] |
|
|
2255. | MicroRNA profile before and after antiviral therapy in liver transplant recipients for Hepatitis C virus cirrhosis |
|
Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, Sarvary E, Doros A, Gerlei Z, Nagy P, Schaff Z, Kiss A. J Gastroenterol Hepatol. 2013 Aug 22. doi: 10.1111/jgh.12362. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2260. | Protective effects of higher cognitive reserve for neuropsychological and daily functioning among individuals infected with hepatitis C |
|
Sakamoto M, Woods SP, Kolessar M, Kriz D, Anderson JR, Olavarria H, Sasaki AW, Chang M, Flora KD, Loftis JM, Huckans M. J Neurovirol. 2013 Oct;19(5):442-51. doi: 10.1007/s13365-013-0196-4. Epub 2013 Sep 10. |
|
|
2261. | Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease |
|
Himoto T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Senda S, Haba R, Ueno M, Yamaoka G, Masaki T. Diabetol Metab Syndr. 2013 Sep 9;5(1):51. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2265. | Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration |
|
Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D. HIV Med. 2013 Sep 6. doi: 10.1111/hiv.12082. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2281. | Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial |
|
Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309. |
|
|
2282. | A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C |
|
Gentile I, Coppola N, Pasquale G, Liuzzi R, D'Armiento M, Di Lorenzo ME, Capoluongo N, Buonomo AR, Sagnelli E, Morisco F, Caporaso N, Borgia G. Hepat Mon. 2013 May 8;13(5):e8352. doi: 10.5812/hepatmon.8352. eCollection 2013. |
|
|
|
|
2284. | Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: A metabolomics analysis |
|
Saito T, Sugimoto M, Igarashi K, Saito K, Shao L, Katsumi T, Tomita K, Sato C, Okumoto K, Nishise Y, Watanabe H, Tomita M, Ueno Y, Soga T. Metabolism. 2013 Nov;62(11):1577-86. doi: 10.1016/j.metabol.2013.07.002. Epub 2013 Aug 15. |
|
|
|
|
2286. | Association of the IFNL4-?G Allele With Impaired Spontaneous Clearance of Hepatitis C Virus |
|
Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR. J Infect Dis. 2013 Sep 4. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2295. | Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial |
|
Rusu E, Jinga M, Enache G, Rusu F, Dragomir AD, Ancuta I, Dragu? R, Parpala C, Nan R, Sima I, Ateia S, Stoica V, Che?a DM, Radulian G. Nutr J. 2013 Aug 14;12:119. doi: 10.1186/1475-2891-12-119. |
|
|
2296. | IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection |
|
Taliani G, Spaziante M, Biliotti E, Borro M, Palazzo D, Grieco S, Franchi C, Iaiani G, Furlan C, Gallinaro V, Simmaco M. PLoS One. 2013 Aug 1;8(8):e67301. doi: 10.1371/journal.pone.0067301. Print 2013. |
|
|
|
|
|
|
|
|
2300. | Faldaprevir and deleobuvir for HCV genotype 1 infection |
|
Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ. N Engl J Med. 2013 Aug 15;369(7):630-9. doi: 10.1056/NEJMoa1213557. |
|
|
|
|
|
|
2303. | Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE |
|
Ferrín G, Ranchal I, Llamoza C, Rodríguez-Perálvarez ML, Romero-Ruiz A, Aguilar-Melero P, López-Cillero P, Briceño J, Muntané J, Montero-Álvarez JL, De la Mata M. Liver Int. 2013 Jul 22. doi: 10.1111/liv.12277. [Epub ahead of print] |
|
|
2304. | Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results |
|
Lacombe K, Valin N, Stitou H, Gozlan J, Thibault V, Boyd A, Poirier JM, Meynard JL, Valantin MA, Bottero J, Girard PM. AIDS. 2013 May 15;27(8):1356-9. doi: 10.1097/QAD.0b013e32836138d0. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2311. | Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients |
|
Petta S, Marchesini G, Caracausi L, Macaluso FS, Cammà C, Ciminnisi S, Cabibi D, Porcasi R, Craxì A, Di Marco V. J Hepatol. 2013 Aug 6. pii: S0168-8278(13)00553-9. doi: 10.1016/j.jhep.2013.07.037. [Epub ahead of print] |
|
|
|
|
2313. | Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection-A Randomized Trial |
|
Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators. Gastroenterology. 2013 Nov;145(5):1035-1044.e5. doi: 10.1053/j.gastro.2013.07.051. Epub 2013 Aug 4. |
|
|
|
|
2315. | Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis |
|
Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, Cheng J, Srinivasan P, Nasheri N, Russell RS, Lorne D, Pezacki JP. Hepatology. 2013 Jul 29. doi: 10.1002/hep.26634. [Epub ahead of print] |
|
|
|
|
2317. | |
|
Brunings P, Klar S, Butt G, Nijkamp MD, Buxton JA. Gastroenterol Nurs. 2013 Jul-Aug;36(4):249-57. doi: 10.1097/SGA.0b013e31829f3f9e. |
|
|
|
|
|
|
|
|
|
|
2322. | Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1 |
|
Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2336. | A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C |
|
Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Kumada H. J Med Virol. 2013 Oct;85(10):1746-53. doi: 10.1002/jmv.23673. Epub 2013 Jul 16. |
|
|
|
|
2338. | Assessment of health-related quality of life predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C |
|
Matsushita H, Ikeda F, Iwasaki Y, Seki H, Nanba S, Takeuchi Y, Moritou Y, Yasunaka T, Onishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K. J Gastroenterol Hepatol. 2013 Jul 22. doi: 10.1111/jgh.12337. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2342. | Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin |
|
Par G, Szereday L, Berki T, Palinkas L, Halasz M, Miseta A, Hegedus G, Szekeres-Bartho J, Vincze A, Hunyady B, Par A. PLoS One. 2013 Jul 9;8(7):e67770. doi: 10.1371/journal.pone.0067770. Print 2013. |
|
|
|
|
|
|
|
|
|
|
2347. | Excellent liver retransplantation outcomes in hepatitis C-infected recipients |
|
Kressel A, Therapondos G, Bohorquez H, Borg B, Bruce D, Carmody I, Cohen A, Girgrah N, Joshi S, Reichman T, Loss GE. Clin Transplant. 2013 Jul;27(4):E512-20. doi: 10.1111/ctr.12182. Epub 2013 Jul 16. |
|
|
|
|
2349. | Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C |
|
Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group. Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. doi: 10.1128/AAC.00565-13. Epub 2013 Jul 15. |
|
|
|
|
2351. | A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection |
|
Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, Grilnberger-Franz E, Dulic-Lakovic E, Stauber R, Laferl H, Aberle JH, Holzmann H, Krall C, Vogel W, Ferenci P, Hofer H. J Hepatol. 2013 Jul 10. pii: S0168-8278(13)00446-7. doi: 10.1016/j.jhep.2013.06.028. [Epub ahead of print] |
|
|
2352. | In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellualr carcimona, with better tolerance and similar survival |
|
Shingina A, Hashim AM, Haque M, Suen M, Yoshida EM, Gill S, Donnellan F, Weiss AA. Can J Gastroenterol. 2013 Jul;27(7):393-6. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2365. | Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection |
|
Sagrini E, Ardoino I, Marano G, Gianstefani A, Orlandini A, Sebastiani G, Donati G, Cucchetti A, Pelosi G, Ferrari C, Alberti A, Biganzoli E, Piscaglia F, Bolondi L. Eur J Gastroenterol Hepatol. 2013 Jul 3. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2370. | Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients |
|
Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafigli M, Silveri MC, Vecchiet J, Cauda R, Di Giambenedetto S. Infection. 2013 Jul 10. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2386. | A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C |
|
Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R. J Hepatol. 2013 Jun 26. pii: S0168-8278(13)00435-2. doi: 10.1016/j.jhep.2013.06.019. [Epub ahead of print] |
|
|
|
|
|
|
2389. | Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection |
|
Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES. Gastroenterology. 2013 Jun 26. pii: S0016-5085(13)00995-5. doi: 10.1053/j.gastro.2013.06.051. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2393. | Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis |
|
Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C, Zeuzem S, Hofmann WP. PLoS One. 2013 Aug 1;8(8):e71262. doi: 10.1371/journal.pone.0071262. Print 2013. |
|
|
|
|
|
|
|
|
2397. | Chronic hepatitis C infection is associated with insulin resistance and lipid profiles |
|
Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, Lin ZY, Chen SC, Wang LY, Chuang WL, Yu ML, Tung HD. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12313. [Epub ahead of print] |
|
|
|
|
2399. | Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C |
|
Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, Sagnelli E, Perrone L, Adinolfi LE, Miraglia del Giudice E. J Viral Hepat. 2013 Aug;20(8):517-23. doi: 10.1111/jvh.12053. Epub 2013 Jan 7. |
|
|
|
|
|
|
2402. | Long-term clearance of hepatitis C virus following interferon ?-2b or peginterferon ?-2b, alone or in combination with ribavirin |
|
Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC. J Viral Hepat. 2013 Aug;20(8):524-9. doi: 10.1111/jvh.12074. Epub 2013 Mar 3. |
|
|
|
|
|
|
|
|
|
|
|
|
2408. | The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: A randomized controlled trial |
|
Chapplain JM, Bellissant E, Guyader D, Molina JM, Poizot-Martin I, Perré P, Pialoux G, Turlin B, Mouchel C, Renault A, Michelet C; ANRS HC-12 Study Group. J Infect. 2013 Jun 22. pii: S0163-4453(13)00152-7. doi: 10.1016/j.jinf.2013.05.007. [Epub ahead of print] |
|
|
|
|
2410. | Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse |
|
Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G. Scand J Gastroenterol. 2013 Jul;48(7):839-47. doi: 10.3109/00365521.2013.793389. |
|
|
2411. | Prediction of hepatic fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus based on genetic markers |
|
Fernández-Rodríguez A, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Micheloud D, Miralles P, López JC, Bellón JM, Aldamiz-Echevarria T, García-Broncano P, Carrero A, Alvarez E, Resino S. J Acquir Immune Defic Syndr. 2013 Jun 21. [Epub ahead of print] |
|
|
|
|
2413. | Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C |
|
Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, Morris DW, Younes Z, Fried MW, Bourlière M, Hézode C, Reddy KR, Massoud O, Abrams GA, Ratziu V, He B, Eley T, Ahmad A, Cohen D, Hindes R, McPhee F, Reilly B, Mendez P, Hughes E. Antivir Ther. 2013 Jun 26. doi: 10.3851/IMP2660. [Epub ahead of print] |
|
|
|
|
|
|
2416. | Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with HCV Genotype 1 |
|
Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Clin Microbiol. 2013 Jun 19. [Epub ahead of print] |
|
|
|
|
2418. | Role of IL28B Gene Polymorphism and Cell-Mediated Immunity in Spontaneous Resolution of Acute Hepatitis C |
|
Spada E, Amoroso P, Taliani G, Zuccaro O, Chiriacò P, Maio P, Maio G, Esposito ML, Mariano C, Rinaldi R, Bellissima P, Tosti ME, Del Porto P, Francavilla R, Mellace V, Garbuglia AR, Folgori A, Mele A; for the Acute Hepatitis Italian Study Group. Clin Infect Dis. 2013 Jul 9. [Epub ahead of print] |
|
|
|
|
|
|
2421. | Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study |
|
Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, Guzman L, Kletter E, Seewald RM, Des-Jarlais DC, Sorensen JL, Perlman DC. Harm Reduct J. 2013 Jun 20;10:10. doi: 10.1186/1477-7517-10-10. |
|
|
2422. | Outbreak of hepatitis C virus infections at an outpatient hemodialysis facility: the importance of infection control competencies |
|
Rao AK, Luckman E, Wise ME, MacCannell T, Blythe D, Lin Y, Xia G, Drobeniuc J, Noble-Wang J, Arduino MJ, Thompson ND, Patel PR, Wilson LE. Nephrol Nurs J. 2013 Mar-Apr;40(2):101-10, 164; quiz 111. |
|
|
|
|
|
|
2425. | Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis |
|
Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N. Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10. |
|
|
2426. | Comparative Analysis of T-Cell Depletion Method for Clinical Immunotherapy-Anti-Hepatitis C Effects of Natural Killer Cells Via Interferon-? Production |
|
Ohira M, Nishida S, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, Ohdan H, Tzakis AG. http://www.ncbi.nlm.nih.gov/pubmed/23769105# |
|
|
|
|
|
|
|
|
|
|
2431. | Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma |
|
Littera R, Zamboni F, Tondolo V, Fantola G, Chessa L, Orrù N, Sanna M, Valentini D, Cappai L, Mulargia M, Caocci G, Arras M, Floris A, Orrù S, La Nasa G, Carcassi C. Hum Immunol. 2013 Jun 10. pii: S0198-8859(13)00148-1. doi: 10.1016/j.humimm.2013.05.007. [Epub ahead of print] |
|
|
2432. | Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres |
|
Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Del Poggio P, Rapaccini G, Di Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Svegliati Baroni G, Morisco F, Pecorelli A, Farinati F; for the ITA.LI.CA Group. Liver Int. 2013 May 9. doi: 10.1111/liv.12208. [Epub ahead of print] |
|
|
2433. | New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection |
|
Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y. J Med Virol. 2013 Sep;85(9):1523-33. doi: 10.1002/jmv.23626. Epub 2013 Jun 17. |
|
|
|
|
|
|
2436. | Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial |
|
Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators. Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12. |
|
|
|
|
2438. | Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics |
|
Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Antiviral Res. 2013 Jun 7;99(3):214-220. doi: 10.1016/j.antiviral.2013.05.015. [Epub ahead of print] |
|
|
2439. | Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C |
|
Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M. Mol Ther. 2013 Jun 11. doi: 10.1038/mt.2013.119. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2444. | Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts |
|
Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH. Am J Kidney Dis. 2013 Jun 5. pii: S0272-6386(13)00782-8. doi: 10.1053/j.ajkd.2013.03.037. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2454. | Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients |
|
Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N. Hepatol Res. 2013 Jun 6. doi: 10.1111/hepr.12179. [Epub ahead of print] |
|
|
|
|
|
|
2457. | Therapy of chronic hepatitis C with PEG-IFN ?-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses |
|
Fabris P, Carlotto A, Bianco TD, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
2463. | Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients |
|
Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N. Hepatol Res. 2013 Jun 6. doi: 10.1111/hepr.12179. [Epub ahead of print] |
|
|
|
|
|
|
2466. | Therapy of chronic hepatitis C with PEG-IFN ?-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses |
|
Fabris P, Carlotto A, Bianco TD, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2470. | Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development |
|
Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group. PLoS One. 2013 May 29;8(5):e64053. doi: 10.1371/journal.pone.0064053. Print 2013. |
|
|
|
|
|
|
2473. | Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies |
|
Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB, Forns X, Alter H, Foung SK, Law M, Gottwein J, Weis N, Bukh J. Hepatology. 2013 May 31. doi: 10.1002/hep.26524. [Epub ahead of print] |
|
|
2474. | Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation |
|
García-Reyne A, Lumbreras C, Fernández I, Colina F, Abradelo M, Magan P, San-Juan R, Manrique A, López-Medrano F, Fuertes A, Lizasoain M, Moreno E, Aguado JM. Transpl Infect Dis. 2013 Jun 3. doi: 10.1111/tid.12097. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2484. | Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy |
|
Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Lédinghen V. Antivir Ther. 2013 May 23. doi: 10.3851/IMP2632. [Epub ahead of print] |
|
|
2485. | Current and future disease progression of the chronic HCV population in the United States |
|
Zalesak M, Francis K, Gedeon A, Gillis J, Hvidsten K, Kidder P, Li H, Martyn D, Orne L, Smith A, Kwong A. PLoS One. 2013 May 21;8(5):e63959. doi: 10.1371/journal.pone.0063959. Print 2013. |
|
|
2486. | Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C |
|
Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Del Giudice EM, Rossi F. Clin Gastroenterol Hepatol. 2013 May 21. pii: S1542-3565(13)00687-3. doi: 10.1016/j.cgh.2013.05.008. [Epub ahead of print] |
|
|
|
|
|
|
2489. | Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis |
|
Noureddin M, Wright EC, Alter H, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner D, Liang TJ, Ghany MG. Hepatology. 2013 May 23. doi: 10.1002/hep.26506. [Epub ahead of print] |
|
|
|
|
2491. | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy |
|
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. J Hepatol. 2013 May 23. pii: S0168-8278(13)00348-6. doi: 10.1016/j.jhep.2013.05.017. [Epub ahead of print] |
|
|
2492. | Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial |
|
Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Ann Intern Med. 2013 May 17. doi: 10.7326/0003-4819-159-2-201307160-00654. [Epub ahead of print] |
|
|
2493. | Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays |
|
Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Okada K, Kainuma M, Hayashi J. Antiviral Res. 2013 May 14;99(2):119-124. doi: 10.1016/j.antiviral.2013.05.002. [Epub ahead of print] |
|
|
|
|
|
|
2496. | Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation |
|
Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Liver Transpl. 2013 Jul;19(7):690-700. doi: 10.1002/lt.23669. Epub 2013 Jun 3. |
|
|
2497. | Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in chronic hepatitis C |
|
Boursier J, de Ledinghen V, Sturm N, Amrani L, Bacq Y, Sandrini J, Le Bail B, Chaigneau J, Zarski JP, Gallois Y, Leroy V, Al Hamany Z, Oberti F, Fouchard-Hubert I, Dib N, Bertrais S, Rousselet MC, Calès P; Multicentre group ANRS HC EP23 FIBROSTAR. J Gastroenterol. 2013 May 17. [Epub ahead of print] |
|
|
2498. | Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1 |
|
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T. J Gastroenterol. 2013 May 21. [Epub ahead of print] |
|
|
2499. | IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection |
|
Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. J Gastroenterol. 2013 May 22. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2516. | A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis |
|
Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R. Clin Infect Dis. 2013 May 14. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2521. | Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C |
|
Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, Pellegrini E, Renzo S, Leoncini L, Marra F, Laffi G, Milani S, Pinzani M. Dig Liver Dis. 2013 May 6. pii: S1590-8658(13)00143-6. doi: 10.1016/j.dld.2013.03.023. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2525. | Development of oleanane-type triterpenes as a new class of HCV entry inhibitors |
|
Yu F, Wang Q, Zhang Z, Peng Y, Qiu Y, Shi Y, Zheng Y, Xiao S, Wang H, Huang X, Zhu L, Chen K, Zhao C, Zhang C, Yu M, Sun D, Zhang L, Zhou D. J Med Chem. 2013 Jun 13;56(11):4300-19. doi: 10.1021/jm301910a. Epub 2013 May 28. |
|
|
|
|
2527. | Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome |
|
Pedersen J, Jensen TB, Carlsen TH, Schønning K, Christensen PB, Laursen AL, Krarup H, Bukh J, Weis N. PLoS One. 2013 May 7;8(5):e62674. doi: 10.1371/journal.pone.0062674. Print 2013. |
|
|
|
|
|
|
|
|
2531. | Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma |
|
Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY; Swiss Hepatitis C Cohort Study Group. J Hepatol. 2013 May 8. pii: S0168-8278(13)00287-0. doi: 10.1016/j.jhep.2013.04.032. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2536. | A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis |
|
Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R. Clin Infect Dis. 2013 May 14. [Epub ahead of print] |
|
|
|
|
|
|
2539. | High tumor necrosis factor-?/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C |
|
Aroucha DC, do Carmo RF, Moura P, Silva JL, Vasconcelos LR, Cavalcanti MS, Muniz MT, Aroucha ML, Siqueira ER, Cahú GG, Pereira LM, Coêlho MR. Cytokine. 2013 Jun;62(3):421-5. doi: 10.1016/j.cyto.2013.03.024. Epub 2013 Apr 16. |
|
|
|
|
2541. | Sofosbuvir for previously untreated chronic hepatitis C infection |
|
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853. Epub 2013 Apr 23. |
|
|
2542. | Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options |
|
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23. |
|
|
2543. | aProspective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8900 high-risk patients |
|
Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. HPB (Oxford). 2013 Apr 22. doi: 10.1111/hpb.12080. [Epub ahead of print] |
|
|
|
|
2545. | Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients |
|
Shinohara Y, Imajo K, Yoneda M, Tomeno W, Ogawa Y, Fujita K, Kirikoshi H, Takahashi J, Funakoshi K, Ikeda M, Kato N, Nakajima A, Saito S. Hepatol Res. 2013 Jan 14. doi: 10.1111/hepr.12072. [Epub ahead of print] |
|
|
|
|
2547. | Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 |
|
Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Ann Rheum Dis. 2013 Apr 20. [Epub ahead of print] |
|
|
2548. | Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 |
|
Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Ann Rheum Dis. 2013 Apr 20. [Epub ahead of print] |
|
|
|
|
2550. | Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis |
|
Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Niinomi T, Ito T, Hasegawa R, Ando Y, Yamamoto K, Tanaka T. Hepatol Res. 2013 Mar 29. doi: 10.1111/hepr.12120. [Epub ahead of print] |
|
|
|
|
2552. | Impact of new therapeutics for hepatitis C virus infection in incarcerated populations |
|
Spaulding AS, Kim AY, Harzke AJ, Sullivan JC, Linas BP, Brewer A, Dickert J, McGovern BH, Strick LB, Trestman R, Ferguson WJ. Top Antivir Med. 2013 Feb-Mar;21(1):27-35. |
|
|
|
|
|
|
2555. | Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance |
|
Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. ACS Chem Biol. 2013 May 1. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2560. | Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes |
|
Benegiamo G, Mazzoccoli G, Cappello F, Rappa F, Scibetta N, Oben J, Greco A, Williams R, Andriulli A, Vinciguerra M, Pazienza V. PLoS One. 2013 Apr 8;8(4):e60527. doi: 10.1371/journal.pone.0060527. Print 2013. |
|
|
2561. | CCR5-?32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection |
|
Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Nattermann J, Mueller T, Riordan S, Stewart GJ, George J, Booth DR, Ahlenstiel G; and the International Hepatitis C Genetics Consortium (IHCGC), Michalk M, Malik B, McClure P, Smith S, Sheridan D, Snape E, Fragomeli V, Norris R, How-Chow D, Jonsson JR, Barrie H, Stelzer-Braid S, Fletcher S, Applegate T, Grebely J, Matthews G, Bharadwaj M, Smedile A. Genes Immun. 2013 Apr 18. doi: 10.1038/gene.2013.15. [Epub ahead of print] |
|
|
2562. | Presentation, Outcomes, and Response to Therapy Among Patients with Acute Exacerbation of Chronic Hepatitis C |
|
Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N. Clin Gastroenterol Hepatol. 2013 Apr 13. pii: S1542-3565(13)00466-7. doi: 10.1016/j.cgh.2013.03.025. [Epub ahead of print] |
|
|
2563. | Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials |
|
Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Clin Infect Dis. 2013 May 7. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2573. | Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy |
|
Yamashita YI, Shirabe K, Toshima T, Tsuijita E, Takeishi K, Harimoto N, Ikegami T, Yoshizumi T, Ikeda T, Soejima Y, Maehara Y. Hepatol Res. 2013 Mar 27. doi: 10.1111/hepr.12091. [Epub ahead of print] |
|
|
|
|
2575. | Telaprevir-related dermatitis |
|
Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. JAMA Dermatol. 2013 Feb;149(2):152-8. |
|
|
|
|
|
|
2578. | Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin |
|
Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML. J Gastroenterol Hepatol. 2013 Apr 5. doi: 10.1111/jgh.12211. [Epub ahead of print] |
|
|
|
|
2580. | IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients |
|
Jiménez-Sousa MA, Berenguer J, Rallón N, Guzmán-Fulgencio M, López JC, Soriano V, Fernández-Rodríguez A, Cosín J, Restrepo C, García-Álvarez M, Miralles P, Benito JM, Resino S. J Viral Hepat. 2013 May;20(5):358-66. doi: 10.1111/jvh.12041. Epub 2012 Dec 20. |
|
|
2581. | Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results |
|
Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Böcher WO, Mensa FJ. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2567. [Epub ahead of print] |
|
|
2582. | Hepatocyte destruction with enhanced collagen synthesis: characteristic feature of chronic hepatitis C patients on haemodialysis |
|
Ue M, Ikebe N, Munekage K, Ochi T, Hirose A, Kataoka H, Fujimoto S, Kikuchi K, Okuhara Y, Ono M, Saibara T. J Viral Hepat. 2013 May;20(5):350-7. doi: 10.1111/jvh.12031. Epub 2012 Dec 11. |
|
|
|
|
|
|
2585. | ?-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C |
|
Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26442. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2595. | Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study |
|
Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M. J Gastroenterol. 2013 Mar 30. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2600. | Treatment of HCV infection by targeting microRNA |
|
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2609. | Prediction of efficacy to pegylated interferon-?-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks |
|
Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y, Moribata K, Miyata K, Higashi K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Hepatol Res. 2013 Feb 25. doi: 10.1111/hepr.12101. [Epub ahead of print] |
|
|
2610. | Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients |
|
Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Lin YC, Yu ML. PLoS One. 2013;8(3):e58882. doi: 10.1371/journal.pone.0058882. Epub 2013 Mar 19. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2621. | Management of Hepatitis C Virus Infection in Heavy Drinkers |
|
Costentin CE, Trabut JB, Mallet V, Darbeda S, Thépot V, Nalpas B, Badin de Montjoye B, Lavielle B, Vallet-Pichard A, Sogni P, Pol S. Alcohol Alcohol. 2013 Mar 21. [Epub ahead of print] |
|
|
2622. | Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial |
|
Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; for The Hep-Net Acute HCV-III Study Group. Lancet Infect Dis. 2013 Mar 21. pii: S1473-3099(13)70059-8. doi: 10.1016/S1473-3099(13)70059-8. [Epub ahead of print] |
|
|
|
|
2624. | Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir |
|
McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26388. [Epub ahead of print] |
|
|
|
|
|
|
2627. | Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation |
|
Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. PLoS One. 2013;8(3):e58380. doi: 10.1371/journal.pone.0058380. Epub 2013 Mar 7. |
|
|
|
|
|
|
|
|
|
|
|
|
2633. | Hepatitis C virus vaccines - Progress and perspectives |
|
Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print] |
|
|
|
|
2635. | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial |
|
Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print] |
|
|
2636. | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial |
|
Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print] |
|
|
|
|
2638. | IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication |
|
Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7. |
|
|
2639. | Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study |
|
Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4. |
|
|
2640. | 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy |
|
Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print] |
|
|
2641. | Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance |
|
Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2645. | Hepatitis C virus vaccines - Progress and perspectives |
|
Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print] |
|
|
|
|
2647. | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial |
|
Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print] |
|
|
2648. | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial |
|
Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print] |
|
|
|
|
2650. | IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication |
|
Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7. |
|
|
2651. | Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study |
|
Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4. |
|
|
2652. | 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy |
|
Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print] |
|
|
2653. | Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance |
|
Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2663. | A high MELD score, combined with the presence of hepatitis C, is associated with a poor prognosis in living donor liver transplantation |
|
Ikegami T, Shirabe K, Yoshiya S, Yoshizumi T, Yamashita YI, Harimoto N, Toshima T, Uchiyama H, Soejima Y, Maehara Y. Surg Today. 2013 Feb 23. [Epub ahead of print] |
|
|
2664. | Antiviral Activity of Boceprevir Monotherapy in Treatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3 |
|
Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA. J Hepatol. 2013 Feb 27. pii: S0168-8278(13)00140-2. doi: 10.1016/j.jhep.2013.02.018. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
2670. | Serum fibrinogen alpha C-chain 5.9 kDa fragment (FIC 5.9) as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus |
|
Sogawa K, Noda K, Umemura H, Seimiya M, Kuga T, Tomonaga T, Nishimura M, Kanai F, Imazeki F, Takizawa H, Yoneda M, Nakajima A, Tsutsumi M, Yokosuka O, Nomura F. Proteomics Clin Appl. 2013 Feb 4. doi: 10.1002/prca.201200094. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2674. | Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting |
|
Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H, Cornberg M. PLoS One. 2013;8(2):e55285. doi: 10.1371/journal.pone.0055285. Epub 2013 Feb 1. |
|
|
|
|
|
|
|
|
2678. | Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin |
|
Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, Lee KW, Kim W, Kim YJ, Yoon JH, Lee HS, Kim DG. J Gastroenterol. 2013 Mar 6. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2690. | Association of Interleukin 28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C |
|
Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S. Clin Cancer Res. 2013 Feb 20. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2694. | Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-?2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial |
|
Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY. Antivir Ther. 2013 Feb 12. doi: 10.3851/IMP2549. [Epub ahead of print] |
|
|
2695. | Vitamin D deficiency and vitamin D therapy in chronic hepatitis C |
|
Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA. Ann Hepatol. 2013 Mar;12(2):199-204. |
|
|
|
|
|
|
|
|
|
|
2700. | Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B |
|
Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Hepatol Res. 2012 Oct 18. doi: 10.1111/hepr.12005. [Epub ahead of print] |
|
|
2701. | The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance |
|
Himoto T, Tani J, Miyoshi H, Yoneyama H, Mori H, Inukai M, Masugata H, Goda F, Senda S, Haba R, Masaki T. Nutr Res. 2013 Jan;33(1):27-33. doi: 10.1016/j.nutres.2012.11.007. Epub 2012 Dec 20. |
|
|
|
|
2703. | Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting |
|
Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, Boonwaat L, Forrest G, Douglas J, Monkley D. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
2708. | Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence |
|
Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, Kwak MS, Cheong JY, Cho SW, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Shin HD, Kim YJ. Intervirology. 2013 Jan 22. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2715. | Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis |
|
Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N. Pharmazie. 2012 Dec;67(12):963-72. |
|
|
|
|
|
|
2718. | Prognostic Gene-Expression Signature for Patients with Hepatitis C-Related Early-Stage Cirrhosis |
|
Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Gastroenterology. 2013 Jan 17. pii: S0016-5085(13)00078-4. doi: 10.1053/j.gastro.2013.01.021. [Epub ahead of print] |
|
|
|
|
|
|
2721. | Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma |
|
Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R, Kato J. J Gastroenterol. 2013 Jan 19. [Epub ahead of print] |
|
|
|
|
2723. | Performance of liver stiffness measurements by Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in chronic hepatitis |
|
Ferraioli G, Tinelli C, Bello BD, Zicchetti M, Lissandrin R, Filice G, Filice C, Above E, Barbarini G, Brunetti E, Calderon W, Gregorio MD, Gulminetti R, Lanzarini P, Ludovisi S, Maiocchi L, Malfitano A, Michelone G, Minoli L, Mondelli M, Novati S, Patruno SF, Perretti A, Poma G, Sacchi P, Zanaboni D, Zaramella M. World J Gastroenterol. 2013 Jan 7;19(1):49-56. doi: 10.3748/wjg.v19.i1.49. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2736. | Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy |
|
Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Hepat Mon. 2012 Nov;12(11):e7292. doi: 10.5812/hepatmon.7292. Epub 2012 Nov 30. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2753. | Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C |
|
Shimoyama Y, Nozaki A, Morimoto M, Moriya S, Kondo M, Fukuda H, Numata K, Miyajima E, Oba MS, Taguri M, Morita S, Maeda S, Tanaka K. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12037. [Epub ahead of print] |
|
|
|
|
2755. | Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin |
|
Yu ML, Liu CH, Huang CF, Tseng TC, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Kao JH. PLoS One. 2012;7(12):e52048. doi: 10.1371/journal.pone.0052048. Epub 2012 Dec 21. |
|
|
|
|
|
|
2758. | Low Oxygen Tension Enhances Hepatitis C Virus Replication |
|
Vassilaki N, Kalliampakou KI, Kotta-Loizou I, Befani C, Liakos P, Simos G, Mentis AF, Kalliaropoulos A, Doumba PP, Smirlis D, Foka P, Bauhofer O, Poenisch M, Windisch MP, Lee ME, Koskinas J, Bartenschlager R, Mavromara P. J Virol. 2012 Dec 26. [Epub ahead of print] |
|
|
2759. | Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C |
|
Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12032. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2767. | Vitamin A deficiency is associated with HCV chronic infection and with unresponsiveness to interferon based antiviral therapy |
|
Bitetto D, Bortolotti N, Falleti E, Vescovo S, Fabris C, Fattovich G, Cussigh A, Cmet S, Fornasiere E, Ceriani E, Pirisi M, Toniutto P. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26186. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2774. | Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases |
|
Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, Mawatari H, Fujita K, Shibata W, Kirikoshi H, Maeda S, Nakajima A, Saito S. Hepatol Res. 2012 Nov 12. doi: 10.1111/hepr.12023. [Epub ahead of print] |
|
|
2775. | Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States |
|
Scott JD, Unruh KT, Catlin MC, Merrill JO, Tauben DJ, Rosenblatt R, Buchwald D, Doorenbos A, Towle C, Ramers CB, Spacha DH. J Telemed Telecare. 2012;18(8):481-4. doi: 10.1258/jtt.2012.GTH113. Epub 2012 Dec 3. |
|
|
|
|
2777. | Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C |
|
Petta S, Rosso C, Leung R, Abate ML, Booth D, Salamone F, Gambino R, Rizzetto M, Caviglia P, Smedile A, Grimaudo S, Cammà C, Craxì A, George J, Bugianesi E. Clin Gastroenterol Hepatol. 2012 Dec 4. pii: S1542-3565(12)01422-X. doi: 10.1016/j.cgh.2012.11.022. [Epub ahead of print] |
|
|
|
|
|
|
2780. | Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C |
|
Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B., Ph.D., Robert H. Hyland, D.Phil., Xiao Ding, Ph.D., Evguenia Svarovskaia, Ph.D., William T. Symonds, Pharm.D., Robert G. Hindes, M.D., and M. Michelle Berrey, M.D., M.P.H. N Engl J Med 2013; 368:34-44January 3, 2013DOI: 10.1056/NEJMoa1208953 |
|
|
|
|
|
|
2783. | Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C |
|
Fred Poordad, M.D., Eric Lawitz, M.D., Kris V. Kowdley, M.D., Daniel E. Cohen, M.D., Thomas Podsadecki, M.D., Sara Siggelkow, R.N., Michele Heckaman, M.S., Lois Larsen, Ph.D., Rajeev Menon, Ph.D., Gennadiy Koev, Ph.D., Rakesh Tripathi, M.S., Tami Pilot-Matias, Ph.D., and Barry Bernstein, M.D. N Engl J Med 2013; 368:45-53January 3, 2013DOI: 10.1056/NEJMoa120880 |
|
|
2784. | Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers |
|
Ponziani FR, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Cescon M, Burra P, Miglioresi L, Merli M, Paolo DD, Fagiuoli S, Pompili M; on behalf of AISF RECOLT-C Group. Transpl Int. 2012 Dec 11. doi: 10.1111/tri.12027. [Epub ahead of print] |
|
|
|
|
|
|
2787. | IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4 |
|
Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY, Negro F. J Viral Hepat. 2013 Jan;20(1):59-64. doi: 10.1111/j.1365-2893.2012.01621.x. Epub 2012 May 24. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2794. | Relationship of ?-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis |
|
Taura N, Fukuda S, Ichikawa T, Miyaaki H, Shibata H, Honda T, Yamaguchi T, Kubota Y, Uchida S, Kamo Y, Yoshimura E, Isomoto H, Matsumoto T, Takeshima F, Tsutsumi T, Tsuruta S, Nakao K. Exp Ther Med. 2012 Dec;4(6):972-976. Epub 2012 Sep 17. |
|
|
|
|
|
|
|
|
|
|
2799. | Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2 |
|
Taura N, Ichikawa T, Miyaaki H, Kadokawa Y, Tsutsumi T, Tsuruta S, Kato Y, Inoue O, Kinoshita N, Ohba K, Kato H, Ohata K, Masuda J, Hamasaki K, Yatsuhashi H, Nakao K. Gastroenterol Res Pract. 2012;2012:317580. doi: 10.1155/2012/317580. Epub 2012 Nov 5. |
|
|
2800. | Exploratory study on telaprevir given every 8?h at 500?mg or 750?mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients |
|
Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12009. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2810. | Telaprevir-Related Dermatitis |
|
Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Arch Dermatol. 2012 Nov 19:1-7. doi: 10.1001/jamadermatol.2013.938. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|